---
document_datetime: 2023-09-21 20:02:09
document_pages: 111
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/alunbrig-h-c-4248-ii-0003-epar-assessment-report-variation_en.pdf
document_name: alunbrig-h-c-4248-ii-0003-epar-assessment-report-variation_en.pdf
version: success
processing_time: 191.5109138
conversion_datetime: 2025-12-21 18:58:04.693046
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
27 February 2020 EMA/140650/2020

Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

Invented name: Alunbrig

International non-proprietary name: brigatinib / brigatinib

Procedure No. EMEA/H/C/004248/II/0003

Marketing authorisation holder (MAH) Takeda Pharma A/S

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

●

●

The Netherlands

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                           |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                           |
| 2. Scientific discussion                                                                                                    | ................................................................................7                         |
| 2.1. Introduction.........................................................................................................7 |                                                                                                           |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................7             |
| 2.1.2. About the product..............................................................................................9     |                                                                                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................10            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................10                                               |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................11      |
| 2.3.1. Introduction....................................................................................................11   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................11      |                                                                                                           |
| 2.3.3. PK/PD modelling..............................................................................................15      |                                                                                                           |
| 2.3.4. Discussion on clinical pharmacology...................................................................20             |                                                                                                           |
| 2.3.5. Conclusions on clinical pharmacology                                                                                 | .................................................................21                                       |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................22      |
| 2.4.1. Dose response study........................................................................................22        |                                                                                                           |
| 2.4.2. Main study......................................................................................................22   |                                                                                                           |
| 2.4.3. Discussion on clinical efficacy............................................................................57        |                                                                                                           |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................59          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................60    |
| 2.5.1. Discussion on clinical safety ............................................................................           | 102                                                                                                       |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 104                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 104   |
| 2.6. Risk management plan......................................................................................             | 105                                                                                                       |
| 2.7. Update of the Product information                                                                                      | ...................................................................... 106                                |
| 2.7.1. User consultation...........................................................................................         | 106                                                                                                       |
| 3. Benefit-Risk Balance............................................................................106                      |                                                                                                           |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 106             |
| 3.1.1. Disease or condition.......................................................................................          | 106                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 106                                                                                                       |
| 3.1.3. Main clinical studies .......................................................................................        | 107                                                                                                       |
| 3.2. Favourable effects ............................................................................................        | 107                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects                                                                 | ........................................... 107                                                           |
| 3.4. Unfavourable effects.........................................................................................          | 108                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 108                                                               |
| 3.6. Effects Table....................................................................................................      | 109                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 109                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects                                                                    | ............................................ 109                                                          |
| 3.7.2. Balance of benefits and risks...........................................................................             | 110                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                | ......................................... 110                                                             |
| 3.8. Conclusions                                                                                                            | ..................................................................................................... 110 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ...............................................................................  110

5. EPAR changes  ......................................................................................  111

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Term                                                       |
|----------------|------------------------------------------------------------|
| AE             | adverse event                                              |
| ALK            | anaplastic lymphoma kinase                                 |
| ALK+           | anaplastic lymphoma kinase positive                        |
| ALP            | alkaline phosphatase                                       |
| ALT            | alanine aminotransferase                                   |
| AST            | aspartate aminotransferase                                 |
| BID            | twice daily                                                |
| BIRC           | blinded independent review committee                       |
| CNS            | central nervous system                                     |
| CPK            | creatine phosphokinase                                     |
| CR             | complete response                                          |
| CSR            | clinical study report                                      |
| CTCAE          | Common Terminology Criteria for Adverse Events             |
| DCR            | disease control rate                                       |
| DILI           | drug-induced liver injury                                  |
| DMC            | data monitoring committee                                  |
| DOR            | duration of response                                       |
| ECG            | electrocardiogram                                          |
| ECOG           | Eastern Cooperative Oncology Group                         |
| EGFR           | estimated glomerular filtration rate                       |
| EOPE           | early-onset pulmonary event                                |
| EORTC          | European Organisation for Research and Treatment of Cancer |
| ESMO           | European Society for Medical Oncology                      |
| EU             | European Union                                             |
| FDA            | Food and Drug Administration                               |
| FISH           | fluorescence in situ hybridization                         |
| GI             | gastrointestinal                                           |
| HR             | hazard ratio                                               |
| iCNS           | intracranial central nervous system                        |
| iDOR           | intracranial duration of response                          |
| IHC            | immunohistochemistry                                       |
| ILD            | interstitial lung disease                                  |
| iORR           | intracranial objective response rate                       |
| iPFS           | intracranial progression-free survival                     |
| IRC            | independent review committee                               |
| ITT            | intent-to-treat                                            |
| KM             | Kaplan Meier                                               |
| LS             | least squares                                              |
| MAA            | Marketing Authorization Application                        |
| MedDRA         | Medical Dictionary for Regulatory Activities               |
| MRI            | magnetic resonance imaging                                 |
| NCCN           | National Comprehensive Cancer Network                      |
| NE             | not estimable                                              |
| NONMEM         | Nonlinear mixed effects modelling                          |
| NSCLC          | non - small-cell lung cancer                               |
| OS             | overall survival                                           |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Term                                         |
|----------------|----------------------------------------------|
| PD             | progressive disease                          |
| PFS            | progression-free survival                    |
| PK             | pharmacokinetic(s)                           |
| PR             | partial response                             |
| PRO            | patient-reported outcome                     |
| PT             | Preferred Term                               |
| QD             | once daily                                   |
| QLQ            | Quality of Life Questionnaire                |
| QoL            | quality of life                              |
| QTcF           | QT interval corrected (Fridericia)           |
| RECIST         | Response Evaluation Criteria in Solid Tumors |
| SAE            | serious adverse event                        |
| SAP            | statistical analysis plan                    |
| SmPC           | Summary of Product Characteristics           |
| sNDA           | supplementary new drug application           |
| SOC            | System Organ Class                           |
| TEAE           | treatment-emergent adverse event             |
| TKI            | tyrosine kinase inhibitor                    |
| US             | United States                                |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Takeda Pharma A/S submitted to the European Medicines Agency on 17 June 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of indication to include first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor for Alunbrig. The addition of a new indication is supported by data from Study 301 (AP26113-13-301; ALTA 1L), a phase 3, randomized, open label, comparative, multicenter, international phase 3 study. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package leaflet and labelling are updated in accordance. The RMP version 5.1 has also been submitted. Minor editorial corrections are also proposed.

The variation requested amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0350/2018 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication. During the procedure, the MAH withdrew its request.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

N/A

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 17 June 2019      |
| Start of procedure:                                  | 22 June 2019      |
| CHMP Rapporteur Assessment Report                    | 31 July 2019      |
| CHMP Co-Rapporteur Assessment Report                 | 31 July 2019      |
| PRAC Rapporteur Assessment Report                    | 23 August 2019    |
| PRAC members comments                                | 28 August 2019    |
| Updated PRAC Rapporteur Assessment Report            | 29 August 2019    |
| PRAC Outcome                                         | 5 September 2019  |
| CHMP members comments                                | 09 September 2019 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 12 September 2019 |
| Request for supplementary information (RSI)          | 19 September 2019 |
| CHMP Rapporteur Assessment Report                    | 28 January 2020   |
| PRAC Rapporteur Assessment Report                    | 03 February 2020  |
| PRAC members comments                                | 05 February 2020  |
| Updated PRAC Rapporteur Assessment Report            | n/a               |
| PRAC Outcome                                         | 13 Feb 2020       |
| CHMP members comments                                | 17 Feb 2020       |
| Updated CHMP Rapporteur Assessment Report            | 20 Feb 2020       |
| Opinion                                              | 27 Feb 2020       |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The MAH applied for the following indication:

<div style=\"page-break-after: always\"></div>

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor.

## Epidemiology

Lung cancer is one of the most common cancers in the world and is the leading cause of cancer death worldwide. Globally, 2.1 million new lung cancer cases are estimated to have occurred in 2018, and lung cancer was responsible for 1.8 million deaths. In Europe, there were an estimated 470,000 cases of lung cancer diagnosed in 2018 across 40 countries, with 388,000 deaths 1  [GLOBOCAN 2018].

NSCLC is the most prevalent histologic class of lung cancer, accounting for nearly 85% of all cases. Traditionally, NSCLC has been further divided into one of several histologic subtypes, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and bronchioloalveolar carcinoma 2 . Tumours that appear identical by histologic criteria are often driven by distinct oncogenes and, therefore, respond differently to therapeutic interventions because of their individual molecular profiles.

## Biologic features, aetiology and pathogenesis

ALK is a tyrosine kinase encoded on chromosome 2 and is primarily involved in developmental processes and expressed at low levels in adults 3 . The first genetic rearrangement of ALK seen in NSCLC involved a fusion between the echinoderm microtubule-associated protein-like 4 (EML4) gene and the ALK tyrosine kinase domain. EML4-ALK has the capacity to transform fibroblasts grown in culture and as subcutaneous xenografts to induce tumour formation 4 . A number of additional ALK fusion partners have been described in  NSCLC  that  are  believed  to  result  in  aberrant  signalling  and  oncogenic  transformation 5   6 .  ALK rearrangements are more common among patients with adenocarcinoma histology, patients who have never smoked, and patients who have wild-type EGFR and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) 7 .

## Clinical presentation, diagnosis and stage/prognosis

Approximately, one-third of the patients with Stage IIIA disease are considered operable. However, the majority of patients with Stage IIIA/B have inoperable (unresectable) disease, and are amenable to receiving curative intention chemoradiation treatment. The biological characteristics of locally advanced, Stage III disease are poorly defined; the clinical characteristics associated with prognosis are nodal station involvement, size of primary tumour, baseline pulmonary function, gender, presence or absence of significant weight loss, and performance status (PS).

1  Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018.

2  Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-94.

3  Camidge D, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268-77

4  Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-6.

5  Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-203.

6  Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res.2009;15(9):3143-9.

7  Camidge D, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268-77.

<div style=\"page-break-after: always\"></div>

Pathological diagnosis based on tumour samples includes immunohistochemistry (IHC) to identify adenocarcinoma or squamous cell carcinoma and cytogenetic analysis by fluorescence in situ hybridisation (FISH) test to detect ALK rearrangements. Molecular testing should be carried out to determine genetic alterations, such as EGFR mutations and ALK rearrangements which determine choice of targeted treatment.

## Management

## Crizotinib

In a randomized study of crizotinib against pemetrexed platinum doublet chemotherapy in patients with advanced, previously untreated ALK+ NSCLC, the median PFS was 10.9 months in the crizotinib arm and 7.0 months in the chemotherapy arm (HR = 0.45) [10,11].

For patients who respond, the median duration of response (DOR) of less than 1 year (~11 months in previously untreated ALK+ NSCLC and ~7 months in patients previously treated with chemotherapy) [see Xalkori  EPAR].  Among  responders,  ALK-dependent  mechanisms  of  resistance  develop  in approximately 30% 8  and include the acquisition of secondary point mutations in the kinase domain of ALK that interfere with crizotinib binding 9  and/or amplification of the ALK fusion gene.

The central nervous system (CNS) is the first site of progression in approximately 50% of patients 10   11 , suggesting inadequate penetration of crizotinib into the brain (i.e., pharmacologic failure) as the primary cause of resistance in these patients.

Well-described safety and tolerability concerns associated with crizotinib include hepatotoxicity requiring monitoring; severe, life-threatening, or fatal interstitial lung disease (ILD); QT interval prolongation; bradycardia; and severe visual impairment. Other common adverse events (AEs) include gastrointestinal (GI) toxicity and peripheral oedema.

## Recent First-Line Studies With Second- and Third-Generation ALK Inhibitors

Building on the robust efficacy results observed in the post-crizotinib setting, alectinib and ceritinib have been  authorised  in  previously  untreated  ALK+  NSCLC  in  the  EU.  For  alectinib,  clinically  meaningful improvements in PFS were noted in the first-line setting when compared with crizotinib in the ALEX study, with a median PFS (by IRC) of 25.7 months versus 10.4 months, respectively (HR = 0.50) [see Alecensa EPAR].

The first-line approval of ceritinib was based on findings from the phase 3 ASCEND-4 trial, which were observed relative to chemotherapy rather than crizotinib as active control. The median PFS was 16.6 months with ceritinib versus 8.1 months with chemotherapy (HR = 0.55) [see Zykadia EPAR].

## 2.1.2. About the product

Brigatinib is a tyrosine kinase inhibitor that targets ALK, c-ros oncogene 1 (ROS1), and insulin like growth factor 1 receptor (IGF 1R). Brigatinib inhibited autophosphorylation of ALK and ALK mediated phosphorylation of the downstream signalling protein STAT3 in in vitro and in vivo assays (SmPC,

8  Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21(10):2227-35.

9  Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular Mechanisms of Resistance to Firstand Second-Generation ALK Inhibitors in ALKRearranged Lung Cancer. Cancer Discov 2016;6(10):1118-33.

10  Costa D, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-smallcell lung cancer and brain metastases. J Clin Oncol. 2015;33:1881-8.

11  Weickhardt A, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807-14.

<div style=\"page-break-after: always\"></div>

section 5.1). Brigatinib inhibited the in vitro proliferation of cell lines expressing EML4 ALK and NPM ALK fusion proteins and demonstrated dose dependent inhibition of EML4 ALK positive NSCLC xenograft growth in mice. Brigatinib inhibited the in vitro and in vivo viability of cells expressing mutant forms of EML4-ALK associated with resistance to ALK inhibitors, including G1202R and L1196M (SmPC, section 5.1).

In the clinical setting, brigatinib showed efficacy in patients with ALK+ NSCLC previously treated with crizotinib in Study 201. In this study, there was a median PFS greater than 15 months in patients receiving the recommended dose, as assessed by both investigator and IRC (15.6 and 16.7 months, respectively). Based primarily on the results from Study 201, approval was granted in the EU in November 2018 for use of brigatinib as monotherapy in adult patients with ALK+ advanced NSCLC previously treated with crizotinib.

In the context of this procedure and based on the results from study AP26113-13-301 (referred to as Study 301), the CHMP recommends the following indication for approval:

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

The recommended starting dose of Alunbrig is 90 mg once daily for the first 7 days, then 180 mg once daily.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

An updated environmental risk assessment was not included within the Type II variation application for the following additional indication:

'Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor.'

The currently approved indication for Alunbrig is as follows:

'Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC) previously treated with crizotinib.'

In the ERA submitted with the initial MAA, the maximum theoretical use of brigatinib was refined based on the epidemiologically substantiated prevalence of ALK+ NSCLC. This means that the prevalence figure used comprises all expected cases of ALK+ NSCLC, not only the ones previously treated with crizotinib. Hence, the ERA as it stands covers the potential environmental risks deriving from all applications for ALK+ NSCLC. Therefore, no new or updated environmental risk assessment is needed for the current indication extension.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1: Summary of Study 301

|   Study | Description                       | Design                                                                                                                   | #Planned Patients   | PKSamplesforArmA                                                                                                                                     |
|---------|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|     301 | Patients with ALK+ advanced NSCLC | Arm A:brigatinibadministered orallyatadoseof90mgQDfor7 days, then 180 mg QD ArmB:crizotinibadministeredas 250mgorallyBID | ArmA:135 ArmB:135   | Cycle 1 Day1:predose Cycle 2 Day1:predose,and1,4&6 to8hourspostdose; Cycles 3, 4, and 5 Day 1: predose sample& anytime between 1 to 8 hours postdose |

Source: Study 301 PopPK/ER Report, Table 1.

Abbreviations: ALK+, anaplastic lymphoma kinase positive; BID, twice daily; NSCLC, non-small-cell lung cancer; PK,pharmacokinetic;QD,oncedaily.

## 2.3.2. Pharmacokinetics

## Methods

Plasma concentrations of brigatinib were analysed using validated liquid chromatography tandem mass spectrometry  methods.  The  LC-MS/MS  methods  were  validated  for  the  analysis  of  AP26113  and  its metabolite, AP26123, in human K2EDTA plasma; therefore, AP26123 is included in the stocks, standards and quality control  samples.  As  analysis  for  the  metabolite  was  not  required  for  the  study  samples according to the protocol of Study 301, the data was only quantified for AP26113.

The population PK analysis was performed using the NONMEM (Version 7.3.0) software for nonlinear mixed effects models. Data management, exposure-response analyses, and results evaluations were performed using R (version 3.3.1).

## Population PK analysis

The primary objective of the Pop PK analysis was to obtain post hoc exposure estimates for patients from Study 301 to facilitate ER analysis. The Pop PK model for brigatinib (a 3-compartment model with linear kinetics and first-order absorption preceded by a set of transit compartments) was previously developed based on data from 442 subjects (105 healthy subjects and 337 cancer patients) from four phase 1 studies (AP26113-11-101, AP26113-13-102, AP26113-13-103 and AP26113-15-105) and one phase 2 study (Study 201).

<div style=\"page-break-after: always\"></div>

PK data for brigatinib in Study 301 were available for 121 of 137 enrolled patients (88%) in the brigatinib arm.  Brigatinib  concentrations  below  the  limit  of  quantification  (BLQ)  and  data  points  identified  as outliers (CWRES&gt;5) were excluded from the analysis.

A  Bayesian  re-estimation  approach,  leveraging  the  existing  Pop  PK  model  and  the  available  sparse brigatinib concentration data from Study 301, was applied to obtain individual exposure estimates. The Pop PK model parameter values (fixed effects and random effects variances) were fixed to final estimates from the previously developed model with only the individual random effects estimated based on the analysis dataset for Study 301. The final Pop PK model scheme and parameters are presented in Figure 1 and Table 2, respectively.

<!-- image -->

Source: Brigatinib Phase 1 and 2 PopPK Report, Figure 3.

Abbreviations: At , amount in the transit compartment; CL/F, apparent extravascular clearance; Kt, transit rate between transit compartments parameterized as (NTR+1)/MTT); PopPK, population pharmacokinetics;

Q2/F, intercompartmental clearance between the central compartment and the first peripheral compartment;

Q3/F, intercompartmental clearance between the central compartment and the second peripheral compartment;

V1/F, apparent volume of distribution in central compartment; V2/F, apparent volume of distribution in the first peripheral compartment; V3/F, apparent volume of distribution in the second peripheral compartment.

Figure 1: Structural PopPK model for brigatinib

Inter individual variability was estimated on apparent clearance from the central compartment, apparent volume  of  distribution  in  the  central  and  the  first  peripheral  compartments,  the  number  of  transit compartments and mean transit time. The final model included albumin as a covariate on apparent clearance, with apparent clearance increasing with increasing albumin levels.

<div style=\"page-break-after: always\"></div>

Table 2: Final PopPK model parameters for Brigatinib

| Parameter               | Estimate          | %CV   | IIV   | %CV IIV   | Shrinkage   |
|-------------------------|-------------------|-------|-------|-----------|-------------|
| CL/F (L/h)              | 10.6              | 2.65  | 48.4  | 7.09      | 1.96        |
| V1/F (L)                | 207               | 3.82  | 55.6  | 8.38      | 7.24        |
| Q2/F (L/h)              | 12.6              | 9.23  | NA    | NA        | NA          |
| V2/F (L)                | 114               | 11.2  | 95.2  | 12.2      | 16.77       |
| Q3/F (L/h)              | 2.67              | 18.2  | NA    | NA        | NA          |
| V3/F (L)                | 78.5              | 8.64  | NA    | NA        | NA          |
| NTR                     | 2.35              | NA    | 103   | 16.6      | 43.33       |
| MTT (h)                 | 0.907             | 3.55  | 59    | 7.52      | 36.83       |
| ALB on CL/F             | (Albumin/38)0.001 | 10.7  | NA    | NA        | NA          |
| SD (proportional error) | 0.269             | 0.627 | NA    | NA        | 10.65       |
| Cov (CL/F,V1/F)         | 0.228             | 7.81  | NA    | NA        | NA          |

Source: Study 301 PopPK/ER Report, Table 3. Abbreviations: ALB, albumin; CL/F, apparent clearance from the central compartment; %CV, % coefficient variation; Cov, covariance; m, patient-level random effect; IIV, interindividual variability; MTT, mean transit time; NTR, number of transit compartments; PopPK, population pharmacokinetics; Q2/F, intercompartmental distributional clearance between the central and 1\" peripheral compartment; Q3/F, intercompartmental distributional clearance between the central and 2nd peripheral compartment; V1/F, apparent central volume of distribution; V2/F, apparent volume of distribution in the first peripheral compartment; V3/F, apparent volume of distribution in the second peripheral compartment.

Diagnostic  plots  showed  that  individual  predictions  were  consistent  with  the  observed  Study  301 concentrations  and  the  CWRES  were  normally  distributed  and  showed  no  trend  when  related  to population prediction or time. PK parameter estimates were similar for Studies 301 and 201 (Table 3) and confirmed that the Bayesian re-estimation approach was an appropriate method to obtain individual PK parameters and post hoc exposure estimates for Study 301.

Table 3: Summary statistics of post hoc parameter estimates from studies 301 and 201

| Parameter   |   Study |   Geometric mean |     P5 |    P95 |
|-------------|---------|------------------|--------|--------|
| CL/F (L/h)  |     301 |            8.5   |  4.02  |  17.9  |
|             |     201 |            9.9   |  4.06  |  23    |
| V1/F (L)    |     301 |          161     | 68.2   | 302    |
|             |     201 |          199     | 86     | 468    |
| NTR         |     301 |            2.78  |  1.82  |   5.05 |
|             |     201 |            2.72  |  1.85  |   4.46 |
| MTT (b)     |     301 |            1.01  |  0.555 |   2.02 |
|             |     201 |            0.998 |  0.584 |   1.92 |
| KTR (1/h)   |     301 |            3.81  |  2.04  |   8.09 |
|             |     201 |            3.76  |  2.21  |   6.8  |
| Q2/F (L/h)  |     301 |           12.6   | 12.6   |  12.6  |
|             |     201 |           12.6   | 12.6   |  12.6  |
| V2/F (L)    |     301 |          118     | 60.8   | 287    |
|             |     201 |          124     | 78.3   | 259    |
| Q3/F (L/h)  |     301 |            2.67  |  2.67  |   2.67 |
|             |     201 |            2.67  |  2.67  |   2.67 |
| V3/F (L)    |     301 |           78.5   | 78.5   |  78.5  |
|             |     201 |           78.5   | 78.5   |  78.5  |
| CL-ALB      |     301 |            1.03  |  0.874 |   1.13 |
|             |     201 |            0.939 |  0.758 |   1.09 |

Source: 002.GOF\\_plots.r

Abbreviations: ALB = Albumin, CL/F = Apparent clearance firom the central compartment, MTT = Mean transit time, NTR = Number of transit compartments, Q2/F = Inter-compartmental clearance between the central and 1st peripheral compartment, Q3/F = Inter-compartmental clearance between the central and 2nd peripheral compartment, V1/F = Apparent central volume of distribution, V2/F = Apparent volume of distribution in the 1st peripheral compartment, V3/F = Apparent volume of distribution in the 2nd peripheral compartment. P5 and P95 are the 5th and 95t percentiles of the distribution

<div style=\"page-break-after: always\"></div>

For Study 301, exposure estimates, expressed as AUC180, were derived for each patient based on the protocol defined brigatinib dose of 180 mg (Table 4). AUC180 excluded effects of noncompliance or dose interruption due to tolerability.

Table 4: Summary statistics of post hoc steady state AUC

| Exposure          |   Min |   P5 |   Median |   Mean |   P95 |   Max |   Geometric mean |   CV % |   N |
|-------------------|-------|------|----------|--------|-------|-------|------------------|--------|-----|
| AUC180 (μg.hr/mL) |  6.06 | 10.1 |     20.9 |   23.8 |  44.8 |    77 |             21.2 |   53.4 | 121 |

Source: 006.AUC \\_plots.1

Abbreviation: AUC = area under the concentration-time curve

Note: AUCiso is the AUC calculated with post hoc clearance and a dose of 180 mg. P5 and P95 are the 5th and 95th percentiles;

In patients given brigatinib 180 mg once daily, the geometric mean apparent volume of distribution (Vz/F) of brigatinib at steady state was 307 L and the geometric mean apparent oral clearance (CL/F) at steady state was 8.9 L/h.

Table 5: Summary of Brigatinib PK Parameters at Steady-State (C2D1) for Daily Dosing (Study 101)

| Brigatinib Dose (mg)   | Statistic     | Cmax,SS (ng/mL)   | Tmax (4)   | C24 (ng/mL)   | AUC,SS (h·ng/mL)   | CLss/F (L/h)   | Vz/F (L)    | t1/2 (4)    | Accumulation Ratio   |
|------------------------|---------------|-------------------|------------|---------------|--------------------|----------------|-------------|-------------|----------------------|
| 180                    | N             | 63                | 63         | 63            | 63                 | 63             | 63          | 63          | 63                   |
|                        | Mean          | 1694.3            | 2.66       | 615.1         | 23478              | 10.04          | 356.1       | 24.90       | 2.057                |
|                        | GeometricMean | 1451.7            | 2.24       | 519.9         | 20276              | 8.878          | 306.6       | 23.94       | 2.017                |
|                        | SD            | 1014.3            | 1.46       | 408.3         | 14463              | 4.725          | 207.3       | 7.437       | 0.4323               |
|                        | Min           | 473.0             | 0.50       | 164           | 7468               | 2.07           | 83.9        | 13.6        | 1.42                 |
|                        | Median        | 1420.0            | 2.10       | 448.0         | 19230              | 9.360          | 306.0       | 23.90       | 1.990                |
|                        | Max           | 5440              | 6.2        | 2420          | 86970              | 24.1           | 1160        | 51.4        | 3.62                 |
|                        | CV(%)         | 59.9              | 55.0       | 66.4          | 61.6               | 47.1           | 58.2        | 29.9        | 21.0                 |
|                        | 95%CI         | 1438.9-1949.8     | 2.29-3.02  | 512.2-717.9   | 19835-27120        | 8.852-11.23    | 303.8-408.3 | 23.02-26.77 | 1.948-2.165          |

A prediction-corrected visual predictive checks (pcVPC) was performed where observations from Study 301 were overlaid onto model predictions based on 1000 replicate simulations. The pcVPC showed good agreement with a slight under prediction for median concentrations.

<!-- image -->

Source: 003.VPC.r

Note: Black dots are the observed data. Black lines from top to bottom are 97.5th percentile, median and 2.5th percentile of the Brigatinib PK profiles simulated from 1000 replicates

Figure 2: Prediction-corrected VPC vs time since last dose

<div style=\"page-break-after: always\"></div>

To assess the relative effects of covariates on brigatinib exposure in Study 301, post hoc stratification of calculated steady-state AUC following 180 mg doses was performed for covariates of interest and depicted in a Forest plot (Figure 3). Compared to the overall variability in exposure, the magnitude of effects at the 95th percentile and 5th percentile for continuous covariates or between strata of categorical covariates was not clinically meaningful.

<!-- image -->

Fold-change in AuC relative to reference population (9o%Cl)

Source:Study301PopPK/ERReport,Figure12.

Abbreviations:A,Asian;ALT,alanine aminotransferase;AST,aspartate aminotransferase;AUC,area under the concentrationtime curve; BILI, total bilirubin; eGFR, estimated glomerular filtration rate (mL/min/1.73 m²); F, female; M, male; med, median of the group; W, white; yr, years.

Note:Base, asrepresented by theblackvertical line and values,refersto the predicted AUC of brigatinib in atypical patient with baseline albumin of 41 g/dL. The black shaded bar with value at each end illustrates the 5t to 95t percentile exposure range represents the influence of a baseline albumin on exposure. The upper and lower values for the covariate baseline albumin albumin on brigatinib exposure.The lines above theblue-shaded bar represent the different groups for the covariates listed at the left.For continuous covariates,the 2dotsrepresent the ratio of exposure of95thpercentile covariatevs median and5th percentile Vsmedian.Forcategorical covariate,dotsrepresent theratioofexposure ofthecategoriesvsthereferencecategory.The horizontal bars on 2 sides of the dots represent the corresponding 90%confidence interval.

Figure 3: Brigatinib exposure following 180 mg dose of brigatinib stratified by covariates of interest

## 2.3.3. PK/PD modelling

## Exposure-Response analysis

Only data from Study 301 were used in this evaluation. The primary objective of these ER analyses was to evaluate the relationship between brigatinib exposure and clinical efficacy endpoints, selected adverse events (AEs) of clinical interest, and the time to first dose reduction. The exposure-response analysis related reported efficacy outcomes to individual predicted exposures (and other covariates) based on logistic regression or time-to-event models. Only patients assigned to the brigatinib regimen with both PK and response information were included in the analysis. Of the 137 patients enrolled in the brigatinib arm, 16 patients were excluded due to the lack of exposure data, resulting in 121 patients with available post hoc exposure estimates. Exposure endpoints were merged with the efficacy and safety outcomes and with covariate data to construct the analysis dataset.

<div style=\"page-break-after: always\"></div>

Table 6: Overview of patients in the analysis populations

| exposulre-responseendpoint   |   Brigatinibtreatment NITT=137/NiCNS=43 |   Crizotinibtreatment NITT=138/NiCNS=47 |
|------------------------------|-----------------------------------------|-----------------------------------------|
| Efficacy - PFS 1             |                                     121 |                                     133 |
| Efficacy - iPFS 2            |                                      42 |                                      46 |
| Efficacy - ORR 1             |                                     121 |                                     135 |
| Efficacy-iORR 2              |                                      42 |                                      46 |
| Safety 3                     |                                     121 |                                     137 |

Abbreviations: IIT = intent-to-treat, iORR = intracranial confirmed objective response rate, iPFS = intracranial progression-free survival, ORR = confirmed objective response rate, PFS = progression-free survival

1: based on ITT population; 2: based on AlliCNS population; 3: based on TRT population; 4. Data from patients assigned to the crizotinib treatment arm was only summarized and included on plots and tables as a separate, independent category.

## For exposure-efficacy analysis , the following time-averaged AUCs were considered:

1. Time-averaged exposure between the last 2 disease assessment scans preceding PFS, iPFS, ORR or iORR or censoring and a dynamic time-averaged AUC between successive disease assessment scans preceding the event or censoring for PFS and iPFS.
2. Time-averaged AUC until progression
3. Time-averaged AUC to the best response
4. In case of no response, time-averaged AUC until censoring (end of treatment)
5. Daily AUC was based on the cumulative AUC to day i

A Cox proportional hazard model was used to estimate the relationship between exposure and PFS/iPFS. First, a base model was developed to assess the relationship between brigatinib exposure and PFS. If exposure was found to be a significant predictor of PFS, a covariate model was developed. The exposure to  brigatinib  was  characterized  using  a  time-dependent  covariate  in  the  (i)PFS  model.  Kaplan-Meier curves were constructed to visually evaluate the association between quartiles/tertiles of the exposure distribution and PFS/iPFS outcomes. Logistic regression models were used to explore the relationship between exposure and ORR/iORR. For ORR and iORR, each patient was classified as a responder (as defined by CR or PR) or a non-responder. If the ORR or iORR occurred more than once, the time to the first occurrence of the best response was used in the exposure-response analyses. A base model was developed to assess the relationship between exposure and the probability of the first confirmed best clinical  response.  If  brigatinib  exposure  was  not  identified  as  a  statistically  significant  predictor  of response (at p = 0.05), additional covariate analysis was not performed and the final model was identical to the base model.

The developed exposure-response models were evaluated by graphically superposing model predictions on the observed data. Logistic regression models (clinical response, AE) were evaluated by plots showing the  model-predicted  response  compared  to  observations  stratified  by  (binned)  exposure  and  other covariates. Time-to-event models (PFS, time to first dose reduction) were evaluated by plotting KM curves stratified by brigatinib exposure quartiles.

Handling  of  missing  and  incomplete  observations:  If  the  time  of  sample  collection  or  response observation was missing, the data record was excluded from analysis. If dose times were missing, they were imputed carrying forward the last known dose time. Missed doses were not imputed.

<div style=\"page-break-after: always\"></div>

Table 7: Cox PH models for PFS and iPFS based on brigatinib exposure (TASCANPROG for PFS and TASCANIPROG for iPFS)

| Exposure                                                                                                     | Endpoint [N (events)]   | Coefficient (SE)   | HazardRatio (95% CI)   |   P value |
|--------------------------------------------------------------------------------------------------------------|-------------------------|--------------------|------------------------|-----------|
| Brigatinibtime-averaged exposurebetweenlast 2 disease assessment scans preceding event/censoring(TASCANPROG) | PFS [121 (32)]          | 0.028 (0.013)      | 1.028 (1.001, 1.056)   |      0.06 |
| Brigatinib time-averaged exposure between last 2diseaseassessmentscanspreceding event/censoring(TASCANIPROG) | iPFS [42 (11)]          | -0.017 (0.04)      | 0.983 (0.909, 1.063)   |      0.66 |

Abbreviations: PH = Proportional hazards, PFS = Progression free survival, iPFS = Intracranial Progression free survival, TASCANPROG, TASCANIPROG = time-averaged AUC between last 2 disease assessment scans preceding progression or censoring.

Additional  exposure  metrics  including  dynamic  exposure  metrics  (i.e.,  the  dynamic  daily  AUC  and dynamic AUC between successive disease assessment scans) were evaluated and further supported the findings.

<!-- image -->

Source: tgrd-120-er-efficacy-20180712.R

Abbreviations:

Note: Dotted curves represent the 95% CI of the logistic regression model prediction. The horizontal blacl line separated by vertical black solid lines denotes brigatinib exposure range in each quartile (ORR) and tertile (iORR). Black dots (vertical lines) represent the observed proportion of patients (95% CI) in each quartile (ORR) and tertile (iORR). N/N is the number of patients with events/total number of patients in each quartile (ORR) and tertile (iORR). Grey open circles represent observed individual data. TASCANBR/TASCANIBR = time-averaged AUC between last two disease assessment scans preceding confirmed best response.

Figure 4: Observed incidence and predicted probability of ORR (left) or iORR (right) as a function of brigatinib exposure (TASCANBR for ORR and TASCANIBR for iORR) using a logistic regression model

Brigatinib exposure was not a predictor for the confirmed objective response rate (ORR) based on the results from the logistic regression analysis. The results of the logistic regression analysis showed a relationship between brigatinib exposure and iORR with higher exposure associated with higher incidence of intracranial response. Additional covariate analysis was performed only on the iORR logistic regression model and the covariates tested were not found to have a statistically significant impact on the iORR, while the exposure effect remained statistically significant.

<div style=\"page-break-after: always\"></div>

Table 8: Estimated odds ratio (95% CI) for the exposure-clinical response (ORR and iORR) analysis

|       | OddsRatio           |   pvalue |
|-------|---------------------|----------|
| ORRb  | 0.973 (0.936.1.011) |   0.152  |
| iORRb | 1.131 (1.023,1.284) |   0.0305 |

Source:tgrd-120-er-efficacy-20180712.R

Abbreviations: ORR = Objective response rate, iORR = Intracranial objective response rate

Not: Clinical response = responders defined by confirmed (intracranial) complete response or (intracranial) partialresponse

a Estimated odds ratio corresponding to an increase in brigatinib exposure of 1 μg.h/mL/day

b Underlying exposure for ORR and iORR is respectively TASCANBR and TASCANIBR (time averaged AUC between the last 2 disease assessment scans preceding the confirmed best response).

Exposure-response analyses were performed based on data from the second interim analysis of Study 301 (data cutoff date of 28 June 2019). The results of these analyses are described in an updated population PK/exposure-response report.

In the updated exposure-efficacy analyses, a statistically significant (p-value = 0.0486) relationship was identified between brigatinib exposure and iORR, with higher exposure associated with higher iORR (Figure 5).

<!-- image -->

Time-averagedAuCbetweenlasttwoscans(ug.h/mL/day)

Source: Study 301 IA2 Population PK/Exposure-Response Report Figure 14.

Abbreviations: CI, confidence interval; iORR, intracranial objective response rate.

Dotted curves represent the 95% confidence interval of the logistic regression model prediction. The horizontal black line separated by vertical black solid lines denotes the brigatinib exposure range in each tertile. Black dots (vertical lines) represent the observed proportion of patients (95% confidence interval) in each exposure tertile. N/N is the number of patients with events/total number of patients in each exposure tertile. Grey open circles represent observed individual data.

Figure 5: Observed incidence and predicted probability of iORR as a function of brigatinib exposure using a logistic regression model

For exposure-safety analysis , the following exposure metrics were derived:

1. Time-averaged AUC [TAX] until an AE event or until first brigatinib dose reduction
2. In case of no event, TAX until end of treatment of censoring
3. Averaged daily AUC across Days 8 to 14, based on the daily AUC simulations

<div style=\"page-break-after: always\"></div>

Logistic regression models were used to explore the relationship  between exposure and incidence of Grade ≥ 3 and Grade ≥ 2 events of interest. If the AE, occurred more than once, the time to the first occurrence of AE was used in the exposure-response analyses.

Eleven safety endpoints were planned with five endpoints ≥ Grade 3 and six endpoints ≥ Grade 2. Given that three endpoints ≥ Grade 3 (ALT, AST and amylase elevations) had AE rates of less than 6%, ≥ Grade 2 of those endpoints were added for the analysis. Any AE ≥ Grade 3 (CPK, AST, ALT, amylase, lipase elevations  as  well  as  hyperglycaemia,  hypertension,  bradycardia  and  rash)  was  also  added  to  the analysis.

The probability of response (AEs) vs TAX was plotted, with probabilities calculated across sets of patients binned by exposure quartile. The relationship between time-averaged exposure and the probability of developing an AE was examined using the same logistic regression model and covariate analysis methods as for the exposure-clinical response analyses. Results of the comprehensive exposure-response analysis of 15 safety endpoints are presented in the following table:

Table 9: Estimated odds ratio (95% CI) for the exposure-safety analysis of AEs

|                           | Odds Ratio a         |   p-value |
|---------------------------|----------------------|-----------|
| CPK (≥ Grade 3)           | 0.975 (0.919; 1.021) |     0.335 |
| AST (≥ Grade 3)           | 1.022 (0.878; 1.116) |     0.685 |
| ALT (≥ Grade 3)           | 1.022 (0.878; 1.116) |     0.685 |
| Amylase (≥ Grade 3)       | 0.985 (0.892; 1.054) |     0.723 |
| Lipase (≥ Grade 3)        | 1.019 (0.971; 1.064) |     0.397 |
| Any AE (≥ Grade 3)        | 0.976 (0.936; 1.013) |     0.22  |
| Hyperglycemia (≥ Grade 2) | 1.027 (0.887; 1.119) |     0.614 |
| Hypertension (≥ Grade 2)  | 1.000 (0.957; 1.039) |     0.985 |
| Bradycardia (≥ Grade 2)   | 0.890 (0.63; 1.062)  |     0.388 |
| Rash (≥ Grade 2)          | 1.009 (0.913; 1.078) |     0.833 |
| AST (≥ Grade 2)           | 1.024 (0.938; 1.09)  |     0.501 |
| ALT (≥ Grade 2)           | 0.982 (0.909; 1.04)  |     0.602 |
| Amylase (≥ Grade 2)       | 0.996 (0.925; 1.053) |     0.912 |

Source EDA-safety.r

Abbreviations: AE = adverse event, CPK = creatine phosphokinase, AST = aspartate transaminase, ALT = alanine aminotransferase

Note: Any AE included CPK, AST, ALT, amylase, lipase, hyperglycemia, hypertension, bradycardia, rash. Estimated odds ratio corresponding to an increase in brigatinib exposure of 1 μg.h/mL/day.

## Exposure-response analysis for dose reduction

The exposure effect on dose reduction was evaluated by Kaplan Meier plots, see figure below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Numbers atrisk

TAX=time-averagedAUC to thefirst occurrenceof dosereduction

Source:TGRD-CSC-120\\_ER-EFFSAF\\_ANALY\\_20180712.R

Figure 6: Kaplan-Meier estimates for time to first brigatinib dose reduction grouped by brigatinib TAX quartiles and compared to crizotinib

## 2.3.4. Discussion on clinical pharmacology

Overall, the bioanalysis of samples from study 301 was acceptable. Methodologically, the pharmacokinetic and pharmacodynamic modelling were considered acceptable.

Individual parameter values for patients in Study 301 were estimated based on the previously developed population PK model (a 3-compartment model with linear kinetics and first-order absorption preceded by a set of transit compartments). Concentration data &lt;LLOQ were not included. The model parameters were fixed while the random effects (Eta values) were estimated for each individual based on data from Study 301. The GoF plots were acceptable. The pcVPC after 1000 replicates showed the model could capture the trend of data from study 301 with a slight underestimation and was regarded as an external validation of the final population PK model. The under prediction is minor and not considered critical for the subsequent E-R analyses.

Comparison of PK parameters derived for Study 201 and 301 showed good agreement.

Individual patient dosing histories contributed to estimation of individual PK parameters e.g. apparent CL, therefore AUCss could be derived without any additional consideration of non-compliance or dose interruption. No formal covariate analysis was performed. The impact of each covariate on the steady state AUC of brigatinib after 180 mg QD dosing was evaluated and the effect compared to the variability of the study population. No clinically relevant effects of covariates: age, body weight, sex, race, liver function and renal function on brigatinib exposure was observed.  The inter individual variability was also rather high for the parameter estimates in the final model with high shrinkage on MTT and NTR. The variability in predicted exposure for study 301, AUC180 was large (CV% 53.4), but within the variability observed for AUC at steady-state following 180 mg QD dosing in patients (PK Study 101, AUC C2D1, CV% 61.6).

<div style=\"page-break-after: always\"></div>

No  clear  trend  in  the  relationship  between  exposure  to  brigatinib  and  progression  of  disease  was observed. There was no significant relationship identified between brigatinib exposure and PFS, iPFS or ORR. Therefore, the effect of covariates on (i)PFS and ORR were not evaluated. However, a statistically significant relationship (p=0.0305) was identified between brigatinib exposure and iORR, with higher exposure associated with a higher iORR.

The  MAH  performed  an  additional  logistic  regression  model  with  covariates  for  iORR  but  no  other covariates  were  found  to  be  statistically  significant.    The  MAH  submitted  an  update  of  Pop  PK  and exposure-response analysis showing a statistically significant relation (p=0.0486) between iORR and exposure expressed as time-averaged AUC.

Despite the low number of events for most of the individual endpoints, the comprehensive exposureresponse analysis of 15 safety endpoints provided a robust assessment of exposure effects on selected safety endpoints and showed a consistent absence of discernible exposure effects.

The recommended dose of brigatinib for the treatment of ALK+ NSCLC in the post-crizotinib setting is 90 mg QD for 7 days followed by 180 mg QD based on the favourable benefit-risk profile established in Study 201. The results of the Pop PK analysis of Study 301 in the frontline treatment setting in patients not  previously  treated  with  an  ALK  inhibitor  support  consistency  in  systemic  exposures  with  those observed  previously  in  the  Study  201  patient  population.  No  new  or  clinically  relevant  sources  of variability were observed upon inspection of the distributions of brigatinib systemic exposure in the Study 301 patient population stratified by key covariates. As such, from a PK perspective, these results support the  use  of  the  same  dose  of  brigatinib  in  the  frontline  patient  population  as  in  the  post-crizotinib treatment setting.

With the exception of an ER relationship for intracranial response rate (iORR) further supporting selection of  the  180  mg dose (preceded by dosing at 90 mg for 1 week), the exposure-efficacy analyses for PFS/iPFS and ORR did not identify any discernible relationships, indicating consistent treatment benefit of brigatinib over the range of exposures achieved at the dose and regimen used in Study 301 (see also Clinical efficacy). The incidences of most AEs of clinical interest (Grade ≥ 2 or Grade ≥ 3) were relatively low and no relationships to systemic exposures of brigatinib could be discerned in the exposure-safety analyses. (see also Clinical safety section)

As the proposed dose and regimen for frontline treatment is identical to that in the post-crizotinib setting and no readily apparent differences in PK are observed between these populations based on PopPK analysis, the MAH proposed that dosing and administration guidelines across specific clinical contexts of use (e.g., in patients with renal or hepatic impairment, or during coadministration with interacting drugs) for the current proposed indication are identical to those applicable in these respective clinical contexts of use in the post-crizotinib setting.

## 2.3.5. Conclusions on clinical pharmacology

Exposure-response analyses of efficacy and safety in the Study 301 population supported the proposed dosing regimen.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Study 201 (AP26113-13-201; ALTA): a phase 2 study in advanced ALK+ NSCLC patients who progressed on or were intolerant to crizotinib; ongoing (global). Data from the 201 study were assessed in the initial approval of brigatinib, so only the safety data is considered in this AR.

## 2.4.2. Main study

Study AP26113-13-301: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer

## Methods

<!-- image -->

Abbreviations: ALK+, anaplastic lymphoma kinase positive;  BID, twice  daily; BIRC, blinded  independent  review committee; HR,  hazard  ratio; iCNS, intracranial central nervous system; MRI, magnetic resonance imaging; NSCLC, non-small-cell lung cancer; PD, progressive disease; PFS, progression-free survival; QD, once daily; R, randomization; RECIST; Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor; y/n, yes/no.

Disease assessments (including brain MRI for all patients) occurred every 8 weeks.

a  Crossover to brigatinib was allowed for patients randomized to crizotinib (Arm B) after documentation of BIRC-assessed progression.

Figure 7: Study 301: Phase 3, Randomized Study in TKI-Naïve ALK+ NSCLC

## Study participants

## Key Inclusion Criteria

All patients were required to meet all the following eligibility criteria for study entry:

- Had histologically or cytologically confirmed Stage IIIB (locally advanced or recurrent and was not a candidate for definitive multimodality therapy) or Stage IV NSCLC.
- Met one of the following criteria: -Documented ALK rearrangement by a positive result from the Vysis ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit (Abbott Molecular) or the Ventana ALK (D5F3) companion diagnostic assay. The test had to be performed according to the product's instructions for use. -Documented ALK rearrangement by a different test and adequate tissue available for central laboratory testing  by  an  FDA-approved  test.  Confirmation  of  central  test  positivity  was  not  required  before randomization. · Had a least 1 measurable (i.e., target) lesion per Response Evaluation Criteria in Solid Tumors (RECIST)
- v1.1.

<div style=\"page-break-after: always\"></div>

## Key Exclusion Criteria

- Patients meeting any of the criteria below were ineligible for the study: · Received a prior investigational antineoplastic agent for NSCLC. · Previously received any prior TKI, including ALK -targeted TKIs. ·  Previously  received  more  than  1  regimen  of  systemic  anticancer  therapy  for  locally  advanced  or metastatic disease. · Had major surgery within 30 days of the first dose of study drug. · Had symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease  requiring  an  increasing  dose  of  corticosteroids  to  control  symptoms  within  7  days  before randomization. -related  pneumonitis,  or  radiation
-  Presence  or  history  of  pulmonary  interstitial  disease,  drug pneumonitis.

## Treatments

Brigatinib was administered as oral tablets at a dose of 180 mg QD after a 7-day lead-in at 90 mg QD. The treatment regimen for brigatinib is denoted as 90 mg QD → 180 mg QD throughout this document. Crizotinib was administered as oral gelatine capsules at the approved dose of 250 mg twice daily (BID).

## Objectives

## Primary Objective

To compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic NSCLC patients naive to ALK inhibitors, as evidenced by PFS.

## Secondary Objectives

The secondary objectives of the study are:

1.  To  compare  the  efficacy  of  brigatinib  to  that  of  crizotinib,  as  evidenced  by  confirmed  ORR,  time to/duration of response, disease control rate (DCR), and OS.
2. To compare the efficacy in the CNS of brigatinib to that of crizotinib, as evidenced by intracranial response and intracranial PFS in those patients with intracranial CNS (iCNS) metastases at baseline.
3. To assess the safety and tolerability of brigatinib in comparison with crizotinib.
4. To determine pharmacokinetic (PK) parameters of brigatinib through population PK modelling.
5. To assess patient-reported symptoms and health-related quality of life (HRQoL) with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 (version 3.0) and its lung cancer module, QLQ-LC13 (version 3.0) in patients treated with brigatinib compared to those treated with crizotinib.

<div style=\"page-break-after: always\"></div>

## Exploratory Objectives

The exploratory objectives of the study are:

1. To assess confirmed ORR on brigatinib in patients who cross over to brigatinib from arm B (crizotinib); and to assess PFS, from the first dose of brigatinib, in patients who cross over to brigatinib from arm B.
2. To explore relationship of brigatinib exposure with both efficacy and safety.
3. To explore molecular determinants of efficacy and safety for brigatinib and crizotinib.

## Outcomes/endpoints

## Primary Endpoint

The primary endpoint for this study is PFS, as assessed by the BIRC, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. A PFS event in the primary analysis is defined as death, BIRC-determined RECIST progression or receiving radiotherapy for CNS metastases. Radiological scans for the assessment of  disease  progression  and  tumor  response  were  scheduled  to  be  performed  every  8  weeks,  and unscheduled scans could be performed at other times.

## Secondary Endpoints

1. Confirmed ORR, as assessed by the BIRC, per RECIST v1.1
2. Confirmed intracranial ORR, as assessed by the BIRC
3. Intracranial PFS, as assessed by the BIRC
4. OS

The first four endpoints above will be evaluated in a closed testing procedure.

5. Duration of response, as assessed by the BIRC
6. Time to response, as assessed by the BIRC
7. Disease control rate, as assessed by the BIRC
8. Safety and tolerability
9. Change from baseline scores in global health status/quality of life (QOL) assessed with the EORTC QLQ-C30 (v3.0), and time-to-deterioration in dyspnea assessed with the EORTC QLQ-LC13 (v3.0)

## Exploratory Endpoints

1. Confirmed ORR for brigatinib, as assessed by the BIRC, per RECIST v1.1, in patients who crossover from Arm B (crizotinib)
2. PFS from the first dose of brigatinib, as assessed by the BIRC, per RECIST v1.1, in patients who crossover from Arm B (crizotinib)
3. Correlation of brigatinib plasma pharmacokinetics with both efficacy and safety
4. Molecular determinants of efficacy and safety with brigatinib and crizotinib

<div style=\"page-break-after: always\"></div>

## Sample size

For the purposes of this sample size calculation, the median PFS for crizotinib is estimated as 10 months. A total of 198 events (progression or death among the randomized subjects) will provide 90% power to detect a clinically meaningful 6-month improvement in PFS (hazard ratio=0.625). This power projection is  based  on  a  2-sided  log-rank  test,  and  is  controlled  at  the  2-sided  0.043  level,  adjusting  for  the proposed interim analysis plan. Approximately 270 subjects will be randomized in a 1:1 fashion to receive brigatinib or crizotinib.

The number of events is fixed, but the enrolment number may change based on an assessment of the overall event rate pooled across treatment groups (prior to the close of enrolment).

## Randomisation

Patients will be randomized in a 1:1 ratio to receive either brigatinib 90 mg once daily (QD) orally for 7 days followed by 180 mg QD orally continuously (Arm A) or crizotinib 250 mg twice daily (BID) orally (Arm B). Patients will be stratified by the following two factors, each having two levels:

1. Intracranial CNS (iCNS) metastases at baseline (Yes versus No)

2. Prior chemotherapy use for locally advanced or metastatic disease (Yes versus No). For the purposes of stratification, prior chemotherapy is defined as completion of ≥ 1 full cycle of chemotherapy in the locally advanced or metastatic setting.

## Blinding (masking)

This study was unblinded to patients, investigators and the sponsor.

Images from all scans performed from screening through the end of study participation were transferred to the BIRC and evaluated per RECIST v1.1.; validity of the findings of the BIRC was enhanced by using two  primary  readers  supported  by  an  adjudicator.  All  members  of  the  BIRC  were  blinded  to  study treatment and any other information collected on subjects following randomization other than the scans themselves.

## Statistical methods

## Analysis Populations

Intent -to-Treat (ITT) Population: The ITT population includes all subjects randomized to either regimen. The primary analyses of efficacy will be based on the ITT population.

Treated Population: The treated population for each regimen includes all subjects receiving at least one dose of study drug. Safety will be analysed using the treated population.

Per-protocol Population: The per-protocol population will be used for sensitivity analyses in order to characterize the effects of the two treatment regimens when used as intended according to the study protocol.  Considerations  for  inclusion  include  consistency  with  the  intended  treatment  population, adequate exposure to randomized treatment regimen, and sufficient post-exposure disease assessment to determine presence or absence of progressive disease.

<div style=\"page-break-after: always\"></div>

FDA-Approved ALK Test Population: A sensitivity analysis of the primary endpoint will be performed in the 'FDA approved ALK test population'. This population will consist of all subjects in the ITT population who also meet one of the two following criteria: 1) Were determined to be ALK+ by one of the tests identified in Inclusion Criteria; 2) Provided adequate tissue for central testing and were determined to be ALK+ at the central laboratory by the FDA-approved test.

## PFS

The primary analysis of the primary endpoint will be performed using a 2-sided stratified logrank test (stratification factors: presence of CNS metastases at baseline [Yes versus No], and prior chemotherapy for  locally  advanced  or  metastatic  disease  [Yes  versus  No])  to  compare  the  BIRC-assessed  PFS  of subjects randomized to brigatinib with the BIRC-assessed PFS of subjects randomized to crizotinib. The overall (2-sided) Type I error rate will be controlled at 0.05. The primary analysis will be based on the ITT population. Median PFS and 95% confidence intervals will be estimated for each treatment arm using the Kaplan-Meier method. Additionally, hazard ratios will be estimated using the Cox regression model with the stratification factors as covariates. The analysis will use the current values of the stratification factors.

Table 10: The Scheme of Progression and Censoring for the Analysis of PFS (SAP Version 4)

|   #Rule | Situation                                                                      | Date of progression or censoring                                                         | Outcome    |
|---------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------|
|       1 | Missing or incomplete baseline                                                 | Day 1 (randomization date)                                                               | Censored   |
|       2 | tumor assessment No valid post-exposure assessment                             | Day 1 (randomization date)                                                               | Censored   |
|       3 | No measurable disease at baseline                                              | Date of new lesion(s) or substantial worsening in non-                                   | Progressed |
|       3 | No measurable disease at baseline                                              | target disease Date of last evaluable progression-free radiographic                      | Censored   |
|       4 | a) Death, PD, or non-PD observed > 126 days after                              | assessment Date of last evaluable progression-free radiographic assessment               | Censored   |
|       4 | last valid RECIST assessment b) Death or PD ≤ 126 days after last valid RECIST | prior to the 126-day interval Earliest of date of death and date of 1 st PD              | Progressed |
|       5 | assessment No progression or death                                             | Date of last evaluable progression-free radiographic                                     | Censored   |
|       6 | Death before first PD assessment or between                                    | assessment Date of death                                                                 | Progressed |
|       7 | adequate assessment visits Death after one missed                              | Handled according to rule #4                                                             |            |
|       8 | radiographic assessment Death after two or more missed radiographic            | Handled according to rule #4                                                             |            |
|       9 | assessments New anticancer treatment started prior to PFS event                | Date of last evaluable progression-free radiographic assessment prior to initiation of   | Censored   |
|      10 | Cancer-related surgery prior to documented disease                             | new anticancer treatment Date of last evaluable progression-free radiographic assessment | Censored   |
|      11 | progression Disease progression documented between scheduled visits            | prior to surgery Date of progression as reported by BIRC                                 | Progressed |
|      12 | Disease progression preceded by 1 missed follow-up                             | Handled according to rule #4                                                             |            |
|      13 | disease assessment Disease progression preceded by 2 or more consecutive       | Handled according to rule #4                                                             |            |

missed follow-up disease assessments Note:   Evaluable radiographic assessments used for censoring dates are restricted to BIRC assessments and exclude those by iCNS BIRC and investigator.

<div style=\"page-break-after: always\"></div>

Sensitivity analyses Sensitivity Analysis 1 -Censor at date of last treatment administration if PFS event not observed prior to the End of Treatment Visit. Other censoring rules from the primary analysis of PFS remain in effect. Sensitivity Analysis 2 -Do not censor PFS events for reasons of time lapse from last assessment (i.e., no 126-day rule) or usage of disallowed therapies. Each sensitivity analysis is targeted at specific changes to the rules for the primary analysis, and any rules not specified in the sensitivity analysis will remain as specified in the primary analysis. Confirmed ORR, as assessed by the BIRC, per RECIST v1.1 ORR will be calculated using the following formula: ORR per BIRC = (#confirmed BIRC-based CR or PR) / (#Randomized subjects)*100%. Sensitivity analyses of this endpoint using different analysis populations will be calculated in the same manner  after  first  restricting  subjects  included  in  the  denominator  and  eligible  for  inclusion  in  the numerator to those in the analysis population of interest. Confirmed ORR will be analyzed with the Mantel-Haenszel test (using the stratification factors) on the ITT  population  to  compare  the  proportion  of  subjects  achieving  objective  response  between  the  2 treatment arms. The exact 2-sided 95% binomial confidence intervals will be calculated. Any subjects who are identified as having only non-measurable disease at baseline by one of these assessment  mechanisms  (BIRC  or  investigator  assessment)  will  not  be  eligible  to  be  counted  as responders (i.e. overall response of PR or CR) in analyses of results assessed by that mechanism, unless their overall response is CR. Sensitivity analyses to be performed on this endpoint will be:

- 1) ORR defined as all confirmed and unconfirmed responses as determined by BIRC
- 2) Confirmed ORR as determined by the investigator
- 3) ORR defined as all confirmed and unconfirmed responses as determined by the investigator

## Confirmed intracranial ORR, as assessed by the BIRC

iCNS ORR will be calculated in the same manner as for RECIST v1.1 BIRC using confirmed time point responses  from  the  iCNS  BIRC.  Confirmed  iCNS  ORR  will  be  analyzed  for  the  following  subsets  of subjects:

- 1) The measurable iCNS disease population
- 2) The non-measurable iCNS disease population
- 3) The all iCNS disease population

Each of these analyses will be accompanied by a sensitivity analysis restricted to the subset of subjects with active lesions at baseline. Responses of iCNS CR in subjects with non-measurable iCNS disease at baseline will be counted as time point responses in analyses of iCNS ORR. Analysis will differ in that the iCNS ORR will be analyzed with the Mantel-Haenszel test using only the stratification factor of prior chemotherapy. A sensitivity analysis of confirmed + unconfirmed iCNS ORR will be performed.

<div style=\"page-break-after: always\"></div>

## Intracranial PFS, as assessed by the BIRC

Intracranial PFS will be defined and analyzed in the same manner as for PFS used in the primary endpoint with the exceptions that the progression events used will come from the iCNS BIRC and the analysis will be restricted to subjects identified as having brain metastases at baseline in the randomization.

The primary evaluation of iCNS PFS will be performed in the all iCNS disease population, with a sensitivity analysis in the active iCNS disease population. Additional analyses will be performed in the no iCNS disease  population,  in  which  case  PFS  events  would  consist  of  either  the  appearance  of  new  brain metastases or death. iCNS PFS will also be analyzed in the measurable iCNS disease population with a sensitivity analysis in the active measurable iCNS disease population.

Conduct and analysis of iCNS response and progression will occur independently of systemic assessment of disease. If a subject progresses due to lesions outside the iCNS and continues on their randomized study treatment, the subject will continue to be evaluated as SD, PR, or CR in the iCNS until disease progression in the iCNS or the subject discontinues randomized study treatment. Confirmation of CR or PR should be performed 4 weeks (allowing a minus 3-day window) or more after initial response.

## OS

OS is defined as the time interval from the date of randomization until death due to any cause in the ITT population. OS will be censored on the date of last contact for subjects who are still alive. In the primary analysis  of  OS  follow-up  time  will  not  be  censored  for  initiation  of  non-study  anticancer  therapies, including crossover from crizotinib to brigatinib.

The primary analysis of OS will be conducted using the same statistical methods as for the primary endpoint.  Follow-up  time  in  the  primary  analysis  of  OS  will  not  be  censored  for  any  other  reason. Sensitivity analyses using additional censoring rules such as initiation of disallowed anticancer therapies may be performed. For subjects who have been randomized and are not treated, the OS will be defined as the time interval from randomization date to death date or date of the last contact, if available.

## Overall type I error rate for secondary endpoints

The overall type I error rate was set at 0.05. Analysis of a key secondary endpoint will be considered significant if the test for that endpoint and comparisons of all other secondary endpoints with a smaller rank are significant at the two-sided 0.05 significance level. Rank-ordering of key secondary endpoints:

1. Confirmed ORR, as assessed by the BIRC, per RECIST v1.1
2. Confirmed intracranial ORR, as assessed by the BIRC
3. Intracranial PFS, as assessed by the BIRC
4. OS

The primary assessment of the first three endpoints above will be performed at the time when the assessment of the primary endpoint is completed, either when the efficacy boundary is surpassed on one of the interim analyses or at the time the final analysis is done.

The primary assessment of OS will be performed when 198 PFS events to perform the final analysis of the primary endpoint have been observed, or at final database lock if the study is terminated prior to this occurs prior to the observation of 198 PFS events.

## Interim analysis

<div style=\"page-break-after: always\"></div>

Two  interim  analyses  are  planned  after  approximately  50%  and  75%  of  the  total  expected  events (progression or death) have been o bserved. An O'Brien -Fleming Lan-DeMets alpha spending function will be used to control the overall alpha level at 0.05 2-sided.

## Amendments to the statistical analysis plan

Version 3 update was made on March 27, 2018, in which substantive changes were made:

- formal statistical inference will be completed at the first successful evaluation of the primary endpoint.
- Analysis of ORR using BIRC or investigator assessments will treat all subjects assessed as having non-measurable disease at baseline as non-responders.
- The definition of DCR was modified to state that single responses of CR and non-CR/non-PD in subjects with non-measurable disease at baseline will be eligible to contribute to disease control.
- The definition of the Measurable iCNS disease population was changed from being a subset of the ITT population to being a subset of the all iCNS disease population
- Censoring for anticancer therapies recorded during safety follow up will occur as of the date of contact at which the first occurrence of therapy is noted
- The  definition  of  time  to  response  analyses  was  simplified  to  the  presentation  of  summary statistics restricted to responders. Time to event models and figures were eliminated.

Version 4 update was made to this plan on August 19, 2019, which included the following:

- Based on Intent-to-Treat Principle, subjects who were randomized but did not take any study treatment should be analyzed the same way as any other randomized subjects. Therefore, censoring rule for PFS and DOR were modified as below:

The following sentence was removed:

'Randomized subjects who did not receive any of their assigned study drug wi ll be censored at followup Day1.'

The corresponding censoring rule was removed. As a result of this change, subjects who were randomized but untreated will be analyzed based on the remaining progression and censoring. This change applies to the analysis of Duration of Response (DOR), intracranial Progression-free Survival (iPFS), and intracranial Duration of Response (iDOR) as well.

- Based on RECIST criteria v1.1, subjects who only had non-measurable disease at baseline should be counted as a responder if they had an overall response of CR:

'Any subjects who are identifie d as having only non-measurable disease at baseline by one of these assessment mechanisms (BIRC or investigator assessment) will not be eligible to be counted as responders (i.e. overall response of PR or CR) in analysis of results assessed by that mechani sm, unless explicitly stated is exploratory analysis'

## was changed to

'Any subjects who are identified as having only non -measurable disease at baseline by one of these assessment mechanisms (BIRC or investigator assessment) will not be eligible to be counted as responders (i.e. overall response of PR or CR) in analyses of results assessed by that mechanism, unless their overall response is CR.'

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

Source: Study 301 Table 15.1.3 (data cutoff: 19 February 2018).

Abbreviations: AE, adverse event; ITT, intent-to-treat; RECIST, Response Evaluation Criteria in Solid Tumors.

In this study, a total of 311 patients were screened, which led to the inclusion of 275 patients in the ITT population.

## Recruitment

The ALTA 1L study was fully recruited in 14 months and last patient first dose was in August 2017, hence, the median follow-up was initially less than a year. However, the MAH have provided updated data with 24.9 months of follow-up and data cut-off 28 June 2019.

Patients were randomized at 92 study sites in the following regions:

- 143 patients at 55 sites in Europe (Austria, Denmark, France, Germany, Italy, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom);
- 107 patients at 24 sites in the Asia Pacific region (Australia, Hong Kong, Taiwan, Singapore, and South Korea), and
- 25 patients at 13 sites in North America (US and Canada).

<div style=\"page-break-after: always\"></div>

## Conduct of the study

## Protocol amendments

The original protocol (dated 22 October 2015) was amended once, i.e. Protocol Amendment 1 (Dated 21 September 2016).

The following key changes were made in Protocol Amendment 1:

- The EORTC QLQ-LC13 was added as a QoL assessment. Additionally, clarification  was made about signs and symptoms of the QoL assessments and when they will be considered AEs.
- The  required  duration  for  contraceptive  use  after  the  end  of  treatment  with  crizotinib  was amended to be both during the dosing period and for a period of at least 4 months after the end of treatment with brigatinib, and at least 3 months after the end of treatment with crizotinib. This was changed to be consistent with the crizotinib SmPC.
- The definition of highly effective contraception to be used during and after the study was added.
- Wording was amended regarding possible additional drug-drug interactions with crizotinib and the  possibility  that  the  effectiveness  of  oral  contraceptives  may  be  reduced  while  taking crizotinib.
- Investigator guidance for monitoring signs of vision dysfunction and worsening vision disorders was  modified  to  include  brigatinib  in  the  guidance  for  crizotinib,  to  be  consistent  with  the crizotinib SmPC,  and  to specify that for new  or worsening severe vision disorders, ophthalmological evaluation consisting of best corrected visual acuity, retinal photographs, visual fields, optical coherence tomography, and other evaluations should be performed.
- Text  regarding  management  of  additional  selected  treatment-related  AEs  was  modified  to provide guidance on the management of visual disturbance during treatment with brigatinib.
- A clarification was made that patients will continue to receive study drug until discontinuation, as opposed to being transitioned to commercially available brigatinib as stated in the original protocol.
- The timing of the following study procedures was clarified:

-Imaging by CT or MRI should continue until the end of treatment, rather than PD, as some patients may remain on treatment after PD.

-Additional  pregnancy  testing  should  be  performed  if  recommended  or  required  per  local guidelines or regulations.

- Modified inclusion criterion 1 to clarify that eligible patients included those with locally advanced or recurrent Stage IIIB NSCLC; locally advanced or recurrent status was added.
- Modified inclusion criterion 5 to specify that Grade &gt;1 alopecia or peripheral neuropathy related to prior anticancer therapy are allowed if deemed irreversible.
- Clarified that  baseline  laboratory tests that need to  be repeated on Cycle 1 Day 1 (because screening laboratory tests were performed &gt;7 days before the first dose) should be obtained before starting treatment.
- Clarified the following administrative information and processes:

-The process for investigator re porting of SAEs, specifying that the investigator or investigator's designee is required to record all SAE information in the clinical trial database within 24 hours after becoming aware of an SAE, or fax the SAE report to the sponsor if the database is not available.

<div style=\"page-break-after: always\"></div>

- -The process regarding review and approval of protocol amendments, so that any significant change in the study protocol requires an amendment to be submitted to competent authorities and IRB/IEC for review and approval per applicable guidance and regulations.
- -Amended the sponsor contact and signatory information.
- An update was made to Appendix E (Drugs With a Risk of Torsades de Pointes) to be based on a more recent list provided by CredibleMeds (dated 10 August 2016).

Additionally, administrative changes were made to correct typographical and grammatical errors and inconsistencies throughout the protocol.

## Other Changes and Clarifications

The SAP indicates that the primary assessment of OS will be performed when 198 BIRC assessed PFS events are observed, or at final database lock if the study is terminated before the observation of 198 PFS events. However, the primary assessment of OS is planned at approximately 3 years after the last patient  is  enrolled,  when  it  is  anticipated  that  approximately  150  OS  events  would  be  observed. Sensitivity analyses of OS will also be performed at this time.

Table 11: Summary of major protocol deviation (ITT population)

|                                                 | ARMA(brigatinib) (N=137)   | ARMB (crizotinib) (N=138)   | Total (N=275)   |
|-------------------------------------------------|----------------------------|-----------------------------|-----------------|
| Subjectswith atleastone majorprotocol deviation | 82 (59.9%)                 | 75 (54.3%)                  | 157 (57.1%)     |
| Entry criteria - incl/excl                      | 1 (0.7%)                   | 0                           | 1 (0.4%)        |
| Entry criteria - ICF                            | 1 (0.7%)                   | 5 (3.6%)                    | 6 (2.2%)        |
| Procedure not doneperprotocol                   | 56 (40.9%)                 | 47 (34.1%)                  | 103 (37.5%)     |
| Visit out of window                             | 14 (10.2%)                 | 7 (5.1%)                    | 21 (7.6%)       |
| Visit missed                                    | 2 (1.5%)                   | 3 (2.2%)                    | 5 (1.8%)        |
| Study objective or safety                       | 27 (19.7%)                 | 19 (13.8%)                  | 46 (16.7%)      |
| Study medication                                | 9 (6.6%)                   | 12 (8.7%)                   | 21 (7.6%)       |
| Other                                           | 10 (7.3%)                  | 4(2.9%)                     | 14 (5.1%)       |

Source: Study 301 IA2 Table 14.1.1 (Database Cutoff Date: 28 June 2019)

ICF: informed consent form; ITT: intent to treat.

One subject may have more than 1 protocol deviation category.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 12: Demographics (ITT Population; First Interim Analysis)

|                               | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   | Total (N = 275)   |
|-------------------------------|------------------------------|------------------------------|-------------------|
| Age, years                    |                              |                              |                   |
| Mean (SD)                     | 57.9 (13.47)                 | 58.6 (11.42)                 | 58.2 (12.47)      |
| Median                        | 58.0                         | 60.0                         | 59.0              |
| Minimum, maximum              | 27, 86                       | 29, 89                       | 27, 89            |
| Age categories (years), N (%) |                              |                              |                   |
| 18-64                         | 93 (67.9)                    | 95 (68.8)                    | 188 (68.4)        |
| ≥65                           | 44 (32.1)                    | 43 (31.2)                    | 87 (31.6)         |
| 18-49                         | 40 (29.2)                    | 30 (21.7)                    | 70 (25.5)         |
| 50-64                         | 53 (38.7)                    | 65 (47.1)                    | 118 (42.9)        |
| 65-74                         | 26 (19.0)                    | 31 (22.5)                    | 57 (20.7)         |
| ≥75                           | 18 (13.1)                    | 12 (8.7)                     | 30 (10.9)         |
| Gender, N (%)                 |                              |                              |                   |
| Female                        | 69 (50.4)                    | 81 (58.7)                    | 150 (54.5)        |
| Male                          | 68 (49.6)                    | 57 (41.3)                    | 125 (45.5)        |
| Race, N (%)                   |                              |                              |                   |
| Asian                         | 59 (43.1)                    | 49 (35.5)                    | 108 (39.3)        |
| Black or African American     | 0                            | 2 (1.4)                      | 2 (0.7)           |
| White                         | 76 (55.5)                    | 86 (62.3)                    | 162 (58.9)        |
| Unknown                       | 2 (1.5)                      | 1 (0.7)                      | 3 (1.1)           |
| Ethnicity, N (%)              |                              |                              |                   |
| Hispanic, Latino, or Spanish  | 6 (4.4)                      | 10 (7.2)                     | 16 (5.8)          |
| Geographical region, N(%)     |                              |                              |                   |
| Asia Pacific                  | 58 (42.3)                    | 49 (35.5)                    | 107 (38.9)        |
| Europe                        | 69 (50.4)                    | 74 (53.6)                    | 143 (52.0)        |
| North America                 | 10 (7.3)                     | 15 (10.9)                    | 25 (9.1)          |

Source: Table 15.1.6.1 (data cutoff: 19 February 2018).

Abbreviations: ITT, intent to treat.

<div style=\"page-break-after: always\"></div>

Table 13: Baseline Characteristics (ITT Population; First Interim Analysis)

|                                                                   | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   | Total (N = 275)   |
|-------------------------------------------------------------------|------------------------------|------------------------------|-------------------|
| Cigarette smoking history, N (%)                                  |                              |                              |                   |
| Never                                                             | 84 (61.3)                    | 75 (54.3)                    | 159 (57.8)        |
| Current                                                           | 4 (2.9)                      | 7 (5.1)                      | 11 (4.0)          |
| Former                                                            | 49 (35.8)                    | 56 (40.6)                    | 105 (38.2)        |
| ECOG performance status, N (%)                                    |                              |                              |                   |
| 0                                                                 | 58 (42.3)                    | 60 (43.5)                    | 118 (42.9)        |
| 1                                                                 | 73 (53.3)                    | 72 (52.2)                    | 145 (52.7)        |
| 2                                                                 | 6 (4.4)                      | 6 (4.3)                      | 12 (4.4)          |
| Diagnosis stage at study entry, N(%)                              |                              |                              |                   |
| IIIB                                                              | 8 (5.8)                      | 12 (8.7)                     | 20 (7.3)          |
| IV                                                                | 129 (94.2)                   | 126 (91.3)                   | 255 (92.7)        |
| Time since initial diagnosis, months                              |                              |                              |                   |
| Mean (SD)                                                         | 10.23 (23.211)               | 12.51 (27.948)               | 11.38 (25.676)    |
| Median                                                            | 1.68                         | 1.48                         | 1.61              |
| Minimum, maximum                                                  | 0.1, 145.3                   | 0.3, 189.8                   | 0.1, 189.8        |
| Histopathological classification, N (%)                           |                              |                              |                   |
| Adenocarcinoma                                                    | 126 (92.0)                   | 137 (99.3)                   | 263 (95.6)        |
| Adenosquamous carcinoma                                           | 3 (2.2)                      | 1 (0.7)                      | 4 (1.5)           |
| Large-cell                                                        | 2 (1.5)                      | 0                            | 2 (0.7)           |
| Squamous                                                          | 4 (2.9)                      | 0                            | 4 (1.5)           |
| Other                                                             | 2 (1.5)                      | 0                            | 2 (0.7)           |
| Organ involvement at study entry,N (%) a                          |                              |                              |                   |
| Lung                                                              | 126 (92.0)                   | 127 (92.0)                   | 253 (92.0)        |
| Other organ(s)                                                    | 134 (97.8)                   | 133 (96.4)                   | 267 (97.1)        |
| Liver                                                             | 31 (22.6)                    | 24 (17.4)                    | 55 (20.0)         |
| Bone                                                              | 35 (25.5)                    | 50 (36.2)                    | 85 (30.9)         |
| Brain - leptomeningeal                                            | 4 (2.9)                      | 3 (2.2)                      | 7 (2.5)           |
| Brain - parenchymal                                               | 37 (27.0)                    | 39 (28.3)                    | 76 (27.6)         |
| iCNS metastasis at baseline, N (%) b, c                           | 40 (29.2)                    | 41 (29.7)                    | 81 (29.5)         |
| Prior chemotherapy for advanced local/metastatic disease, N (%) c | 36 (26.3)                    | 37 (26.8)                    | 73 (26.5)         |

Source: Study 301 Table 15.1.6.2 (data cutoff: 19 February 2018).

Abbreviations: ECOG, Eastern Cooperative Oncology Group; iCNS, intracranial central nervous system; ITT, intent-to-treat.

a Patients may have more than 1 organ involved at study entry.

b As assessed by the investigator.

c Randomization stratification factor; proportion reflects actual number patients with this baseline characteristic, whether or not recorded at the time of randomization.

Table 14 : ALK Assessments and Baseline Status (ITT Population; First Interim Analysis)

|                                                                         | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   | Total (N = 275)   |
|-------------------------------------------------------------------------|------------------------------|------------------------------|-------------------|
| ALK status assessed locally, N (%)                                      | 137 (100)                    | 138 (100)                    | 275 (100)         |
| Positive ALK status documented locally, N(%)                            | 137 (100)                    | 138 (100)                    | 275 (100)         |
| Positive ALK status documented locally by US FDA-approved test, N (%) a | 123 (89.8)                   | 112 (81.2)                   | 235 (85.5)        |
| Method of local ALKassessment, N(%) b                                   |                              |                              |                   |
| FISH - Vysis                                                            | 79 (57.7)                    | 68 (49.3)                    | 147 (53.5)        |
| IHC - Ventana                                                           | 49 (35.8)                    | 50 (36.2)                    | 99 (36.0)         |
| FISH - non-Vysis                                                        | 4 (2.9)                      | 9 (6.5)                      | 13 (4.7)          |
| IHC - non-Ventana                                                       | 18 (13.1)                    | 17 (12.3)                    | 35 (12.7)         |
| Other                                                                   | 2 (1.5)                      | 8 (5.8)                      | 10 (3.6)          |

Source: Study 301 Table 15.1.6.2 (data cutoff: 19 February 2018).

Abbreviations: ALK, anaplastic lymphoma kinase; FDA, Food and Drug Administration; FISH, fluorescence in situ hybridization;

IHC, immunohistochemistry; ITT, intent-to-treat; US, United States.

a Patients whose ALK+ status was confirmed locally by Vysis FISH or Ventana IHC.

b Patients could have had more than 1 method of ALK assessment.

<div style=\"page-break-after: always\"></div>

## Prior Therapy and Surgeries

Table 15: Prior Anticancer Therapy (ITT Population; First Interim Analysis)

|                                                                 | Number of Patients (%)     | Number of Patients (%)     |
|-----------------------------------------------------------------|----------------------------|----------------------------|
|                                                                 | Arm A Brigatinib (N = 137) | Arm B Crizotinib (N = 138) |
| Prior Systemic Therapy                                          |                            |                            |
| Any prior anticancer therapy for the disease under study, N (%) | 38 (27.7)                  | 43 (31.2)                  |
| Most recent prior systemic therapy, N (%)                       |                            |                            |
| Chemotherapy                                                    | 38 (27.7)                  | 43 (31.2)                  |
| Other                                                           | 0                          | 0                          |
| Number of prior systemic anticancer therapies/regimens, N (%)   |                            |                            |
| 0                                                               | 99 (72.3)                  | 95 (68.8)                  |
| 1                                                               | 34 (24.8)                  | 38 (27.5)                  |
| 2                                                               | 3 (2.2)                    | 4 (2.9)                    |
| 3+                                                              | 1 (0.7)                    | 1 (0.7)                    |
| Prior Surgery and Radiotherapy                                  |                            |                            |
| Prior therapeutic anticancer surgery, N (%)                     | 31 (22.6)                  | 38 (27.5)                  |
| Prior radiation therapy, N (%)                                  | 33 (24.1)                  | 41 (29.7)                  |
| Prior radiotherapy to the brain, N (%)                          | 18 (13.1)                  | 19 (13.8)                  |

Source: Table 15.1.7.1, 15.1.7.2, and 15.1.7.3 (data cutoff: 19 February 2018).

Abbreviation: ITT, intent-to-treat.

## Numbers analysed

The ITT Population included all randomized patients, regardless of whether they received study drug or adhered to their assigned dose. In total, there were 275 patients in the ITT Population, with 137 in the brigatinib arm and 138 in the crizotinib arm. The ITT Population includes 2 patients (1 in each arm) who were never treated. Both withdrew consent after randomization before first dose.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary Endpoint: PFS by BIRC Assessment

<!-- image -->

Source: Study 301 Figure 15.2.1.1.1.1 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; ITT, intent-to-treat; PFS, progression-free survival.

Figure 8: Time-to-Event Analysis of BIRC-Assessed PFS: First Interim of the Primary Analysis (ITT Population -First interim analysis)

Table 16: BIRC-Assessed PFS: First Interim Analysis of the Primary Endpoint (ITT Population -First interim analysis)

|                                             | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|---------------------------------------------|------------------------------|------------------------------|
| Number with events (%)                      | 36 (26.3)                    | 63 (45.7)                    |
| Death                                       | 6 (4.4)                      | 6 (4.3)                      |
| PD                                          | 28 (20.4)                    | 53 (38.4)                    |
| Palliative radiotherapy to the brain        | 2 (1.5)                      | 4 (2.9)                      |
| Number censored (%)                         | 101 (73.7)                   | 75 (54.3)                    |
| PFS, months                                 |                              |                              |
| 25th percentile (95% CI)                    | 7.556 (5.52, NE)             | 3.975 (3.65, 5.55)           |
| Median (95% CI)                             | NE (NE, NE)                  | 9.758 (9.03, 12.88)          |
| 75th percentile (95% CI)                    | NE (NE, NE)                  | NE (NE, NE)                  |
| Minimum, maximum                            | 0.03, 18.33                  | 0.03, 18.33                  |
| KMestimate, %(95% CI) [N at risk]           |                              |                              |
| 6 months                                    | 80.8 (73, 87) [N = 90]       | 67.3 (58, 75) [N = 75]       |
| 12 months                                   | 66.5 (56, 75) [N = 26]       | 42.6 (32, 53) [N = 18]       |
| Log-rank p-value (brigatinib vs crizotinib) | 0.0007                       |                              |
| HR(95% CI) (brigatinib vs crizotinib)       | 0.492 (0.33, 0.74)           |                              |
| P-value                                     | 0.0008                       |                              |

Source: Study 301 Table 15.2.1.1.1 and 99.2.8.1 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; HR, hazard ratio; iCNS, intracranial central nervous system; ITT, intent-to-treat; KM, Kaplan-Meier; NE, not estimable; PD, progressive disease; PFS, progression-free survival. P-values  from  a  log-rank  test  stratified  by  presence  of  iCNS  metastases  and  prior  chemotherapy  for  locally  advanced  or metastatic disease at study entry. The HR and associated p-value were obtained using a Cox proportional hazards model with randomization stratification factors as covariates.

<div style=\"page-break-after: always\"></div>

Table 17: Time-to-event analysis of BIRC-assessed PFS: sensitivity analysis 1, ITT Population -First interim analysis

|                                                                                                                                                                                                            | ARM A Brigatinib (N=137)                                                                                                                    | ARM B Crizotinib (N=138)                                                                                                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Number with events () Death (%) Progressive Disease (%) Palliative Radiotherapy to the Brain (%) Number censored (%) Time to PFS (months) 25th Percentile (95% CI) Median (95 CI) 75th Percentile (95% CI) | 34 (24.8) 5 (3.6) 27 (19.7) 2 (1.5) 103 (75.2) 7.622 (5.55, NE) NE (NE，NE) NE(NE，NE) 0.03,18.33 0.689 (0.59, 0.77) [N=26] NE (NE, NE） [N=O] | 58 (42.0) 4 (2.9) 51 (37.0) 3 (2.2) 80 (58.0) 4.370 ）(3.71, 7.33) 11.072 (9.17, NE) NE (NE, NE) 0.03,18.33 0.455 (0.34， 0.56) [N=18] |
| 12 months 24 months                                                                                                                                                                                        |                                                                                                                                             |                                                                                                                                      |
| Kaplan-Meier Estimates (95% CI) [No. at risk]                                                                                                                                                              |                                                                                                                                             |                                                                                                                                      |
| Log-rank p-value, brigatinib vs crizotinib                                                                                                                                                                 | 0.0016                                                                                                                                      | NE (NE， NE） [N=O]                                                                                                                    |
| p-value, brigatinib vs crizotinib                                                                                                                                                                          | 0.509 (0.33， 0.78) 0.0020                                                                                                                   |                                                                                                                                      |
| Hazard Ratio (95% CI), brigatinib vs crizotinib                                                                                                                                                            |                                                                                                                                             |                                                                                                                                      |

Note: Progression-free survival is defined as time from randomization until the date at which disease progression was first evident or death,whichever comes first.Time to PFs for subjects without progression are included in time to PFs analyses and censored according to the progression and censoring scheme detailed in Section 3.4.3.2 and Table 2 of the Statistical Analysis Plan. Subjects receiving radiotherapy for icNs metastases are considered as having without progression are censored on their first dose of brigatinib.

Note: If a subject experiences more than one of the three PFs-qualifying events on the same day, the subject is counted only once. The subject is categorized as a death if death is one of the events; if death is not one of the qualifying events, the subject is categorized as Progressive Disease.

Note: P-values from a log-rank test stratified by randomization stratification factors (current; presence of iCNS metastases at baseline and prior chemotherapy for locally advanced or metastatic disease). The hazard ratio and associated p-value were obtained using a Cox proportional hazards model with randomization stratification factors (current) as covariates.

Note: For Sensitivity Analysis 1 time to PFs is censored on the date of last treatment administration if PFS event is not observed prior to the End of Treatment Visit. The censoring rules are described in Table A3-l of the SAP.

Cutoff:2018-02-19

Table 18: Time-to-event analysis of BIRC-assessed PFS: sensitivity analysis 2, ITT Population -First interim analysis

|                                                                                                                                                                                                                                                         | ARM A Brigatinib (N=137)                                                                             | ARM B Crizotinib (N=138)                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Number with events (%) Death (%) Progressive Disease (%) Palliative Radiotherapy to the Brain (%) Number censored (%) Time to PFS (months) 25th percentile (95% CI) Median (95 CI) 75th Percentile (95% CI) Kaplan-Meier Estimates (95& CI)[No.at risk] | 40 (29.2) 10 (7.3) 28 (20.4) 2 (1.5) 97 (70.8) 7.556 (5.55， 10.35) NE(NE, NE) NE (NE,NE) 0.03, 18.33 | 69 (50.0) 9 (6.5) 55 (39.9) 5 (3.6) 69 (50.0) 3.877 (3.61， 5.55) 9.396 5(7.43，11.10) NE (12.88, NE) 0.03， 18.33 |
| Log-rank p-value,brigatinib vs crizotinib                                                                                                                                                                                                               | 0.0003                                                                                               |                                                                                                                 |
| Hazard Ratio(95% CI)，brigatinib vs crizotinib p-value, brigatinib vs crizotinib                                                                                                                                                                         | 0.488 (0.33， 0.72) 0.0004                                                                            |                                                                                                                 |

Note: Progression-free survival is defined as time from randomization until the date at which disease progression was first evident or death, whichever comes first. Time to PFs for subjects without progression are included in time to PFS analyses and censored according to the progression and censoring scheme detailed in Section 3.4.3.2 and Table 2 of the Statistical Analysis Plan. Subjects receiving radiotherapy for icNs metastases are considered as having disease progression at the time of initiation of therapy as described in the Protocol. Patients who crossover without progression are censored on their first dose of brigatinib.

Note: If a subject experiences more than one of the three PFS-qualifying events on the same day, the subject is counted only once. The subject is categorized as a death if death is one of the events; if death is not one of the qualifying events, the subject is categorized as Progressive Disease.

Note: P-values from a log-rank test stratified by randomization stratification factors (current; presence of icNS metastases at baseline and prior chemotherapy for locally advanced or metastatic disease). The hazard ratio and associated p-value were obtained using a Cox proportional hazards model with randomization stratification factors (current) as covariates.

Note: For Sensitivity Analysis 2 PFS events are not censored for reasons of time lapse from last assessment (i.e., no 126-day rule) or usage of disallowed therapies. The censoring rules are described in Table A3-2 of the SAP. Cutoff:2018-02-19

<div style=\"page-break-after: always\"></div>

Table 19: BIRC-Assessed PFS (ITT population, second interim analysis)

|                                      | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|--------------------------------------|------------------------------|------------------------------|
| Number with events (%)               | 63 (46.0)                    | 87 (63.0)                    |
| Death                                | 7 (5.1)                      | 5 (3.6)                      |
| PD                                   | 54 (39.4)                    | 74 (53.6)                    |
| Palliative radiotherapy to the brain | 2 (1.5)                      | 8 (5.8)                      |
| Number censored (%)                  | 74 (54.0)                    | 51 (37.0)                    |
| PFS, months                          |                              |                              |
| Median (95% CI)                      | 23.984 (18.46, NE)           | 11.006 (9.17, 12.88)         |
| KM estimate, % (95% CI)              |                              |                              |
| 6 months                             | 80.1 (72, 86)                | 67.3 (58, 75)                |
| 12 months                            | 69.3 (60, 77)                | 45.5 (36, 54)                |
| 18 months                            | 63.4 (54, 71)                | 35.8 (27, 45)                |
| 24 months                            | 48.2 (39, 57)                | 26.0 (18, 35)                |
| Log-rank p-value                     | <0.0001                      |                              |
| HR (95% CI)                          | 0.489 (0.35, 0.68)           |                              |
| P-value                              | <0.0001                      |                              |

Source:IA2 Table 15.2.1.1.1 (data cutoff: 28 June 2019).

BIRC:blinded independent review committee;HR:hazard ratio;ITT: intent to treat;KM:Kaplan-Meier; NE: not estimable; PD: progressive disease; PFS: progression-free survival.

P-values from a log-rank test stratified by presence of brain metastases and prior chemotherapy for locally advanced or metastatic disease at study entry. The HR and associated p-value were obtained using a Cox proportional hazards modelwithrandomization stratificationfactors as covariates.

<!-- image -->

Source:IA2Figure 15.2.1.1.1.1 (data cutoff:28June 2019).

BIRC:blinded independent review committee;ITT:intent to treat;PFS:progression-free survival.

Figure 9: Time-to-event analysis of BIRC-assessed PFS (ITT population, second interim analysis)

## PFS by Investigator Assessment

The updated data for INV-PFS was consistent with the BIRC-assessed data and a similar number of events were observed in the treatment arms. Median INV-PFS for brigatinib was 29.4 months (95%CI: 21.2; NE) and 9.2 months for crizotinib. The sensitivity analyses 1 and 2 showed consistent results to the primary analyses.

<div style=\"page-break-after: always\"></div>

## Key Secondary endpoints

ORR

Table 20: BIRC-Assessed ORR (ITT Population -First interim analysis)

|                                                  | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|--------------------------------------------------|------------------------------|------------------------------|
| Best confirmed response, N(%)                    |                              |                              |
| CR                                               | 5 (3.6)                      | 7 (5.1)                      |
| PR                                               | 92 (67.2)                    | 76 (55.1)                    |
| Stable disease                                   | 17 (12.4)                    | 30 (21.7)                    |
| PD                                               | 7 (5.1)                      | 9 (6.5)                      |
| NE a                                             | 16 (11.7)                    | 16 (11.6)                    |
| Confirmed ORR b                                  |                              |                              |
| N (%)                                            | 97 (70.8)                    | 83 (60.1)                    |
| (95% CI)                                         | (62.43, 78.25)               | (51.47, 68.38)               |
| Odds ratio (95% CI) (brigatinib vs crizotinib) c | 1.59 (0.96, 2.62)            |                              |
| P-value c                                        | 0.0678                       |                              |
| ORR (confirmed + unconfirmed) d                  |                              |                              |
| N (%)                                            | 104 (75.9)                   | 101 (73.2)                   |
| (95% CI)                                         | (67.87, 82.80)               | (64.99, 80.37)               |
| Odds ratio (95% CI) (brigatinib vs crizotinib) c | 1.13 (0.66, 1.97)            |                              |
| P-value c                                        | 0.6512                       |                              |
| DCR e                                            |                              |                              |
| N (%)                                            | 117 (85.4)                   | 119 (86.2)                   |
| (95% CI)                                         | (78.36, 90.85)               | (79.34, 91.50)               |
| Odds ratio (95% CI) (brigatinib vs crizotinib) c | 0.93 (0.47, 1.82)            |                              |
| P-value c                                        | 0.8220                       |                              |

Source: Study 301 Table 15.2.2.1.1 and 15.2.2.2.1 (data cutoff: 19 February 2018).

Abbreviations:  BIRC,  blinded  independent  review  committee;  CR,  complete  response;  DCR,  disease  control  rate;  iCNS, intracranial central nervous system; ITT, intent-to-treat; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.

a Includes patients who had nonmeasurable disease at baseline by BIRC, died early, or with unknown response.

b Confirmed ORR was defined as the proportion of patients who achieved confirmed CR or PR per RECIST v1.1.

c Odds ratios and p-values were from a Cochran-Mantel-Haenszel test stratified by presence of iCNS metastases at baseline, and prior chemotherapy for locally advanced or metastatic disease.

d ORR was defined as the proportion of patients who achieved confirmed/unconfirmed CR or PR per RECIST v1.1.

e DCR was defined as the proportion of randomized patients who achieved confirmed CR, PR, or stable disease. The criteria for stable disease must have been met at least once after randomization at a minimum interval of 6 weeks after randomization.

Table 21: ORR by Investigator Assessment (ITT Population -First interim analysis)

|                                       | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|---------------------------------------|------------------------------|------------------------------|
| Confirmed ORR, N (%) a                | 93 (67.9)                    | 79 (57.2)                    |
| (95% CI)                              | (59.37, 75.60)               | (48.55, 65.63)               |
| Odds ratio (95% CI) b                 | 1.57 (0.96, 2.55)            |                              |
| P-value                               | 0.0710                       |                              |
| ORR (confirmed + unconfirmed), N(%) c | 104 (75.9)                   | 91 (65.9)                    |
| (95% CI)                              | (67.87, 82.80)               | (57.39, 73.79)               |
| Odds ratio (95% CI) b                 | 1.62 (0.95, 2.75)            |                              |
| P-value                               | 0.0735                       |                              |

Source: Study 301 Table 15.2.2.2.2 and 15.2.2.2.3 (data cutoff: 19 February 2018).

Abbreviations: CR, complete response; iCNS, intracranial central nervous system; ORR, objective response rate; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.

a Confirmed ORR was defined as the proportion of patients who achieved confirmed CR or PR per RECIST v1.1.

b Odds ratios and p-values were from a Cochran-Mantel-Haenszel test stratified by presence of iCNS metastases at baseline,

<div style=\"page-break-after: always\"></div>

and prior chemotherapy for locally advanced or metastatic disease.

c ORR was defined as the proportion of patients who achieved confirmed/unconfirmed CR or PR per RECIST v1.1.

<!-- image -->

Source: Study 301 Figure 15.2.8.1.1 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; ITT, intent-to-treat.

Figure 10: Waterfall Plot of BIRC-Assessed Best Percentage Change From Baseline in the Target Lesion Sum By Best Confirmed Response (ITT Population, Brigatinib [Arm A] -First interim analysis)

<!-- image -->

Source: Study 301 Figure 15.2.8.1.2 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; ITT, intent-to-treat.

Figure 11: Waterfall Plot of BIRC-Assessed Best Percentage Change From Baseline in the Target Lesion Sum By Best Confirmed Response (ITT Population, Crizotinib [Arm B] -First interim analysis)

<div style=\"page-break-after: always\"></div>

## Updated data cut-off 28 June 2019 (Second Interim Analysis)

Table 22: ORR (ITT population, second interim analysis)

|                                | BIRC Assessed             | BIRC Assessed              | Investigator Assessed      | Investigator Assessed     |
|--------------------------------|---------------------------|----------------------------|----------------------------|---------------------------|
|                                | Arm A Brigatinib (N =137) | Arm B Crizotinib (N = 138) | Arm A Brigatinib (N = 137) | Arm B Crizotinib (N =138) |
| Best confirmed response, N (%) |                           |                            |                            |                           |
| CR                             | 20 (14.6)                 | 12 (8.7)                   | 5 (3.6)                    | 10 (7.2)                  |
| PR                             | 81 (59.1)                 | 73 (52.9)                  | 94 (68.6)                  | 74 (53.6)                 |
| Stable disease                 | 14 (10.2)                 | 29 (21.0)                  | 19 (13.9)                  | 35 (25.4)                 |
| PD                             | 7 (5.1)                   | 9 (6.5)                    | 6 (4.4)                    | 11 (8.0)                  |
| NEa                            | 15 (10.9)                 | 15 (10.9)                  | 13 (9.5)                   | 8 (5.8)                   |
| Confirmed ORR b                |                           |                            |                            |                           |
| N (%)                          | 101 (73.7)                | 85 (61.6)                  | 99 (72.3)                  | 84 (60.9)                 |
| (95% CI)                       | (65.52,80.87)             | (52.94, 69.74)             | (63.97, 79.57)             | (52.20, 69.06)            |
| Odds ratio (95% C1) °          | 1.73 (1.04, 2.88)         |                            | 1.66 (1.00, 2.76)          |                           |
| P-valuec                       | 0.0342                    |                            | 0.0487                     |                           |
| ORR (confirmed + unconfirmed)° |                           |                            |                            |                           |
| N (%)                          | 108 (78.8)                | 103 (74.6)                 | 108 (78.8)                 | 94 (68.1)                 |
| (95% CI)                       | (71.03, 85.34)            | (66.53, 81.65)             | (71.03, 85.34)             | (59.65, 75.79)            |
| Odds ratio (95% CI) °          | 1.25 (0.71, 2.19)         |                            | 1.74 (1.00, 3.00)          |                           |
| P-value c                      | 0.4376                    |                            | 0.0474                     |                           |

Source:IA2 Table 15.2.2.1.1,15.2.2.2.1,15.2.2.2.2,and 15.2.2.2.3 (data cutoff:28June 2019)

BIRC: blinded independent review committee; CR: complete response; ITT: intent-to-treat; NE: not evaluable; ORR: objective response rate; PD: progressive disease; PR: partial response; RECIST: Response Evaluation Criteria in Solid Tumors.

b Confirmed ORR was defined as the proportion of patients who achieved confirmed CR or PR per RECIST v1.1.

* Includes patients who had nonmeasurable disease at baseline by BIRC with best overall response as PR or nonCR/non-PD, died early, or with unknown response.

Odds ratios and p-values were from a Cochran-Mantel-Haenszel test stratified by presence of brain metastases at baseline and prior chemotherapy for locally advanced or metastatic disease.

d ORR was defined as the proportion of patients who achieved confirmed/unconfirmed CR or PR per RECIST v1.1.

<!-- image -->

Source: IA2 Figure 15.2.8.1.1 (data cutoff: 28 June 2019).

BIRC: blinded independent review committee; ITT: intent-to-treat.

Figure 12: Waterfall Plot of BIRC-Assessed Best Percentage Change From Baseline in the Target Lesion Sum By Best Confirmed Response (ITT Population, Brigatinib [Arm A])

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:IA2Figure15.2.8.1.2 (data cutoff:28June 2019).

BIRC: blinded independent review committee; ITT: intent to treat.

Figure 13: Waterfall Plot of BIRC-Assessed Best Percentage Change From Baseline in the Target Lesion Sum By Best Confirmed Response (ITT Population, Brigatinib [Arm B])

## Time to response and DOR

Table 23: Time to Response and DOR by BIRC Assessment (ITT Population, Confirmed Responders -First interim analysis)

|                                                    | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|----------------------------------------------------|------------------------------|------------------------------|
| Number with confirmed response (%)                 | 97 (70.8)                    | 83 (60.1)                    |
| Number censored (%)                                | 80 (82.5)                    | 58 (69.9)                    |
| Time to response (in confirmed responders), months | (N = 97)                     | (N = 83)                     |
| Median (95% CI)                                    | 1.840 (1.84, 1.87)           | 1.873 (1.84, 1.87)           |
| Minimum, maximum                                   | 1.02, 7.36                   | 0.79, 7.43                   |
| DOR (in confirmed responders), months              | (N = 97)                     | (N = 83)                     |
| Median (95% CI)                                    | NE (NE, NE)                  | 11.072 (9.23, NE)            |
| Minimum, maximum                                   | 1.84, 16.46                  | 1.45, 16.59                  |
| KMestimate, %(95% CI) [N at risk]                  | (N = 97)                     | (N = 83)                     |
| 6 months                                           | 81.3 (71, 88) [N = 56]       | 82.5 (71, 90) [N = 44]       |
| 12 months                                          | 78.0 (67, 86) [N = 7]        | 48.0 (31, 63) [N = 4]        |

Source: Study 301 Table 15.2.6.1 and Table 99.2.6.1 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; DOR, duration of response; ITT, intent-to-treat; KM, KaplanMeier; NE, not estimable.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: Study 301 Figure 15.2.5.1.3.1 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; DOR, duration of response; ITT, intent-to-treat.

Figure 14: DOR by BIRC Assessment (ITT Population, Confirmed Responders -First interim analysis)

Table 24: Time to Response and DOR by Investigator Assessment (ITT Population, Confirmed Responders -First interim analysis)

|                                                    | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|----------------------------------------------------|------------------------------|------------------------------|
| Number censored (%)                                | 82 (88.2)                    | 51 (64.6)                    |
| Time to response (in confirmed responders), months | (N = 93)                     | (N = 79)                     |
| Median (95% CI)                                    | 1.873 (1.84, 1.87)           | 1.873 (1.87, 1.91)           |
| Minimum, maximum                                   | 0.92, 7.39                   | 1.22, 7.56                   |
| DOR (in confirmed responders)                      | (N = 93)                     | (N = 79)                     |
| Median, months (95% CI)                            | NE (NE, NE)                  | 11.006 (7.39, NE)            |
| KMestimate, %(95% CI) [N at risk]                  |                              |                              |
| 12 months                                          | 84.6 (73, 91) [N = 8]        | 48.0 (33, 62) [N = 3]        |

Source: Study 301 Table 15.2.6.2 (data cutoff: 19 February 2018).

Abbreviations: DOR, duration of response; ITT, intent-to-treat; KM, Kaplan-Meier; NE, not estimable.

## Updated data cut-off 28 June 2019 (Second Interim Analysis)

Table 25: DoR in confirmed responders (ITT population, second interim analysis)

|                                    | BIRCAssessed              | BIRCAssessed             | InvestigatorAssessed      | InvestigatorAssessed     |
|------------------------------------|---------------------------|--------------------------|---------------------------|--------------------------|
|                                    | Arm A Brigatinib (N =137) | ArmB Crizotinib (N =138) | Arm A Brigatinib (N =137) | ArmB Crizotinib (N =138) |
| Nunber with confirmed response (%) | 101 (73.7)                | 85 (61.6)                | 99 (72.3)                 | 84 (60.9)                |
| Number censored (%)                | 57 (56.4)                 | 37 (43.5)                | 64 (64.6)                 | 33 (39.3)                |
| DOR,months                         | (N =101)                  | (N = 85)                 | (N = 99)                  | (N = 84)                 |
| Median (95% CI)                    | NE (19.38, NE)            | 13.832 (9.30, 20.80)     | NE (24.94, NE)            | 11.006 (9.00, 13.86)     |
| KM estimate, % (95% CI)            |                           |                          |                           |                          |
| 6months                            | 84.7 (76,90)              | 83.7 (74,90)             | 89.8 (82, 94)             | 73.3 (62, 82)            |
| 12 months                          | 77.5 (68,85)              | 54.4 (42, 65)            | 81.5 (72,88)              | 46.3 (35, 57)            |
| 18 months                          | 62.6 (52,71)              | 45.6 (34, 57)            | 71.0 (61, 79)             | 37.3 (26, 48)            |
| 24 months                          | 51.3 (40, 61)             | 29.6 (18, 42)            | 64.0 (53, 73)             | 29.8 (19, 41)            |

Source:IA2Table 15.2.6.1 and 15.2.6.2 (data cutoff: 28June 2019).

BIRC:blinded independent review committee;DOR: duration ofresponse;ITT:intent to treat;KM:Kaplan-Meier; NE:not estimable.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:IA2Figure15.2.5.1.3.1(datacutoff:28June2019)

BIRC:blindedindependentreviewcommittee;DOR:durationofresponse;ITT:intenttotreat.

Figure 15: Time-to-event analysis of DoR by BIRC assessment in confirmed responders (ITT population, second interim analysis)

## OS

<!-- image -->

Source: Study 301 Figure 15.2.5.1.1.1 (data cutoff: 19 February 2018). Abbreviation: ITT, intent-to-treat: OS, overall survival.

Figure 16: OS (ITT Population; first interim analysis)

<div style=\"page-break-after: always\"></div>

Table 26: OS (ITT Population; First Interim Analysis)

|                                             | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|---------------------------------------------|------------------------------|------------------------------|
| Number with event (death) (%)               | 17 (12.4)                    | 17 (12.3)                    |
| Number censored (%)                         | 120 (87.6)                   | 121 (87.7)                   |
| Time to death, months                       |                              |                              |
| 25th percentile (95% CI)                    | NE (13.01, NE)               | NE (NE, NE)                  |
| Median (95% CI)                             | NE (NE, NE)                  | NE (NE, NE)                  |
| 75th percentile (95% CI)                    | NE (NE, NE)                  | NE (NE, NE)                  |
| Minimum, maximum                            | 0.07, 18.43                  | 0.03, 19.29                  |
| KMestimate, %(95% CI) [N at risk]           |                              |                              |
| 12 months                                   | 85.0 (76, 91) [N = 40]       | 85.7 (77, 91) [N = 41]       |
| Log-rank p-value (brigatinib vs crizotinib) | 0.9386                       |                              |
| HR(95% CI) (brigatinib vs crizotinib)       | 0.983 (0.50, 1.93)           |                              |
| p-value (brigatinib vs crizotinib)          | 0.9611                       |                              |

Source: Study 301 Table 15.2.5.1.1 (data cutoff: 19 February 2018).

Abbreviations: HR, hazard ratio; iCNS, intracranial central nervous system; ITT, intent-to-treat; KM, Kaplan-Meier; NE, not estimable; OS, overall survival.

P-values from a log-rank test stratified by randomization stratification factors at study entry (presence of iCNS metastases at baseline and prior chemotherapy for locally advanced or metastatic disease). The HR and associated p-value were obtained using a Cox proportional hazards model with randomization stratification factors as covariates.

## Updated data cut-off 28 June 2019 (Second Interim Analysis)

Table 27: OS (ITT Population, second interim analysis)

|                         | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N =138)   |
|-------------------------|------------------------------|-----------------------------|
| Number of deaths (%)    | 33 (24.1)                    | 37 (26.8)                   |
| Number censored (%)     | 104 (75.9)                   | 101 (73.2)                  |
| OS,months               |                              |                             |
| Median (95% CI)         | NE (NE, NE)                  | NE (NE, NE)                 |
| KM estimate, % (95% CI) |                              |                             |
| 6 months                | 94.0 (88, 97)                | 90.5 (84, 94)               |
| 12 months               | 85.3 (78, 90)                | 86.8 (80, 91)               |
| 18 months               | 78.2 (70, 84)                | 80.8 (73, 86)               |
| 24months                | 75.8 (67, 82)                | 73.8 (65, 80)               |
| Log-rank p-value        | 0.7710                       |                             |
| HR (95% CI)             | 0.916 (0.57, 1.47)           |                             |
| P-value                 | 0.7134                       |                             |

Source:IA2Table15.2.5.1.1(datacutoff:28June 2019).

HR: hazard ratio; ITT: intent to treat; KM: Kaplan-Meier; NE: not estimable; OS: overall survival.

P-values from a log-rank test stratified by randomization stratification factors at study entry (presence of brain metastases at baseline andprior chemotherapyforlocally advanced ormetastatic disease).TheHR and associated p-value were obtained using a Cox proportional hazards model with randomization stratificationfactors as covariates.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:IA2Figure15.2.5.1.1.1(data cutoff:28June2019).

ITT:intent to treat:OS:overall survival.

Figure 17: Time-to-event analysis of OS (ITT population, second interim analysis)

Intracranial efficacy results (First Interim Analysis)

Table 28: BIRC-Assessed iORR in Patients with iCNS Metastases at Baseline (First Interim Analysis)

| Baseline iCNS metastases:         | Measurable                | Measurable                | Nonmeasurable             | Nonmeasurable             | Any                       | Any                       |
|-----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                   | Arm A Brigatinib (N = 18) | Arm B Crizotinib (N = 21) | Arm A Brigatinib (N = 25) | Arm B Crizotinib (N = 26) | Arm A Brigatinib (N = 43) | Arm B Crizotinib (N = 47) |
| Best Confirmed Response, N (%)    |                           |                           |                           |                           |                           |                           |
| CR                                | 2 (11.1)                  | 0                         | 14 (56.0)                 | 2 (7.7)                   | 16 (37.2)                 | 2 (4.3)                   |
| PR                                | 12 (66.7)                 | 6 (28.6)                  | 1 (4.0)                   | 0                         | 13 (30.2)                 | 6 (12.8)                  |
| Stable disease a                  | 2 (11.1)                  | 11 (52.4)                 | 6 (24.0)                  | 17 (65.4)                 | 8 (18.6)                  | 28 (59.6)                 |
| PD                                | 1 (5.6)                   | 2 (9.5)                   | 2 (8.0)                   | 5 (19.2)                  | 3 (7.0)                   | 7 (14.9)                  |
| NE b                              | 1 (5.6)                   | 2 (9.5)                   | 2 (8.0)                   | 2 (7.7)                   | 3 (7.0)                   | 4 (8.5)                   |
| Confirmed iORR, N (%) c           | 14 (77.8)                 | 6 (28.6)                  | 15 (60.0)                 | 2 (7.7)                   | 29 (67.4)                 | 8 (17.0)                  |
| (95% CI)                          | (52.36, 93.59)            | (11.28, 52.18)            | (38.67, 78.87)            | (0.95, 25.13)             | (51.46, 80.92)            | (7.65, 30.81)             |
| Odds ratio (95% CI) d             | 10.42 (1.90, 57.05)       |                           | 15.00 (2.96, 75.95)       |                           | 13.00 (4.38, 38.61)       |                           |
| P-value d                         | 0.0028                    |                           | <0.0001                   |                           | <0.0001                   |                           |
| iORR (confirmed + unconfirmed), e |                           |                           |                           |                           |                           |                           |
| (%)                               | 15 (83.3)                 | 7 (33.3)                  | 19 (76.0)                 | 4 (15.4)                  | 34 (79.1)                 | 11 (23.4)                 |
| (95% CI)                          | (58.58, 96.42)            | (14.59, 56.97)            | (54.87, 90.64)            | (4.36, 34.87)             | (63.96, 89.96)            | (12.30, 38.03)            |
| Odds ratio (95% CI) d             | 9.29 (1.88,               |                           | 19.57 (4.27,              |                           | 16.30 (5.32,              |                           |
|                                   | 45.85)                    |                           | 89.67)                    |                           | 49.92)                    |                           |
| P-value d                         | 0.0023                    |                           | <0.0001                   |                           | <0.0001                   |                           |

Source: Study 301 Table 15.2.3.1.1, 15.2.3.2.1, 15.2.3.1.3, 15.2.3.2.3, 15.2.3.1.5, and 15.2.3.2.5 (data cutoff: 19 February 2018).

Abbreviations:  BIRC,  blinded  independent  review  committee;  CR,  complete  response;  iCNS,  intracranial  central  nervous  system;  iORR, intracranial objective response rate; NE, not estimable; PD, progressive disease; PR, partial response.

a Stable disease in patients with only nonmeasurable iCNS disease includes those without CR or PD.

b Includes patients who died early, or with unknown response.

c Confirmed iORR was defined as the proportion of patients who achieved confirmed intracranial CR or PR.

d Odds  ratios  and  p-values  were  from  a  Cochran-Mantel-Haenszel  test  stratified  by  presence  of  prior  chemotherapy  for  locally  advanced  or metastatic disease at study entry.

e iORR is defined as the proportion of patients who achieved confirmed or unconfirmed intracranial CR or PR.

<div style=\"page-break-after: always\"></div>

Table 29: BIRC-Assessed Time to Intracranial Response and iDOR (iCNS Disease Population; First Interim Analysis)

| Baseline iCNS metastases:                  | Measurable                                                                    | Measurable                | Any                       | Any                       |
|--------------------------------------------|-------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|
|                                            | Arm A Brigatinib (N = 18)                                                     | Arm B Crizotinib (N = 21) | Arm A Brigatinib (N = 43) | Arm B Crizotinib (N = 47) |
| Number with confirmed response (%)         | 14 (77.8)                                                                     | 6 (28.6)                  | 29 (67.4)                 | 8 (17.0)                  |
| Number censored (%)                        | 10 (71.4)                                                                     | 3 (50.0)                  | 24 (82.8)                 | 5 (62.5)                  |
| Time to response (in confirmed responders) |                                                                               |                           |                           |                           |
| Median, months (95% CI)                    | 1.856 (1.77, 3.55)                                                            | 1.791 (0.79, 1.87)        | 1.873 (1.87, 3.61)        | 1.823 (0.79, 5.72)        |
| iDOR (in confirmed responders)             |                                                                               |                           |                           |                           |
| Median, months (95% CI)                    | NE (4.50, NE)                                                                 | 9.232 (3.88, 9.23)        | NE (NE, NE)               | 9.232 (3.88, 9.23)        |
| KMestimate, %(95% CI) [N at risk]          |                                                                               |                           |                           |                           |
| 6 months                                   | 72.9 (37, 91) [N=6]                                                           | 60.0 (13, 88) [n=1]       | 87.4 (66, 96) [n=16]      | 68.6 (21, 91) [n=1]       |
| 12 months                                  | 60.8 (25, 84) [N = 1] NE (NE, NE) [N = 75.8 (50, 89) [N =3] NE (NE, NE) [N 0] | 0]                        |                           | =                         |

Source: Study 301 Table 15.2.7.2, 15.2.7.4, 99.2.7.2, and 99.2.7.4 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; iCNS, intracranial central nervous system; iDOR, intracranial duration of response; KM, Kaplan-Meier; NE, not estimable.

Table 30: BIRC-Assessed iPFS by Baseline iCNS Metastases and for the Full ITT Population (First Interim Analysis)

| Baseline Metastases:                 | iCNS Any                  |                           | None                      |                           | Full ITT Population        | Full ITT Population        |
|--------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------|----------------------------|
|                                      | Arm A Brigatinib (N = 43) | Arm B Crizotinib (N = 47) | Arm A Brigatinib (N = 94) | Arm B Crizotinib (N = 91) | Arm A Brigatinib (N = 137) | Arm B Crizotinib (N = 138) |
| N with events (%)                    | 11 (25.6)                 | 28 (59.6)                 | 11 (11.7)                 | 11 (12.1)                 | 22 (16.1)                  | 39 (28.3)                  |
| Death                                | 0                         | 2 (4.3)                   | 9 (9.6)                   | 4 (4.4)                   | 9 (6.6)                    | 6 (4.3)                    |
| PD                                   | 10 (23.3)                 | 24 (51.1)                 | 2 (2.1)                   | 7 (7.7)                   | 12 (8.8)                   | 31 (22.5)                  |
| Palliative radiotherapy to the brain | 1 (2.3)                   | 2 (4.3)                   | 0                         | 0                         | 1 (0.7)                    | 2 (1.4)                    |
| N censored (%)                       | 32 (74.4)                 | 19 (40.4)                 | 83 (88.3)                 | 80 (87.9)                 | 115 (83.9)                 | 99 (71.7)                  |
| PFS                                  |                           |                           |                           |                           |                            |                            |
| Median, months (95% CI)              | NE (10.97, NE)            | 5.585 (4.07, 9.17)        | NE (NE, NE)               | NE (NE, NE)               | NE (NE, NE)                | NE (11.07, NE)             |
| KMestimate,%                         |                           |                           |                           |                           |                            |                            |
| (95% CI) [N at risk] 12 months       | 66.7 (47, 80) [N = 9]     | 20.8 (6, 42) [N = 2]      | 84.1 (72, 91) [N = 18]    | 81.7 (68, 90) [N = 15]    | 78.0 (68, 85) [N = 27]     | 61.1 (50, 71) [N = 17]     |
| Log-rank p-value a                   | <0.0001                   |                           | 0.9274                    |                           | 0.0006                     |                            |
| HR (95% CI) a                        | 0.265 (0.13, 0.54)        |                           | 0.960 (0.42, 2.22)        |                           | 0.415 (0.24, 0.70)         |                            |
| P-value a                            | 0.0002                    |                           | 0.9234                    |                           | 0.0011                     |                            |

Source: Study 301 Table 15.2.4.1.1, 15.2.4.1.2, and 15.2.4.1.4 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; HR, hazard ratio; iCNS, intracranial central nervous system; iPFS, intracranial progression-free survival; ITT, intent-to-treat; KM, Kaplan-Meier; NE, not estimable; PD, progressive disease; PFS, progression-free survival. P-values from a log-rank test stratified by presence of iCNS metastases at baseline and prior chemotherapy for locally advanced or metastatic disease at study entry. The HR and associated p-value were obtained using a Cox proportional hazards model with randomization stratification factors as covariates.

a Brigatinib versus crizotinib.

<div style=\"page-break-after: always\"></div>

## Updated data cut-off 28 June 2019 (Second Interim Analysis)

Table 31: iORR (second interim analysis)

| BaselineBrainMetastases:                        | Measurable                | Measurable                | Nonmeasurable             | Nonmeasurable            | Any                       | Any                      |
|-------------------------------------------------|---------------------------|---------------------------|---------------------------|--------------------------|---------------------------|--------------------------|
|                                                 | Arm A Brigatinib (N = 18) | Arm B Crizotinib (N = 23) | Arm A Brigatinib (N = 29) | ArmB Crizotinib (N = 26) | Arm A Brigatinib (N = 47) | ArmB Crizotinib (N = 49) |
| Best Confirmed Response, N (%)                  |                           |                           |                           |                          |                           |                          |
| CR                                              | 5 (27.8)                  | 0                         | 16 (55.2)                 | 2 (7.7)                  | 21 (44.7)                 | 2 (4.1)                  |
| PR                                              | 9 (50.0)                  | 6 (26.1)                  | 1 (3.4)                   | 0                        | 10 (21.3)                 | 6 (12.2)                 |
| Stable diseasea                                 | 2 (11.1)                  | 11 (47.8)                 | 5 (17.2)                  | 16 (61.5)                | 7 (14.9)                  | 27 (55.1)                |
| PD                                              | 1 (5.6)                   | 2 (8.7)                   | 3 (10.3)                  | 5 (19.2)                 | 4 (8.5)                   | 7 (14.3)                 |
| NE b                                            | 1 (5.6)                   | 4 (17.4)                  | 4 (13.8)                  | 3 (11.5)                 | 5 (10.6)                  | 7 (14.3)                 |
| ConfirmediORR,N(%)°                             | 14 (77.8)                 | 6 (26.1)                  | 17 (58.6)                 | 2 (7.7)                  | 31 (66.0)                 | 8 (16.3)                 |
| (95% CI)                                        | (52.36, 93.59)            | (10.23, 48.41)            | (38.94, 76.48)            | (0.95, 25.13)            | (50.69, 79.14)            | (7.32, 29.66)            |
| Odds ratio (95% C1) d                           | 11.67 (2.15, 63.27)       |                           | 14.76 (3.00, 72.72)       |                          | 11.75 (4.19, 32.91)       |                          |
| P-value d                                       | 0.0014                    |                           | 0.0001                    |                          | <0.0001                   |                          |
| iORR (confirmed + unconfirmed), N (%)  (95% CI) | 14 (77.8) (52.36, 93.59)  | 7 (30.4) (13.21, 52.92)   | 19 (65.5) (45.67, 82.06)  | 3 (11.5) (2.45,30.15)    | 33 (70.2) (55.11, 82.66)  | 10 (20.4) (10.24, 34.34) |
| Odds ratio (95% C1) d                           | 9.22 (1.76, 48.43)        |                           | 14.20 (3.35, 60.10)       |                          | 11.10 (4.06, 30.39)       |                          |
| P-value d                                       | 0.0036                    |                           | <0.0001                   |                          | <0.0001                   |                          |

Source: IA2 Table 15.2.3.1.1, 15.2.3.2.1, 15.2.3.1.3, 15.2.3.2.3,15.2.3.1.5, and 15.2.3.2.5 (data cutoff: 28 June 2019).

a Stable disease in patients with only non-measurable brain disease includes those without CR or PD.

Confirmed iORR was defined as the proportion of patients who achieved confirmed intracranial CR or PR.

b Includes patients who died early, or with unknown response.

d Odds ratios and p-values were from a Cochran-Mantel-Haenszel test stratified by prior chemotherapy for locally advanced or metastatic disease at study entry.

e iORR is defined as the proportion of patients who achieved confirmed or unconfirmed intracranial CR or PR.

Table 32: iDOR in confirmed responders (second interim analysis)

| BaselineBrainMetastases:       | Measurable                | Measurable                | Any                      | Any                      |
|--------------------------------|---------------------------|---------------------------|--------------------------|--------------------------|
|                                | Arm A Brigatinib (N = 18) | Arm B Crizotinib (N = 23) | ArmA Brigatinib (N = 47) | ArmB Crizotinib (N = 49) |
| Numberwithconfirmedresponse(%) | 14 (77.8)                 | 6 (26.1)                  | 31 (66.0)                | 8 (16.3)                 |
| Nunbercensored (%)             | 10 (71.4)                 | 3 (50.0)                  | 19 (61.3)                | 5 (62.5)                 |
| Median (95% CI)                | NE (5.65, NE)             | 9.232 (3.88, 9.23)        | 24.016 (16.92, NE)       | 9.232 (3.88, NE)         |
| KM estimate, % (95% CI)        |                           |                           |                          |                          |
| 6 months                       | 83.3 (48, 96)             | 60.0 (13,88)              | 93.1 (75,98)             | 71.4 (26, 92)            |
| 12months                       | 75.0 (41, 91)             | NE (NE, NE)               | 79.2 (59, 90)            | 35.7 (1, 78)             |
| 18months                       | 64.3 (30, 85)             | NE (NE, NE)               | 67.5 (47, 82)            | 35.7 (1, 78)             |
| 24 months                      | 64.3 (30, 85)             | NE (NE, NE)               | 55.0 (32,73)             | NE (NE, NE)              |

Source:IA2Table15.2.7.2,and 15.2.7.4(data cutoff:28June 2019)

iDOR:intracranial duration ofresponse;KM:Kaplan-Meier;NE:not estimable.

<div style=\"page-break-after: always\"></div>

Table 33: iPFS (second interim analysis)

| BaselineBrainMetastases:   | Any                                  | Any                       | None                      | None                     |
|----------------------------|--------------------------------------|---------------------------|---------------------------|--------------------------|
|                            | ArmA Brigatinib (N = 47)             | Arm B Crizotinib (N = 49) | Arm A Brigatinib (N = 90) | ArmB Crizotinib (N = 89) |
| Nunber with events (%)     | 21 (44.7)                            | 32 (65.3)                 | 19 (21.1)                 | 19 (21.3)                |
| Number censored (%)        | 26 (55.3)                            | 17 (34.7)                 | 71 (78.9)                 | 70 (78.7)                |
| iPFS,months                |                                      |                           |                           |                          |
| Median (95% CI)            | 23.951 (12.91, NE)5.585 (3.71, 7.52) |                           | 32.296 (NE,NE)            | NE (24.61, NE)           |
| KM estimate, % (95% CI)    |                                      |                           |                           |                          |
| 6 months                   | 87.7 (73, 95)                        | 44.4 (30, 58)             | 91.3 (83, 96)             | 92.5 (84, 97)            |
| 12 months                  | 74.8 (58, 86)                        | 25.6 (12, 42)             | 85.8 (76, 92)             | 80.3 (68, 88)            |
| 18 months                  | 61.3 (44, 75)                        | 20.5 (8, 37)              | 82.8 (72, 90)             | 78.3 (66, 87)            |
| 24 months                  | 47.9 (30, 63)                        | 15.4 (5, 32)              | 74.1 (62, 83)             | 67.2 (52, 79)            |
| Log-rank p-value           | <0.0001                              |                           | 0.3470                    |                          |
| HR (95% CI)                | 0.311 (0.17, 0.56)                   |                           | 0.779 (0.41, 1.48)        |                          |
| P-value                    | <0.0001                              |                           | 0.4447                    |                          |

Sources: IA2 Table 15.2.4.1.2 and 15.2.4.1.4 (data cutoff: 28 June 2019).

iPFS: intracranial progression-free survival; KM: Kaplan-Meier; NE: not estimable; HR: hazard ratio.

P-values from a log-rank test stratified by prior chemotherapy for locally advanced or metastatic disease at study entry. The HR and associated p-value were obtained using a Cox proportional hazards model with randomization stratificationfactors ascovariates.

## Patient-Reported Outcomes (PRO) (First Interim Analysis)

Global health status/quality of life (QoL) and other health-related quality of life (HRQoL) domains were assessed as change in score of the EORTC QLQ C30 (version 3.0) questionnaire. Change in symptoms of lung cancer was evaluated as time to deterioration in dyspnea as assessed by the EORTC lung cancer module, QLQ-LC13 (version 3.0).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Brigatinib

Crizotinib

Source: Study 301 Table 15.2.9.1.1.

Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; ITT, intent to treat; QLQ, Quality of Life Questionnaire;

QoL, quality of life; PRO, patient-reported outcome.

Data are shown for each cycle with a sample size of &gt;20 patients in either treatment arm.

a Values are LS mean (95% CI) at all visits except baseline, which shows the unadjusted mean.

* P &lt;0.05.

Figure 18: LS Mean (95% CI) EORTC QLQ-C30 Global Health Status/QoL Score Over Time (PRO-ITT Population)

Table 34: Time to Worsening Dyspnoea by EORTC QLQ-LC13 Scale (Second Interim Analysis)

|                                   | Arm A Brigatinib (N = 63)   | Arm B Crizotinib (N = 78)   |
|-----------------------------------|-----------------------------|-----------------------------|
| Number with worsening dyspnea (%) | 14 (22.2)                   | 26 (33.3)                   |
| Number censored (%)               | 49 (77.8)                   | 52 (66.7)                   |
| Time to worsening dyspnea, months |                             |                             |
| Median (95% CI)                   | NE                          | NE (17.08, NE)              |
| Minimum, maximum                  | 0.85, 31.21                 | 0.43, 31.47                 |
| KMestimate, %(95% CI)             |                             |                             |
| 6 months                          | 85 (72, 92)                 | 71 (59, 80)                 |
| 12 months                         | 77 (63, 86)                 | 67 (54, 77)                 |
| 18 months                         | 74 (60, 84)                 | 63 (49, 75)                 |
| 24 months                         | 74 (60, 84)                 | 59 (43, 72)                 |
| Log-rank p-value                  | 0.0515                      | --                          |
| HR (95% CI)                       | 0.54 (0.28, 1.04)           | --                          |
| P-value                           | 0.0658                      | --                          |

Source: IA2 Table 15.2.9.2.2 (data cutoff: 28 June 2019).

EORTC: European Organisation for Research and Treatment of Cancer; HR: hazard ratio; KM: KaplanMeier; NE: not evaluable; QLQ: Quality of Life Questionnaire.

P-values from a log-rank test stratified by presence of brain metastases and prior chemotherapy for locally advanced or metastatic disease at study entry. The HR and associated p-value were obtained using a Cox proportional hazards model with randomization stratification factors as covariates.

<div style=\"page-break-after: always\"></div>

Figure 19: Between-Group Mean Differences in Overall Change from Baseline in EORTC QLQ-C30 Subscale Scores: Global QoL and Functioning Scores (PRO-ITT Population; Second Interim Analysis)

<!-- image -->

## Ancillary analyses

## PFS by BIRC

Additional sensitivity analyses:

Because of data errors identified and corrected during preparation for IA2 that affected data relevant to IA1, the MAH decided in August 2019 to perform an IA1 sensitivity analysis, which was conducted with corrected data using the original IA1 data cut-off date 19 February 2018. The decision to conduct this sensitivity analysis was made to ascertain the precise nature and impact of these data corrections. This was especially important given that IA1 data were used to declare statistical significance of the Study 301 results.

The documentation errors identified during the additional data review are summarized below:

- -Seven  tumour-related  intervention  procedures  had  been  entered  incorrectly  in  the  clinical database. Concern was raised that these data errors could potentially affect censoring of PFS events and the results of the PFS analysis. After carefully evaluating the data corrections and confirming that these corrections were incorporated in IA2, it became clear that for these patients, PFS events and censoring by the IA1 data cut-off date (19 Feb 2018) were affected, and the PFS HR for the ITT population at IA1 could change as well.
- -A single death event was identified in August 2019 that had been captured only in a free-text data field in the clinical database. It was therefore not able to be captured in the analysis, which could potentially affect the number of PFS events and would definitely affect the OS events for IA1.
- -Twenty-one baseline scans were identified that had no BIRC assessment performed; thus, these patients were treated as not having brain metastasis at baseline in the original IA1 database. This issue was caused by the BIRC Charter requirement that baseline scans be sent to the BIRC for review together with the first postbaseline assessment. However, as these patients had discontinued from the study without having any follow-up scans, these baseline scans had not been submitted for BIRC assessment for the original IA1 analysis. These issues were not expected to affect the primary  endpoint  analysis  but  could  affect  key  secondary  endpoints  of  intracranial  PFS  and intracranial ORR.

The IA1 sensitivity analysis results are presented in the table below:

<div style=\"page-break-after: always\"></div>

Table 35: Summary of sensitivity analysis for key efficacy endpoints (original IA1 vs IA1 sensitivity analysis)

|                                            | Original IA1         | Original IA1         | IA1 Sensitivity Analysis   | IA1 Sensitivity Analysis   |
|--------------------------------------------|----------------------|----------------------|----------------------------|----------------------------|
|                                            | Brigatinib (N = 137) | Crizotinib (N = 138) | Brigatinib (N = 137)       | Crizotinib (N =138)        |
| BIRC PFS                                   |                      |                      |                            |                            |
| Number of patients with events, n (%)      | 36 (26.3)            | 63 (45.7)            | 36 (26.3)                  | 63 (45.7)                  |
| Log-rank p-value, brigatinib vs crizotinib | 0.0007               | 0.0007               | 0.0006                     | 0.0006                     |
| HR (95% CI), brigatinib vs crizotinib      | 0.492 (0.33, 0.74)   | 0.492 (0.33, 0.74)   | 0.490 (0.32, 0.74)         | 0.490 (0.32, 0.74)         |
| Confirmed ORR                              |                      |                      |                            |                            |
| Confirmed ORR n (%)                        | 97 (70.8)            | 83 (60.1)            | 98 (71.5)                  | 84 (60.9)                  |
| Odds ratio                                 | 1.59                 | 1.59                 | 1.59                       | 1.59                       |
| P-value                                    | 0.0678               | 0.0678               | 0.0658                     | 0.0658                     |
| OS                                         |                      |                      |                            |                            |
| Number of deaths n (%)                     | 17 (12.4)            | 17 (12.3)            | 18 (13.1)                  | 17 (12.3)                  |
| Log-rank p-value                           | 0.9386               | 0.9386               | 0.8934                     | 0.8934                     |
| HR (95% CI), brigatinib vs crizotinib      | 0.983 (0.50, 1.93)   | 0.983 (0.50, 1.93)   | 1.049 (0.54, 2.04)         | 1.049 (0.54, 2.04)         |

Sources:IA1 Original Tables 15.2.1.1.1,15.2.2.1.1, and 15.2.5.1.1;IA1 Sensitivity Analysis Tables 15.2.1.1.1,15.2.2.1.1,and 15.2.5.1.1 (data cutoff 19 February 2018).

BIRC: blinded independent review committee; HR: hazard ratio; IA1:first interim analysis; ORR: objective response rate; OS: overall survival; PFS: progression-free survival.

A total of 7 patients had their PFS event/censoring status and/or event/censoring date updated after the original IA1 analysis, including 4 patients in the crizotinib arm whose PFS event/censoring status changed and  3  patients  in  brigatinib  arm  whose  PFS  event/censoring  status  remained  the  same  but  their event/censoring date changed. The total number of patients with PFS events by BIRC did not change in either arm and remained at 99 events for the IA1 sensitivity analysis.

Overall, the confirmed ORR by BIRC was updated from 70.8% versus 60.1% to 71.5% versus 60.9% for the brigatinib arm and the crizotinib arm, respectively. Only 2 patients had their best confirmed response changed from the original IA1 to the updated IA1 analysis: 1 patient in each treatment arm.

<div style=\"page-break-after: always\"></div>

Table 36: Time-to-Event Analysis of BIRC-Assessed PFS by Prior Chemotherapy Use for Advanced Local or Metastatic Disease (ITT Population, Current, second interim analysis)

|                                      | Prior Chemotherapy       | Prior Chemotherapy       | No Prior Chemotherapy     | No Prior Chemotherapy      |
|--------------------------------------|--------------------------|--------------------------|---------------------------|----------------------------|
|                                      | Arm A Brigatinib (N =36) | Arm B Crizotinib (N =37) | Arm A Brigatinib (N =101) | Arm B Crizotinib (N = 101) |
| Number with events (%o)              | 16 (44.4)                | 26 (70.3)                | 47 (46.5)                 | 61 (60.4)                  |
| Death                                | 0                        | 2 (5.4)                  | 7 (6.9)                   | 3 (3.0)                    |
| PD                                   | 15 (41.7)                | 22 (59.5)                | 39 (38.6)                 | 52 (51.5)                  |
| Palliative radiotherapy to the brain | 1 (2.8)                  | 2 (5.4)                  | 1 (1.0)                   | 6 (5.9)                    |
| Number censored (%o)                 | 20 (55.6)                | 11 (29.7)                | 54 (53.5)                 | 40 (39.6)                  |
| PFS, months                          |                          |                          |                           |                            |
| Median (95% CI)                      | 24.016 (16.62, NE)       | 11.006 (7.16, 21.16)     | 23.951 (18.37, NE)        | 10.842 (9.13, 15.61)       |
| KM estimate, % (95% CI)              |                          |                          |                           |                            |
| 6 months                             | 88.1 (71, 95)            | 70.3 (53, 82)            | 77.1 (67, 84)             | 66.2 (55, 75)              |
| 12 months                            | 78.7 (60, 89)            | 48.9 (32, 64)            | 65.9 (55, 75)             | 44.0 (33, 54)              |
| 18 months                            | 66.1 (47, 80)            | 39.7 (24, 55)            | 62.5 (52, 72)             | 34.1 (24, 45)              |
| 24 months                            | 53.3 (35, 69)            | 25.9 (12, 42)            | 46.0 (35, 57)             | 26.1 (17, 37)              |
| Log-rank p-value                     | 0.0095                   |                          | 0.0005                    |                            |
| HR (95% C1)                          | 0.438 (0.23, 0.83)       |                          | 0.519 (0.35, 0.77)        |                            |
| P-value                              | 0.0120                   |                          | 0.0010                    |                            |

Source:IA2 Table 15.2.1.3.10 (data cutoff: 28 June 2019).

BIRC: blinded independent review committee; HR: hazard ratio; ITT: intent-to-treat; KM: Kaplan-Meier; NE: not estimable; PD: progressive disease; PFS: progression-free survival.

Prior chemotherapy for advanced or metastatic disease.

P-values from a log-rank test stratified by presence of brain metastases at baseline. The HR and associated p-value were obtained using a Cox proportional hazards model with randomization stratification factors as covariates.

<!-- image -->

| Subgroup                                               | Category             | Sample Size   | Sample Size   | HR                | (95% CI)                                  | HR (95% CI)   |
|--------------------------------------------------------|----------------------|---------------|---------------|-------------------|-------------------------------------------|---------------|
| Subgroup                                               | Category             | Brigatinib    | Crizotinib    | HR                | (95% CI)                                  | HR (95% CI)   |
| Age                                                    | 18-64 ≥65            | 93 44         | 95 43         | 0.44 0.59         | (0.26, 0.74) (0.30, 1.18)                 |               |
| Gender                                                 | Female Male          | 69 68         | 81 57         | 0.44 0.49         | (0.24, 0.84) (0.28, 0.85)                 |               |
| Race                                                   | Asian Non-Asian      | 59 78         | 49 89         | 0.41 0.54         | (0.20, 0.86) (0.33,0.90)                  |               |
| Smoking status                                         | Never Former Current | 84 49 4       | 75 56 7       | 0.47 0.51 --      | (0.27, 0.84) (0.27, 0.97) --              |               |
| ECOG NSCLC stage at entry                              | 0 1 2                | 58 73 6       | 60 72 6       | 0.19 0.60 --      | (0.06, 0.55) (0.37, 0.98) --              |               |
|                                                        | IV IIIB              | 129 8         | 126 12        | 0.48 --           | (0.32, 0.74) --                           |               |
| ALK status by FDA-approved test a Prior chemotherapy b | Yes No Yes No        | 132 5 36 101  | 131 7 37 101  | 0.49 -- 0.35 0.55 | (0.32, 0.75) -- (0.14, 0.85) (0.34, 0.88) |               |
| Brain metastases at baseline c                         | Yes No               | 40 97         | 41 97         | 0.20 0.72         | (0.09, 0.46) (0.44,                       |               |
|                                                        |                      | 137           | 138           |                   | 1.18)                                     |               |
| ITT Population                                         |                      |               |               | 0.49              | 0.0 (0.33, 0.74)                          | 0.5 1.0 1.5   |

Source: Study 301 Table 15.2.1.1.1, 15.2.1.3.1, 15.2.1.3.2, 15.2.1.3.3, 15.2.1.3.9, 15.2.1.3.10, 15.2.1.3.13, 15.2.1.3.15, 15.2.1.3.16, 15.2.1.3.17, and Figure 15.2.1.1.5.2 (data cutoff: 19 February 2018).

Abbreviations: ALK, anaplastic lymphoma kinase; BIRC, blinded independent review committee; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; NSCLC; non-small-cell lung cancer; PFS, progression-free survival.

a Documented ALK+ status by a US FDA-approved test either locally or centrally.

b Chemotherapy for locally advanced or metastatic disease.

c Presence of baseline metastases as determined by the investigator.

-- indicates insufficient data to complete the analysis due to small sample size.

Figure 20: Subgroup Analyses of BIRC-Assessed PFS (ITT Population)

<div style=\"page-break-after: always\"></div>

Table 37: BIRC-Assessed PFS by iCNS Metastases at Baseline (ITT Population, Current; First Interim Analysis)

|                                             | iCNS Metastases           | iCNS Metastases           | No iCNS Metastases        | No iCNS Metastases        |
|---------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                             | Arm A Brigatinib (N = 40) | Arm B Crizotinib (N = 41) | Arm A Brigatinib (N = 97) | Arm B Crizotinib (N = 97) |
| Number with events (%)                      | 8 (20.0)                  | 24 (58.5)                 | 28 (28.9)                 | 39 (40.2)                 |
| Death                                       | 0                         | 5 (12.2)                  | 6 (6.2)                   | 1 (1.0)                   |
| Progressive disease                         | 6 (15.0)                  | 16 (39.0)                 | 22 (22.7)                 | 37 (38.1)                 |
| Palliative radiotherapy to the brain        | 2 (5.0)                   | 3 (7.3)                   | 0                         | 1 (1.0)                   |
| Number censored (%)                         | 32 (80.0)                 | 17 (41.5)                 | 69 (71.1)                 | 58 (59.8)                 |
| PFS, months                                 |                           |                           |                           |                           |
| Median (95% CI)                             | NE (NE, NE)               | 5.552 (3.84, 11.07)       | NE (NE, NE)               | 11.105 (9.20, NE)         |
| Minimum, maximum                            | 0.03, 15.84               | 0.03, 13.14               | 0.03, 18.33               | 0.03, 18.33               |
| KM estimate, %(95% CI) [N at risk]          |                           |                           |                           |                           |
| 12 months                                   | 74.9 (56, 87) [N = 9]     | 24.9 (8, 46) [N = 3]      | 63.2 (50, 74) [N = 17]    | 49.0 (36, 61) [N = 15]    |
| Log-rank p-value (brigatinib vs crizotinib) | <0.0001                   |                           | 0.2019                    |                           |
| HR (95% CI) (brigatinib vs crizotinib)      | 0.204 (0.09, 0.46)        |                           | 0.723 (0.44, 1.18)        |                           |
| P-value                                     | 0.0001                    |                           | 0.1909                    |                           |

Source: Study 301 Table 15.2.1.3.9 (data cutoff: 19 February 2018).

Abbreviations: BIRC, blinded independent review committee; HR, hazard ratio; iCNS, intracranial central nervous system; ITT, intent-to-treat;

KM, Kaplan-Meier; NE, not estimable; PFS, progression-free survival.

Patient status (presence/absence of iCNS metastases) is based on investigator determination.

Table 38: Competing Risks Analysis (ITT Population; First Interim Analysis)

|                                                               | Arm A Brigatinib (N = 137)   | Arm B Crizotinib (N = 138)   |
|---------------------------------------------------------------|------------------------------|------------------------------|
| Time to iCNS progression (without prior systemic progression) |                              |                              |
| Number with an event (%)                                      | 12 (8.8)                     | 26 (18.8)                    |
| Cause-specific HR(95% CI)                                     | 0.30 (0.15, 0.60)            |                              |
| Log-rank p-value (brigatinib vs crizotinib)                   | <0.001                       |                              |
| Cumulative Incidence Rate, %(95% CI)                          |                              |                              |
| 6 months                                                      | 4.0 (1.5, 8.5)               | 15.5 (9.9, 22.3)             |
| 12 months                                                     | 12.0 (6.4, 19.5)             | 22.6 (15.2, 31.0)            |
| Time to systemic progression (without prior iCNS progression) |                              |                              |
| Number with an event (%)                                      | 22 (16.1)                    | 40 (29.0)                    |
| Cause-specific HR(95% CI)                                     | 0.51 (0.30, 0.86)            |                              |
| Log-rank p-value (brigatinib vs crizotinib)                   | 0.017                        |                              |
| Cumulative Incidence Rate, %(95% CI)                          |                              |                              |
| 6 months                                                      | 12.6 (7.6, 19.1)             | 20.0 (13.6, 27.3)            |
| 12 months                                                     | 20.2 (12.8, 28.9)            | 36.8 (27.2, 46.5)            |
| Time to death (without prior iCNS or systemic progression)    |                              |                              |
| Number with an event (%)                                      | 10 (7.3)                     | 7 (5.1)                      |
| Cause-specific HR(95% CI)                                     | 1.23 (0.46, 3.24)            |                              |
| Log-rank p-value (brigatinib vs crizotinib)                   | 0.729                        |                              |
| Cumulative Incidence Rate, %(95% CI)                          |                              |                              |
| 6 months                                                      | 3.9 (1.5, 8.4)               | 4.6 (1.9, 9.1)               |
| 12 months                                                     | 9.5 (4.7, 16.3)              | 5.6 (2.5, 10.8)              |

Source: Appendix 1 Table 99.1.1.1, 99.2.1.1.1, 99.2.4.1.1, and 99.2.5.1.1 (data cutoff: 19 February 2018).

Abbreviations: HR, hazard ratio; iCNS, intracranial central nervous system; ITT, intent-to-treat.

Updated data cut-off 28 June 2019 (Second Interim Analysis)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: IA2 Figure 15.2.1.1.5.1 and 15.2.1.1.5.2 (data cutoff: 28 June 2019).

BIRC: blinded independent review committee; ECOG: Eastern Cooperative Oncology Group; HR: hazard ratio;

ITT, intent to treat; PFS: progression-free survival.

-- indicates insufficient data to complete the analysis due to small sample size.

Presence of baseline metastases as determined by the investigator.

a Chemotherapy for locally advanced or metastatic disease.

Figure 21: Subgroup Analyses of BIRC-Assessed PFS (ITT Population, second interim analysis)

Table 39: BIRC-assessed PFS in patients with and without brain metastases at baseline (ITT population, current, second interim analysis)

|                                      | Brain Metastases        | Brain Metastases         | No Brain Metastases      | No Brain Metastases      |
|--------------------------------------|-------------------------|--------------------------|--------------------------|--------------------------|
|                                      | ArmA Brigatinib (N =40) | ArmB Crizotinib (N = 41) | ArmA Brigatinib (N = 97) | ArmB Crizotinib (N = 97) |
| Number with events (%o)              | 20 (50.0)               | 30 (73.2)                | 43 (44.3)                | 57 (58.8)                |
| Death                                | 0                       | 4 (9.8)                  | 7 (7.2)                  | 1 (1.0)                  |
| PD                                   | 18 (45.0)               | 20 (48.8)                | 36 (37.1)                | 54 (55.7)                |
| Palliative radiotherapy to the brain | 2 (5.0)                 | 6 (14.6)                 | 0                        | 2 (2.1)                  |
| Number censored (%)                  | 20 (50.0)               | 11 (26.8)                | 54 (55.7)                | 40 (41.2)                |
| PFS, months                          |                         |                          |                          |                          |
| Median (95% CI)                      | 23.951 (18.37, NE)      | 5.552 (3.84, 9.40)       | 24.016 (15.67, NE)       | 13.010 (9.46, 21.13)     |
| KM estimate, % (95% C1)              |                         |                          |                          |                          |
| 6 months                             | 89.0 (73, 96)           | 47.5 (31, 62)            | 76.3 (66, 84)            | 75.7 (65, 83)            |
| 12 months                            | 77.9 (61, 88)           | 21.9 (9, 38)             | 65.8 (55, 75)            | 54.6 (43, 65)            |
| 18 months                            | 72.1 (54, 84)           | 14.6 (5,30)              | 59.8 (49, 69)            | 44.0 (33, 54)            |
| 24 months                            | 42.9 (25, 59)           | 9.7 (2, 25)              | 50.4 (39, 61)            | 32.1 (22,43)             |
| Log-rank p-value                     | <0.0001                 |                          | 0.0298                   |                          |
| HR (95% CI)                          | 0.249 (0.14, 0.46)      |                          | 0.649 (0.44, 0.97)       |                          |
| P-value                              | <0.0001                 |                          | 0.0333                   |                          |

Source:IA2 Table 15.2.1.3.9 (data cutoff:28June 2019).

BIRC: blinded independent review committee;HR: hazard ratio;ITT: intent to treat; KM: Kaplan-Meier;NE: not estimable; PD: progressive disease; PFS: progression-free survival.

Patientstatus(presence/absenceofbrainmetastases)isbasedoninvestigator determination.

P-values from a log-rank test stratified by prior chemotherapy for locally advanced or metastatic disease at study entry.TheHR and associatedp-valuewere obtained using a Coxproportional hazards modelwithrandomization stratificationfactors ascovariates.

<div style=\"page-break-after: always\"></div>

Table 40: Competing Risks Analysis (ITT Population, second interim analysis)

|                                                                       | Arm A Brigatinib (N = 137)   | ArmB Crizotinib (N =138)   |
|-----------------------------------------------------------------------|------------------------------|----------------------------|
| Time to intracranial progression(vithoutprior systemic progression)   |                              |                            |
| Number with an event (%)                                              | 22 (16.1)                    | 36 (26.1)                  |
| Cause-specific HR (95% CI)                                            | 0.30 (0.17, 0.53)            |                            |
| Cumulative incidence rate, % (95% CI)                                 |                              |                            |
| 12 months                                                             | 7.8 (4.0, 13.3)              | 22.4 (15.6, 29.9)          |
| 24 months                                                             | 17.4 (11.1, 24.8)            | 27.8 (20.2, 35.9)          |
| Time to systemic progression (without prior intracranial progression) |                              |                            |
| Number with an event (%)                                              | 39 (28.5)                    | 54 (39.1)                  |
| Cause-specific HR (95% CI)                                            | 0.54 (0.36, 0.82)            |                            |
| Cumulative incidence rate, % (95% CI)                                 |                              |                            |
| 12 months                                                             | 19.5 (13.1, 26.8)            | 31.3 (23.4, 39.5)          |
| 24 months                                                             | 30.5 (22.6, 38.8)            | 44.1 (35.0, 52.9)          |
| Time to death(vithout priorintracranial orsystemicprogression)        |                              |                            |
| Number with an event (%)                                              | 14 (10.2)                    | 11 (8.0)                   |
| Cause-specific HR (95% CI)                                            | 0.99 (0.45, 2.21)            |                            |
| Cumulative incidence rate, % (95% CI)                                 |                              |                            |
| 12 months                                                             | 7.8 (4.0, 13.3)              | 5.3 (2.3, 10.1)            |
| 24 months                                                             | 10.2 (5.7, 16.1)             | 8.7 (4.6, 14.5)            |

Sources: IA2 Table 99.1.1.1, 99.2.1.1.1, 99.2.4.1.1, and 99.2.5.1.1 (data cutoff: 28 June 2019).

HR: hazard ratio; ITT: intent-to-treat.

## Summary of main study

The following table summarises the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 41: Summary of Efficacy for trial ALTA 1 L

| Title: ALTA 1 L           | Title: ALTA 1 L                                                                                             | Title: ALTA 1 L                                                                                             | Title: ALTA 1 L                                                                                                                  |
|---------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Study identifier          | AP26113-13-301                                                                                              | AP26113-13-301                                                                                              | AP26113-13-301                                                                                                                   |
| Design                    | Randomised comparative phase 3 study of brigatinib vs crizotinib in the first- line treatment of ALK+ NSCLC | Randomised comparative phase 3 study of brigatinib vs crizotinib in the first- line treatment of ALK+ NSCLC | Randomised comparative phase 3 study of brigatinib vs crizotinib in the first- line treatment of ALK+ NSCLC                      |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                              | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                              | ~3 years not applicable not applicable                                                                                           |
| Hypothesis                | Superiority                                                                                                 | Superiority                                                                                                 | Superiority                                                                                                                      |
| Treatments groups         | Brigatinib arm                                                                                              | Brigatinib arm                                                                                              | Brigatinib 90 mg QD for 7 days, then 180 mg QD. Until PD, N=137                                                                  |
| Treatments groups         | Crizotinib arm                                                                                              | Crizotinib arm                                                                                              | Crizotinib 250 mg BID. Until PD, N=138                                                                                           |
| Endpoints and definitions | Primary endpoint                                                                                            | PFS by BIRC                                                                                                 | Progression-free survival by blinded independent review committee                                                                |
| Endpoints and definitions | Key secondary endpoints:                                                                                    | Confirmed ORR, confirmed iORR, iPFS, and OS                                                                 | Confirmed overall response rate, intracranial overall response rate, intracranial progression-free survival and overall survival |
| Database cutoff date      | 19 February 2018                                                                                            | 19 February 2018                                                                                            | 19 February 2018                                                                                                                 |
| Results and Analysis      | Results and Analysis                                                                                        | Results and Analysis                                                                                        | Results and Analysis                                                                                                             |
| Analysis description      | Primary Analysis                                                                                            | Primary Analysis                                                                                            | Primary Analysis                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | Intent to treat                                                        | Intent to treat                                                        | Intent to treat                                                        | Intent to treat                                                        |
|--------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                        | Brigatinib                                                             | Crizotinib                                                             | Hazard Ratio/ p-value                                                  |
| Descriptive statistics and estimate variability  | Number of subjects                                                     | N=137                                                                  | N=138                                                                  |                                                                        |
| Descriptive statistics and estimate variability  | Median PFS by BIRC (months)                                            | NE                                                                     | 9.758                                                                  | 0.492/ 0.0007                                                          |
| Descriptive statistics and estimate variability  | 95%CI                                                                  | NE; NE                                                                 | 9.03; 12.88                                                            | 0.33;0.74                                                              |
| Descriptive statistics and estimate variability  | ORR by BIRC                                                            | 70.8%                                                                  | 60.1%                                                                  | / 0.0678                                                               |
| Descriptive statistics and estimate variability  | 95%CI                                                                  | 62.43; 78.25                                                           | 51.47; 68.38                                                           |                                                                        |
| Descriptive statistics and estimate variability  | Median OS (months) 95%CI                                               | NE NE; NE                                                              | NE NE; NE                                                              | 0.983 0.50; 1.93                                                       |
| Analysis description                             | Secondary analysis data cutoff 28 June 2019                            | Secondary analysis data cutoff 28 June 2019                            | Secondary analysis data cutoff 28 June 2019                            | Secondary analysis data cutoff 28 June 2019                            |
| Descriptive statistics and estimate variability  | Treatment group                                                        | Brigatinib                                                             | Crizotinib                                                             | Hazard Ratio/ p-value                                                  |
|                                                  | Number of subjects                                                     | N=137                                                                  | N=138                                                                  |                                                                        |
|                                                  | Median PFS by BIRC (months)                                            | 23.984                                                                 | 11.006                                                                 | 0.489/ <0.0001                                                         |
|                                                  | 95%CI                                                                  | 18.46; NE                                                              | 9.17; 12.88                                                            | 0.35;0.68                                                              |
|                                                  | ORR by BIRC                                                            | 73.7%                                                                  | 61.6                                                                   | / 0.0342                                                               |
|                                                  | 95%CI                                                                  | 65.52; 80.87                                                           | 52.94; 69.74                                                           |                                                                        |
|                                                  | Median OS (months) 95%CI                                               | NE NE; NE                                                              | NE NE; NE                                                              | 0.916 0.57; 1.47                                                       |
| Notes                                            | Intracranial efficacy results and exploratory endpoints are not shown. | Intracranial efficacy results and exploratory endpoints are not shown. | Intracranial efficacy results and exploratory endpoints are not shown. | Intracranial efficacy results and exploratory endpoints are not shown. |

## 2.4.3. Discussion on clinical efficacy

In order to support this extension of indication for brigatinib in patients with ALK+ NSCLC previously not treated with an ALK inhibitor, the MAH submitted the results from the multicenter, randomised phase 3 ALTA 1L trial, comparing brigatinib with crizotinib in the TKI-naïve setting. 275 patients were randomised 1:1 in 92 investigational sites across the world, mainly in the EU (55 sites) and the AsiaPacific (24 sites). The study was fully recruited by 14 months. Updated efficacy data are presented with longer follow-up (24.8 months for the brigatinib arm) and from the data cut-off of 28 June 2019.

<div style=\"page-break-after: always\"></div>

## Design and conduct of clinical studies

The design of the pivotal ALTA 1L is acceptable. The randomisation, sample size and statistical methods used are generally endorsed. Additional sensitivity analyses and clarifications were requested and were in line with the primary analysis.

The comparator of crizotinib, which is a first-generation ALK-TKI, is now an inferior treatment considering the current treatment landscape with several second-generation ALK-TKIs, of which some are approved for first-line treatment (alectinib and ceritinib). However, it is acknowledged that crizotinib was the standard of care in the first-line setting, when the pivotal 301 study was planned and initiated. The pivotal 301 study was also the confirmatory study for the initially planned CMA for Alunbrig in the second-line setting. Hence, the comparator of crizotinib has already been accepted in the procedure for the initial MAA, despite the fact that Alunbrig was given a full approval. Crizotinib was also accepted as comparator in the approval for first-line treatment with alectinib. In that context, crizotinib as comparator in the pivotal 301 study is considered acceptable.

The primary objective of the pivotal trial is efficacy measured using PFS by BIRC as primary endpoint and the key secondary endpoints tested hierarchically are confirmed ORR, intracranial ORR, intracranial PFS, and OS. As the study was not blinded, it is endorsed that the blinded independent review of PFS is the primary endpoint to minimise bias from the investigators, who know the allocated treatment. The key secondary endpoints are also endorsed, as response to treatment both systemically and intracranially are clinically relevant endpoints due to the high risk of brain metastases with ALK+ NSCLC. Due to database entry errors discovered when the second IA was prepared, an extra sensitivity analyses of the first IA was done and was in line with the primary analysis. Moreover, these errors were not deemed to have had relevant clinical impact on the study results.

The majority of included patients were white (58.9%) or Asian (39.3), which is reflective of the sites of the study and is acceptable. The median age was 59 years (range 27-89), slightly more women were included and most were non-smokers (57.8%), which is reflective of the patient population. It is considered possible to extrapolate efficacy in the Asian population to the European mainly white population, as brigatinib is a specific targeted treatment for ALK+ NSCLC. Only 4.4% of the patients had PS 2, while the remaining patients had PS 0-1, which is reflective of a study population but not the general patient population. This is acceptable for the clinical study setting and these patients were evenly distributed between the treatment arms, minimising the bias of poor performance status. The organ involvement including the CNS is considered reflective of the patient population. Overall, the baseline characteristics are reflective of the targeted disease and patient population and there are no major clinically important imbalances between the treatment arms.

## Efficacy data and additional analyses

The primary efficacy analysis, PFS by BIRC, is from the primary analysis and the primary endpoint was met. Updated data from the second IA show that the median PFS by BIRC was improved from 11.0 months to 24.0 months (95%CI: 18.5, NE) with a HR of 0.489 and based on 46% events with brigatinib vs 63% events with crizotinib. The 13 months improvement is statistically significant and highly clinically meaningful for the targeted patient population.

The key secondary endpoint of confirmed ORR was improved by approximately 10%, which is considered clinically relevant, because it translates into better disease control and symptom relief. It is noted that more patients had a confirmed complete response (CR) with brigatinib vs crizotinib (14.6% vs 8.7%). In addition, more patients had an overall response to brigatinib 73.7% (95%CI: 65.52; 80.87) compared to crizotinib 61.6% (95%CI: 52.94; 69.74), while similar disease control rates were observed in both arms  (~83%).  Updated  data  now  show  that  the  difference  in  ORR  by  BIRC  and  INV  is  considered supportive of the primary objective.

<div style=\"page-break-after: always\"></div>

Updated  confirmed  Intracranial  ORR  for  patients  with  any  brain  metastases  at  baseline  (n=90)  is markedly improved with brigatinib i.e. 66% (95%CI: 50.69; 79.14) vs 16.3% (95%CI: 7.32; 29.66) with crizotinib,  which is also supported by intracranial PFS in patients with any brain metastases at baseline with a median iPFS of 24 months with brigatinib vs 5.6 months with crizotinib. Regardless of the presence of brain metastases at baseline, the updated PFS was ~24 months with brigatinib versus a PFS of ~13 months on crizotinib if there were no brain metastases at baseline and as mentioned, only 5.6 months with brain metastases at baseline. Hence, these data show a superior iPFS with brigatinib regardless of the presence of brain metastases at baseline, indicating that brigatinib can prevent the occurrence of de novo brain metastases, as the brain is often the site of progression.

Overall, 70 deaths have been reported by the time of the latest data cut-off, and consequently the median OS has still not been reached in either arm. The event rate is 24.1% in the brigatinib arm and 26.8%  in  the  crizotinib  arm,  which  is  reflective  of  the  multiple  treatment  options  beyond  first-line treatment. Although OS data are still immature, there are no sign of a detrimental effect of brigatinib treatment and it is considered encouraging that the OS events are occurring slower than anticipated. Hence, it is acceptable that the final OS and PFS analyses are provided by 30 June 2021.

Time to response were similar between the arms and the median was approximately 1.8 months, which is consistent with previous data on brigatinib and other ALKTKI's. The median DOR by BIRC was not reached for brigatinib (95%CI: 19.38, NE) and 13.8 months (95%CI: 9.30; 20.8) for crizotinib. The DOR by INV was similar and considered supportive of the BIRC assessed data. The prolonged DOR with brigatinib is considered clinically relevant, and the updated data is considered mature.

PRO data have been presented and results indicate no detrimental effect of brigatinib. However, these data should be interpreted with caution as there was no blinding of the study treatment and bias cannot be ruled out. Moreover, the type I error was neither controlled for the multiple secondary endpoints (of which PRO is number 9) nor the multiple symptoms being assessed with the PRO tools.

Updated subgroup analyses of BIRC-Assessed PFS by prior chemotherapy are in favour of treatment with brigatinib and the results are consistent with those in the ITT population. Hence, one treatment with chemotherapy, as allowed in the inclusion criteria, is acceptable for the applied indication of brigatinib. Overall, the subgroup analyses favour brigatinib, especially if brain metastases were present at baseline, which is considered supported of improved intracranial efficacy results. The Competing Risks Analysis shows evidence of more CNS progressions with crizotinib than with brigatinib (26.1% vs 16.1% events), also  supportive  of  improved  intracranial  efficacy  with  brigatinib.  There  were  no  detrimental  effects observed regarding advanced age (≥ 65 years), gender, race, smoking status, or ECOG performance status.

## 2.4.4. Conclusions on the clinical efficacy

Efficacy results from the pivotal study ALTA 1L show superior efficacy of brigatinib versus crizotinib both systemically and intracranially for the treatment of patients with locally advanced or metastatic ALK+ NSCLC, who had not received prior treatment with an ALK-inhibitor.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

The  evaluation  of  safety  was  initially  based  on  data  from  phase  3  Study  301  (data  cut-off  date: 19 February 2018), which comprises 273 patients who received ≥1 dose of study drug: 136 brigatinib and 137 crizotinib. Updated safety data from the 301 study have now been provided using the data cutoff 28 June 2019. In addition, safety data is reported from the phase 2 study 201 in patients with locally advanced or metastatic ALK+ NSCLC, who had progressed on crizotinib (222 patients were randomized, and 219 patients received ≥ 1 dose of brigatinib of which 110 patients received the recommended dose of brigatinib i.e. 90 mg QD → 180 mg QD (data cut-off: 29 September 2017).

## Patient exposure

Table 42: Overall Extent of Exposure to Study Drug in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                 | Study 301                       |                       | Study 201                           | Total Brigatinib                        |
|---------------------------------|---------------------------------|-----------------------|-------------------------------------|-----------------------------------------|
|                                 | Brigatinib 90mgQD → 180 mgQD    | Crizotinib 250 mg BID | Brigatinib 90mgQD → 180mgQD N = 110 | Brigatinib 90 mg QD → 180 mg QD N = 246 |
|                                 | N = 136                         |                       |                                     |                                         |
|                                 |                                 | N = 137               |                                     |                                         |
| Duration of exposure (months) a | Duration of exposure (months) a |                       |                                     |                                         |
| Mean (SD)                       | 8.8 (4.49)                      | 7.7 (4.18)            | 16.6 (11.01)                        | 12.3 (8.95)                             |
| Median                          | 9.2                             | 7.4                   | 17.2                                | 10.3                                    |
| Min, max                        | 0, 18                           | 0, 19                 | 0, 39                               | 0, 39                                   |
| Duration of exposure [n (%)]    | Duration of exposure [n (%)]    |                       |                                     |                                         |
| <1 month                        | 11 (8.1)                        | 7 (5.1)               | 8 (7.3)                             | 19 (7.7)                                |
| 1 to <3 months                  | 10 (7.4)                        | 12 (8.8)              | 6 (5.5)                             | 16 (6.5)                                |
| 3 to <6 months                  | 10 (7.4)                        | 32 (23.4)             | 12 (10.9)                           | 22 (8.9)                                |
| 6 to <12 months                 | 72 (52.9)                       | 64 (46.7)             | 20 (18.2)                           | 92 (37.4)                               |
| ≥12 months                      | 33 (24.3)                       | 22 (16.1)             | 64 (58.2)                           | 97 (39.4)                               |
| Number of days dosed            | Number of days dosed            |                       |                                     |                                         |
| Mean (SD)                       | 266.3 (138.11)                  | 231.3 (131.00)        | 492.0 (329.90)                      | 367.3 (267.53)                          |
| Median                          | 287.0                           | 225.0                 | 516.0                               | 319.0                                   |
| Min, max                        | 2, 560                          | 4, 603                | 2, 1130                             | 2, 1130                                 |
| Observed total dose (mg)        | Observed total dose (mg)        |                       |                                     |                                         |
| Mean (SD)                       | 43,002.6 (23,714.10)            | 111,870.8 (65,548.94) | 78,467.5 (54,522.18)                | 58,860.9 (44,097.63)                    |
| Median                          | 44,415.0                        | 112,000.0             | 75,780.0                            | 50,940.0                                |
| Min, max                        | 180, 99,720                     | 2000, 296,000         | 180, 183,870                        | 180, 183,870                            |
| Dose intensity (mg/day)         | Dose intensity (mg/day)         |                       |                                     |                                         |
| Mean (SD)                       | 156.3 (35.31)                   | 469.6 (72.48)         | 151.5 (34.46)                       | 154.2 (34.94)                           |
| Median                          | 173.7                           | 500.0                 | 168.8                               | 171.7                                   |
| Min, max                        | 37, 198                         | 216, 633              | 39, 179                             | 37, 198                                 |
| Relative dose intensity (%) b   | Relative dose intensity (%) b   |                       |                                     |                                         |
| Mean (SD)                       | 89.3 (18.14)                    | 92.3 (14.03)          | 88.4 (17.24)                        | 88.9 (17.71)                            |
| Median                          | 99.6                            | 99.6                  | 98.2                                | 98.7                                    |
| Min, max                        | 24, 137                         | 43, 127               | 33, 101                             | 24, 137                                 |

Source: Table 15.3.9.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; max, maximum; min, minimum; QD, once daily; SD, standard deviation.

a Time (months) on study treatment = (last non-zero dose date - first dose date + 1)/30.4375.

b Observed total dose divided by expected total dose × 100.

<div style=\"page-break-after: always\"></div>

## Updated safety study 301 data cut-off 28 June 2019

Table 43: Treatment exposure (treated population, second interim analysis)

|                             | ArmA Brigatinib (N = 136)   | ArmB Crizotinib (N = 137)   |
|-----------------------------|-----------------------------|-----------------------------|
| Duration ofexposure(months) |                             |                             |
| Median                      | 24.28                       | 8.38                        |
| Minimum,maximum             | 0.1, 34.6                   | 0.1, 36.0                   |
| Duration ofexposure (n [%]) |                             |                             |
| <1 month                    | 11 (8.1)                    | 7 (5.1)                     |
| 1 to<3months                | 10 (7.4)                    | 12 (8.8)                    |
| 3 to <6 months              | 9 (6.6)                     | 32 (23.4)                   |
| 6 to<12 months              | 14 (10.3)                   | 34 (24.8)                   |
| ≥12 months                  | 92 (67.6)                   | 52 (38.0)                   |
| Number of days dosed        |                             |                             |
| Median                      | 705.5                       | 255.0                       |
| Minimum,maximum             | 2,1046                      | 4,1096                      |
| Total cumulative dose(mg)   |                             |                             |
| Median                      | 88185.0                     | 125000.0                    |
| Minimum,maximum             | 180,187020                  | 2000,537250                 |
| Dose intensity (ng/day)     |                             |                             |
| Median                      | 163.83                      | 495.64                      |
| Minimum, maximum            | 36.9, 180.0                 | 215.5,500.0                 |
| Relative dose intensity (%) |                             |                             |
| Median                      | 96.89                       | 99.12                       |
| Minimum,maximum             | 23.7,136.8                  | 43.1, 100.0                 |

Source:IA2 Table15.1.9 (data cutoff: 28June 2019).

SD:standard deviation.

Total cumulative dose does not include doses with *Other Dose Schedule of Administration\" equal to “Other.\"

q Time (months) on study treatment = (last nonzero dose date-first dose date + 1) / 30.4375.

Total cumulative dose (mg) / time (days) on study treatment.

d Total cumulative dose (mg) administered / total dose planned x 100%.

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 44 : Overview of TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                                           | Study 301                                     |                                     | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                                           | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with TEAEs                                       | 132 (97.1)                                    | 137 (100)                           | 110 (100)                                     | 242 (98.4)                                    |
| Drug related                                              | 116 (85.3)                                    | 131 (95.6)                          | 105 (95.5)                                    | 221 (89.8)                                    |
| Grade ≥3                                                  | 83 (61.0)                                     | 76 (55.5)                           | 78 (70.9)                                     | 161 (65.4)                                    |
| Grade ≥3, drug related                                    | 63 (46.3)                                     | 39 (28.5)                           | 50 (45.5)                                     | 113 (45.9)                                    |
| Leading to study drug discontinuation a                   | 16 (11.8)                                     | 12 (8.8)                            | 12 (10.9)                                     | 28 (11.4)                                     |
| Leading to dose reduction                                 | 39 (28.7)                                     | 29 (21.2)                           | 32 (29.1)                                     | 71 (28.9)                                     |
| Leading to dose interruption                              | 72 (52.9)                                     | 58 (42.3)                           | 68 (61.8)                                     | 140 (56.9)                                    |
| Patients with SAEs                                        | 34 (25.0)                                     | 45 (32.8)                           | 62 (56.4)                                     | 96 (39.0)                                     |
| Drug related                                              | 13 (9.6)                                      | 5 (3.6)                             | 20 (18.2)                                     | 33 (13.4)                                     |
| Deaths within 30 days after last dose or possibly related | 7 (5.1)                                       | 7 (5.1)                             | 11 (10.0)                                     | 18 (7.3)                                      |

Source: Table 15.3.1.1.1 and 15.3.2.11 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

a Study  201  does  not  include  patients  who  had  an  AE  action  of  'Drug  Withdrawn'  and  a  primary  reason  for  treatment discontinuation of 'Progressive Disease.'

## Treatment-emergent AEs

Table 45 : TEAEs Occurring in ≥10% of Patients in Either Study or With a ≥5% Absolute Difference Between Arms in Study 301, All Grades by SOC and PT in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| System Organ Class Preferred Term       | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any TEAE                  | 132 (97.1)                                    | 137 (100)                           | 110 (100)                                     | 242 (98.4)                                    |
| Infections and infestations             | 50 (36.8)                                     | 55 (40.1)                           | 65 (59.1)                                     | 115 (46.7)                                    |
| Pneumonia                               | 8 (5.9)                                       | 5 (3.6)                             | 18 (16.4)                                     | 26 (10.6)                                     |
| Viral upper respiratory tract infection | 6 (4.4)                                       | 10 (7.3)                            | 15 (13.6)                                     | 21 (8.5)                                      |
| Urinary tract infection                 | 7 (5.1)                                       | 10 (7.3)                            | 11 (10.0)                                     | 18 (7.3)                                      |
| Metabolism and nutrition disorders      | 42 (30.9)                                     | 44 (32.1)                           | 57 (51.8)                                     | 99 (40.2)                                     |
| Decreased appetite                      | 10 (7.4)                                      | 27 (19.7)                           | 27 (24.5)                                     | 37 (15.0)                                     |
| Hypokalaemia                            | 7 (5.1)                                       | 0                                   | 4 (3.6)                                       | 11 (4.5)                                      |
| Hypoalbuminaemia                        | 1 (0.7)                                       | 8 (5.8)                             | 2 (1.8)                                       | 3 (1.2)                                       |
| Nervous system disorders                | 51 (37.5)                                     | 65 (47.4)                           | 77 (70.0)                                     | 128 (52.0)                                    |
| Headache                                | 20 (14.7)                                     | 18 (13.1)                           | 43 (39.1)                                     | 63 (25.6)                                     |
| Dizziness                               | 13 (9.6)                                      | 21 (15.3)                           | 18 (16.4)                                     | 31 (12.6)                                     |
| Paraesthesia                            | 7 (5.1)                                       | 7 (5.1)                             | 12 (10.9)                                     | 19 (7.7)                                      |
| Dysgeusia                               | 6 (4.4)                                       | 26 (19.0)                           | 6 (5.5)                                       | 12 (4.9)                                      |
| Eye disorders                           | 19 (14.0)                                     | 74 (54.0)                           | 28 (25.5)                                     | 47 (19.1)                                     |
| Visual impairment                       | 0                                             | 22 (16.1)                           | 4 (3.6)                                       | 4 (1.6)                                       |
| Photopsia                               | 1 (0.7)                                       | 28 (20.4)                           | 1 (0.9)                                       | 2 (0.8)                                       |
| Ear and labyrinth disorders             | 2 (1.5)                                       | 10 (7.3)                            | 15 (13.6)                                     | 17 (6.9)                                      |
| Vertigo                                 | 0                                             | 2 (1.5)                             | 12 (10.9)                                     | 12 (4.9)                                      |

<div style=\"page-break-after: always\"></div>

|                                                        | Study 301                                     |                                     | Study 201                                     | Total Brigatinib                              |
|--------------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| System Organ Class Preferred Term                      | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Cardiac disorders                                      | 18 (13.2)                                     | 33 (24.1)                           | 21 (19.1)                                     | 39 (15.9)                                     |
| Bradycardia                                            | 7 (5.1)                                       | 17 (12.4)                           | 2 (1.8)                                       | 9 (3.7)                                       |
| Vascular disorders                                     | 36 (26.5)                                     | 31 (22.6)                           | 36 (32.7)                                     | 72 (29.3)                                     |
| Hypertension                                           | 31 (22.8)                                     | 10 (7.3)                            | 30 (27.3)                                     | 61 (24.8)                                     |
| Deep vein thrombosis                                   | 0                                             | 8 (5.8)                             | 1 (0.9)                                       | 1 (0.4)                                       |
| Respiratory, thoracic, and                             | 77 (56.6)                                     | 65 (47.4)                           | 73 (66.4)                                     | 150 (61.0)                                    |
| Cough                                                  | 34 (25.0)                                     | 22 (16.1)                           | 45 (40.9)                                     | 79 (32.1)                                     |
| Dyspnoea                                               | 24 (17.6)                                     | 25 (18.2)                           | 30 (27.3)                                     | 54 (22.0)                                     |
| Oropharyngeal pain                                     | 6 (4.4)                                       | 6 (4.4)                             | 11 (10.0)                                     | 17 (6.9)                                      |
| Epistaxis                                              | 8 (5.9)                                       | 0                                   | 7 (6.4)                                       | 15 (6.1)                                      |
| Pleural effusion                                       | 2 (1.5)                                       | 9 (6.6)                             | 1 (0.9)                                       | 3 (1.2)                                       |
| Gastrointestinal disorders                             | 96 (70.6)                                     | 119 (86.9)                          | 90 (81.8)                                     | 186 (75.6)                                    |
| Diarrhoea                                              | 67 (49.3)                                     | 75 (54.7)                           | 50 (45.5)                                     | 117 (47.6)                                    |
| Nausea                                                 | 36 (26.5)                                     | 77 (56.2)                           | 55 (50.0)                                     | 91 (37.0)                                     |
| Vomiting                                               | 25 (18.4)                                     | 54 (39.4)                           | 38 (34.5)                                     | 63 (25.6)                                     |
| Constipation                                           | 20 (14.7)                                     | 57 (41.6)                           | 25 (22.7)                                     | 45 (18.3)                                     |
| Abdominal pain                                         | 11 (8.1)                                      | 17 (12.4)                           | 9 (8.2)                                       | 20 (8.1)                                      |
| Abdominal pain upper                                   | 6 (4.4)                                       | 18 (13.1)                           | 11 (10.0)                                     | 17 (6.9)                                      |
| Dyspepsia                                              | 8 (5.9)                                       | 18 (13.1)                           | 7 (6.4)                                       | 15 (6.1)                                      |
| Gastrooesophageal reflux disease                       | 1 (0.7)                                       | 12 (8.8)                            | 2 (1.8)                                       | 3 (1.2)                                       |
| Skin and subcutaneous tissue disorders                 | 60 (44.1)                                     | 38 (27.7)                           | 60 (54.5)                                     | 120 (48.8)                                    |
| Pruritus                                               | 18 (13.2)                                     | 6 (4.4)                             | 13 (11.8)                                     | 31 (12.6)                                     |
| Rash erythematous                                      | 7 (5.1)                                       | 1 (0.7)                             | 12 (10.9)                                     | 19 (7.7)                                      |
| Rash                                                   | 14 (10.3)                                     | 3 (2.2)                             | 2 (1.8)                                       | 16 (6.5)                                      |
| Dermatitis acneiform                                   | 9 (6.6)                                       | 2 (1.5)                             | 3 (2.7)                                       | 12 (4.9)                                      |
| Musculoskeletal and connective tissue disorders        | 61 (44.9)                                     | 62 (45.3)                           | 71 (64.5)                                     | 132 (53.7)                                    |
| Back pain                                              | 17 (12.5)                                     | 17 (12.4)                           | 26 (23.6)                                     | 43 (17.5)                                     |
| Muscle spasms                                          | 10 (7.4)                                      | 13 (9.5)                            | 26 (23.6)                                     | 36 (14.6)                                     |
| Arthralgia                                             | 10 (7.4)                                      | 14 (10.2)                           | 19 (17.3)                                     | 29 (11.8)                                     |
| Myalgia                                                | 8 (5.9)                                       | 6 (4.4)                             | 15 (13.6)                                     | 23 (9.3)                                      |
| Musculoskeletal pain                                   | 5 (3.7)                                       | 8 (5.8)                             | 14 (12.7)                                     | 19 (7.7)                                      |
| Pain in extremity                                      | 6 (4.4)                                       | 17 (12.4)                           | 11 (10.0)                                     | 17 (6.9)                                      |
| Neck pain                                              | 1 (0.7)                                       | 2 (1.5)                             | 11 (10.0)                                     | 12 (4.9)                                      |
| General disorders and                                  | 68 (50.0)                                     | 99 (72.3)                           | 79 (71.8)                                     | 147 (59.8)                                    |
| administration site conditions Fatigue                 | 24 (17.6)                                     | 28 (20.4)                           | 38 (34.5)                                     | 62 (25.2)                                     |
| Asthenia                                               | 15 (11.0)                                     | 22 (16.1)                           | 18 (16.4)                                     | 33 (13.4)                                     |
| Pyrexia                                                | 15 (11.0)                                     | 17 (12.4)                           | 12 (10.9)                                     | 27 (11.0)                                     |
| Oedema peripheral                                      | 6 (4.4)                                       | 53 (38.7)                           | 12 (10.9)                                     | 18 (7.3)                                      |
| Investigations                                         | 86 (63.2)                                     | 83 (60.6)                           | 70 (63.6)                                     | 156 (63.4)                                    |
| Blood creatine phosphokinase increased                 | 53 (39.0)                                     | 21 (15.3)                           | 39 (35.5)                                     | 92 (37.4)                                     |
| Aspartate aminotransferase increased                   | 31 (22.8)                                     | 34 (24.8)                           | 22 (20.0)                                     | 53 (21.5)                                     |
| Lipase increased                                       | 26 (19.1)                                     | 16 (11.7)                           | 20 (18.2)                                     | 46 (18.7)                                     |
| Alanine aminotransferase increased                     | 26 (19.1)                                     | 44 (32.1)                           | 18 (16.4)                                     | 44 (17.9)                                     |
| Amylase increased                                      | 19 (14.0)                                     | 9 (6.6)                             | 20 (18.2)                                     | 39 (15.9)                                     |
| Blood alkaline phosphatase increased                   | 13 (9.6)                                      | 17 (12.4)                           | 6 (5.5)                                       | 19 (7.7)                                      |
| Blood creatinine increased                             | 3 (2.2) 7 (5.1)                               | 19 (13.9) 0                         | 7 (6.4) 2 (1.8)                               | 10 (4.1) 9 (3.7)                              |
| Blood cholesterol increased Neutrophil count decreased | 2 (1.5)                                       | 12 (8.8)                            | 3 (2.7)                                       | 5 (2.0)                                       |

<div style=\"page-break-after: always\"></div>

|                                   | Study 301                       |                       | Study 201                                     | Total Brigatinib                |
|-----------------------------------|---------------------------------|-----------------------|-----------------------------------------------|---------------------------------|
|                                   | Brigatinib 90 mg QD → 180 mg QD | Crizotinib 250 mg BID | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD |
| System Organ Class Preferred Term | N = 136 n (%)                   | N = 137 n (%)         |                                               | N = 246 n (%)                   |

Source: Table 15.3.2.1.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥10% of patients in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201 or that had a ≥5% absolute difference between arms in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib in Study 301 within the SOC.

<div style=\"page-break-after: always\"></div>

Table 46: TEAEs Grade ≥3 Occurring in ≥2% of Patients in Either Study, by SOC and PT in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                                                      | Study 301                                     | Study 301                           | Study 201 Total Brigatinib                    | Study 201 Total Brigatinib                  |
|----------------------------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|---------------------------------------------|
| System Organ Class Preferred Term                                    | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180mgQD N = 246 n (%) |
| Patients with any Grade ≥3 TEAE                                      | 83 (61.0)                                     | 76 (55.5)                           | 78 (70.9)                                     | 161 (65.4)                                  |
| Infections and infestations                                          | 9 (6.6)                                       | 10 (7.3)                            | 15 (13.6)                                     | 24 (9.8)                                    |
| Pneumonia                                                            | 5 (3.7)                                       | 4 (2.9)                             | 6 (5.5)                                       | 11 (4.5)                                    |
| Urinary tract infection                                              | 1 (0.7)                                       | 3 (2.2)                             | 0                                             | 1 (0.4)                                     |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 4 (2.9)                                       | 5 (3.6)                             | 14 (12.7)                                     | 18 (7.3)                                    |
| Neoplasm progression                                                 | 1 (0.7)                                       | 3 (2.2)                             | 9 (8.2)                                       | 10 (4.1)                                    |
| Malignant pleural effusion                                           | 2 (1.5)                                       | 0                                   | 4 (3.6)                                       | 6 (2.4)                                     |
| Blood and lymphatic system disorders                                 | 3 (2.2)                                       | 5 (3.6)                             | 2 (1.8)                                       | 5 (2.0)                                     |
| Neutropenia                                                          | 0                                             | 3 (2.2)                             | 0                                             | 0                                           |
| Metabolism and nutrition disorders                                   | 7 (5.1)                                       | 10 (7.3)                            | 9 (8.2)                                       | 16 (6.5)                                    |
| Hyponatraemia                                                        | 1 (0.7)                                       | 1 (0.7)                             | 3 (2.7)                                       | 4 (1.6)                                     |
| Decreased appetite                                                   | 1 (0.7)                                       | 4 (2.9)                             | 2 (1.8)                                       | 3 (1.2)                                     |
| Nervous system disorders                                             | 6 (4.4)                                       | 6 (4.4)                             | 12 (10.9)                                     | 18 (7.3)                                    |
| Cognitive disorder                                                   | 0                                             | 0                                   | 3 (2.7)                                       | 3 (1.2)                                     |
| Vascular disorders                                                   | 14 (10.3)                                     | 5 (3.6)                             | 10 (9.1)                                      | 24 (9.8)                                    |
| Hypertension                                                         | 13 (9.6)                                      | 4 (2.9)                             | 10 (9.1)                                      | 23 (9.3)                                    |
| Respiratory, thoracic, and mediastinal disorders                     | 13 (9.6)                                      | 10 (7.3)                            | 14 (12.7)                                     | 27 (11.0)                                   |
| Pneumonitis                                                          | 2 (1.5)                                       | 1 (0.7)                             | 4 (3.6)                                       | 6 (2.4)                                     |
| Pulmonary embolism                                                   | 3 (2.2)                                       | 4 (2.9)                             | 3 (2.7)                                       | 6 (2.4)                                     |
| Dyspnoea                                                             | 3 (2.2)                                       | 6 (4.4)                             | 2 (1.8)                                       | 5 (2.0)                                     |
| Hypoxia                                                              | 0                                             | 0                                   | 3 (2.7)                                       | 3 (1.2)                                     |
| Gastrointestinal disorders                                           | 9 (6.6)                                       | 19 (13.9)                           | 6 (5.5)                                       | 15 (6.1)                                    |
| Nausea                                                               | 2 (1.5)                                       | 4 (2.9)                             | 1 (0.9)                                       | 3 (1.2)                                     |
| Diarrhoea                                                            | 2 (1.5)                                       | 3 (2.2)                             | 0                                             | 2 (0.8)                                     |
| Vomiting                                                             | 1 (0.7)                                       | 3 (2.2)                             | 0                                             | 1 (0.4)                                     |
| General disorders and administration site conditions                 | 6 (4.4)                                       | 9 (6.6)                             | 8 (7.3)                                       | 14 (5.7)                                    |
| Influenza like illness                                               | 0                                             | 0                                   | 3 (2.7)                                       | 3 (1.2)                                     |
| Non-cardiac chest pain                                               | 0                                             | 3 (2.2)                             | 1 (0.9)                                       | 1 (0.4)                                     |
| Investigations                                                       | 48 (35.3)                                     | 34 (24.8)                           | 31 (28.2)                                     | 79 (32.1)                                   |
| Blood creatine phosphokinase increased                               | 22 (16.2)                                     | 2 (1.5)                             | 16 (14.5)                                     | 38 (15.4)                                   |
| Lipase increased                                                     | 18 (13.2)                                     | 7 (5.1)                             | 6 (5.5)                                       | 24 (9.8)                                    |
| Amylase increased                                                    | 7 (5.1)                                       | 1 (0.7)                             | 2 (1.8)                                       | 9 (3.7)                                     |
| Alanine aminotransferase increased                                   | 2 (1.5)                                       | 13 (9.5)                            | 4 (3.6)                                       | 6 (2.4)                                     |
| Aspartate aminotransferase increased                                 | 2 (1.5)                                       | 8 (5.8)                             | 3 (2.7)                                       | 5 (2.0)                                     |
| Blood alkaline phosphatase increased                                 | 3 (2.2)                                       | 1 (0.7)                             | 1 (0.9)                                       | 4 (1.6)                                     |
| Neutrophil count decreased                                           | 0                                             | 6 (4.4)                             | 2 (1.8)                                       | 2 (0.8)                                     |

Source: Table 15.3.2.5.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; incl, including; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥2% of patients in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD →

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib in Study 301 within the SOC.

180 mg QD arm in Study 201.

<div style=\"page-break-after: always\"></div>

## Updated safety study 301 data cut-off 28 June 2019

Table 47: Overview of TEAEs (treated population, second interim analysis)

|                                                         | Number of Patients (%)   | Number of Patients (%)    |
|---------------------------------------------------------|--------------------------|---------------------------|
|                                                         | ArmA Brigatinib (N =136) | ArmB Crizotinib (N = 137) |
| PatientswithTEAEs                                       | 135 (99.3)               | 137 (100.0)               |
| Drug related                                            | 124 (91.2)               | 131 (95.6)                |
| Grade 3 or 4                                            | 90 (66.2)                | 73 (53.3)                 |
| Grade3or4,drugrelated                                   | 76 (55.9)                | 48 (35.0)                 |
| Leading to study drug discontinuation                   | 17 (12.5)                | 12 (8.8)                  |
| Leadingtodosereduction                                  | 52 (38.2)                | 34 (24.8)                 |
| Leading to dose interruption                            | 90 (66.2)                | 64 (46.7)                 |
| PatientswithSAEs                                        | 45 (33.1)                | 51 (37.2)                 |
| Drug related                                            | 16 (11.8)                | 5 (3.6)                   |
| Deathswithin30 days after last dose or possibly related | 9 (6.6)                  | 11 (8.0)                  |

Source: IA2 Table 15.3.1.1 and 15.3.1.2.6 (data cutoff: 28 June 2019).

IA2:secondinterim analysis;SAE:serious adverseevent;TEAE:treatment-emergentadverseevent.

<div style=\"page-break-after: always\"></div>

Table 48 : TEAEs (in ≥10% of either treatment arm or ≥5% absolute difference between arms) by preferred term (treated population, second interim analysis)

|                                         | Number of Patients (%)        | Number of Patients (%)    |
|-----------------------------------------|-------------------------------|---------------------------|
| PreferredTerm                           | Arm A Brigatinib (N =136)     | ArmB Crizotinib (N = 137) |
| Patients With Any TEAE                  | 135 (99.3)                    | 137 (100.0)               |
| Diarrhoea                               | 71 (52.2)                     | 77 (56.2)                 |
| Blood Creatine Phosphokinase Increased  | 63 (46.3)                     | 23 (16.8)                 |
| Cough                                   | 47 (34.6)                     | 27 (19.7)                 |
| Hypertension                            | 43 (31.6)                     | 11 (8.0)                  |
| Nausea                                  | 41 (30.1)                     | 80 (58.4)                 |
| Aspartate Aminotransferase Increased    | 35 (25.7)                     | 36 (26.3)                 |
| Lipase Increased                        | 31 (22.8)                     | 21 (15.3)                 |
| Alanine AminotransferaseIncreased       | 29 (21.3)                     | 48 (35.0)                 |
| Back Pain                               | 29 (21.3)                     | 23 (16.8)                 |
| Headache                                | 29 (21.3)                     | 23 (16.8)                 |
| Vomiting                                | 28 (20.6)                     | 60 (43.8)                 |
| Dyspnoea                                | 28 (20.6)                     | 28 (20.4)                 |
| Fatigue                                 | 26 (19.1)                     | 31 (22.6)                 |
| Constipation                            | 25 (18.4)                     | 57 (41.6)                 |
| Pruritus                                | 25 (18.4)                     | 7 (5.1)                   |
| Amylase Increased                       | 24 (17.6)                     | 12 (8.8)                  |
| Asthenia                                | 21 (15.4)                     | 26 (19.0)                 |
| Dizziness                               | 20 (14.7)                     | 28 (20.4)                 |
| Rash                                    |                               |                           |
| Arthralgia                              | 20 (14.7) 20 (14.7) 19 (14.0) | 4 (2.9) 17 (12.4)         |
| Muscle Spasms                           | 19 (14.0)                     | 14 (10.2)                 |
| Abdominal Pain                          | 18 (13.2)                     | 20 (14.6)                 |
| BloodAlkalinePhosphataseIncreased       | 16 (11.8)                     | 17 (12.4)                 |
| UpperRespiratoryTractInfection          | 16 (11.8)                     | 13 (9.5)                  |
| Decreased Appetite                      | 12 (8.8)                      | 26 (19.0)                 |
| Dermatitis acneiform                    | 12 (8.8)                      | 3 (2.2)                   |
| Dyspepsia                               | 11 (8.1)                      | 22 (16.1)                 |
| Bradycardia                             | 11 (8.1)                      | 21 (15.3)                 |
| Nasopharyngitis                         | 11 (8.1)                      | 15 (10.9)                 |
| Oedema Peripheral                       | 9 (6.6)                       | 61 (44.5)                 |
| Blood Cholesterol Increased             | 9 (6.6)                       | 1 (0.7)                   |
| Abdominal Pain Upper                    | 8 (5.9)                       | 24 (17.5)                 |
|                                         | 8 (5.9)                       | 1 (0.7)                   |
| Hypokalaemia                            | 8 (5.9)                       |                           |
| Rash erythematous Hypercholesterolaemia |                               | 1 (0.7)                   |
|                                         | 8 (5.9)                       | 0 20 (14.6)               |
| Pain In Extremity                       | 7 (5.1) 5 (3.7)               | 20 (14.6)                 |
| Blood Creatinine Increased Dysgeusia    | 4 (2.9)                       | 19 (13.9)                 |
| Dysphagia                               | 3 (2.2)                       | 12 (8.8)                  |
| Pleural Effusion                        | 3 (2.2)                       | 11 (8.0)                  |
|                                         | 2 (1.5)                       | 14 (10.2)                 |
| Neutrophil Count Decreased              |                               | 10 (7.3)                  |
| Hypocalcaema                            | 2 (1.5) 1(0.7)                | 28 (20.4)                 |
| Photopsia                               |                               |                           |
| Gastrooesophageal RefluxDisease         | 1 (0.7)                       | 15 (10.9)                 |
| Hypoalbuminaemia                        | 1 (0.7)                       | 10 (7.3)                  |
| Hypotension                             | 1 (0.7)                       | 10 (7.3)                  |
| Visual Impairment                       | 0                             | 23 (16.8)                 |
| Deep vein thrombosis                    | 0                             | 9 (6.6)                   |

Source:IA2Table 15.3.1.2.1.2(data cutoff:28June 2019)

MedDRA: Medical Dictionary for RegulatoryActivities;PT:preferred term;TEAE: treatment-emergent adverse event.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Patients with 1 or more TEAEs within a level of MedDRA term are counted only once in that level.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no laterthan the earliest of(1)30days afterthelast dose ofthe treatment towhich the patient was assigned,or(2) the day before start of brigatinib therapy in crossover patients.

<div style=\"page-break-after: always\"></div>

Table 49 : Grade ≥3 TEAEs (in ≥2% of patients in either treatment arm) by system organ class and preferred term (treated population, second interim analysis)

|                                                                           | Number of Patients (%)    | Number of Patients (%)    | Number of Patients (%)    | Number of Patients (%)    |
|---------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| System Organ Class                                                        | Arm A Brigatinib (N =136) | Arm A Brigatinib (N =136) | ArmB Crizotinib (N = 137) | ArmB Crizotinib (N = 137) |
| Preferred Term                                                            | Any                       | Grade ≥3                  | Any                       | Grade ≥3                  |
| PatientswithanyGrade≥3TEAE                                                | 135 (99.3)                | 99 (72.8)                 | 137 (100)                 | 84 (61.3)                 |
| Infections and infestations                                               | 68 (50.0)                 | 11 (8.1)                  | 69 (50.4)                 | 12 (8.8)                  |
| Pneumonia                                                                 | 10 (7.4)                  | 5 (3.7)                   | 7 (5.1)                   | 5 (3.6)                   |
| Urinary tract infection                                                   | 8 (5.9)                   | 1 (0.7)                   | 12 (8.8)                  | 3 (2.2)                   |
| Neoplasms benign, malignant, and unspecified (including cysts and polyps) | 17 (12.5)                 | 8 (5.9)                   | 11 (8.0)                  | 6 (4.4)                   |
| Neoplasm progression                                                      | 3 (2.2)                   | 3 (2.2)                   | 4 (2.9)                   | 3 (2.2)                   |
| Blood andlymphatic system disorders                                       | 14 (10.3)                 | 6 (4.4)                   | 18 (13.1)                 | 6 (4.4)                   |
| Anaemia                                                                   | 10 (7.4)                  | 4 (2.9)                   | 9 (6.6)                   | 1 (0.7)                   |
| Neutropenia                                                               | 1 (0.7)                   | 1 (0.7)                   | 6 (4.4)                   | 4 (2.9)                   |
| Metabolism and nutrition disorders                                        | 51 (37.5)                 | 11 (8.1)                  | 48 (35.0)                 | 10 (7.3)                  |
| Decreased appetite                                                        | 12 (8.8)                  | 1 (0.7)                   | 26 (19.0)                 | 4 (2.9)                   |
| Nervous System Disorders                                                  | 65 (47.8)                 | 10 (7.4)                  | 70 (51.1)                 | 7 (5.1)                   |
| Headache                                                                  | 29 (21.3)                 | 3 (2.2)                   | 23 (16.8)                 | 0                         |
| Vascular disorders                                                        | 48 (35.3)                 | 18 (13.2)                 | 35 (25.5)                 | 5 (3.6)                   |
| Hypertension                                                              | 43 (31.6)                 | 16 (11.8)                 | 11 (8.0)                  | 4 (2.9)                   |
| Respiratory, thoracic, and mediastinal disorders                          | 88 (64.7)                 | 14 (10.3)                 | 70 (51.1)                 | 12 (8.8)                  |
| Dyspnoea                                                                  | 28 (20.6)                 | 3 (2.2)                   | 28 (20.4)                 | 6 (4.4)                   |
| Pleural Effusion                                                          | 3 (2.2)                   | 2 (1.5)                   | 11 (8.0)                  | 3 (2.2)                   |
| Pulmonary embolism                                                        | 3 (2.2)                   | 3 (2.2)                   | 8 (5.8)                   | 5 (3.6)                   |
| Gastrointestinal disorders                                                | 104 (76.5)                | 12 (8.8)                  | 121 (88.3)                | 21 (15.3)                 |
| Diarhoea                                                                  | 71 (52.2)                 | 3 (2.2)                   | 77 (56.2)                 | 4 (2.9)                   |
| Nausea                                                                    | 41 (30.1)                 | 3 (2.2)                   | 80 (58.4)                 | 4 (2.9)                   |
| Vomiting                                                                  | 28 (20.6)                 | 1 (0.7)                   | 60 (43.8)                 | 3 (2.2)                   |
| Investigations                                                            | 96 (70.6)                 | 62 (45.6)                 | 89 (65.0)                 | 39 (28.5)                 |
| Blood creatine phosphokinase increased                                    | 63 (46.3)                 | 33 (24.3)                 | 23 (16.8)                 | 2 (1.5)                   |
| Aspartate aminotransferase increased                                      | 35 (25.7)                 | 5 (3.7)                   | 36 (26.3)                 | 9 (6.6)                   |
| Alanine aminotransferase increased                                        | 29 (21.3)                 | 5 (3.7)                   | 48 (35.0)                 | 14 (10.2)                 |
| Lipase increased                                                          | 31 (22.8)                 | 19 (14.0)                 | 21 (15.3)                 | 9 (6.6)                   |
| Amylase increased                                                         | 24 (17.6)                 | 8 (5.9)                   | 12 (8.8)                  | 2 (1.5)                   |
| Blood alkalinephosphatase increased                                       | 16 (11.8)                 | 4 (2.9)                   | 17 (12.4)                 | 1 (0.7)                   |
| Gamma-glutamyltransferase increased                                       | 3 (2.2)                   | 2 (1.5)                   | 8 (5.8)                   | 3 (2.2)                   |
| Neutrophil count decreased                                                | 2 (1.5)                   | 0                         | 14 (10.2)                 | 7 (5.1)                   |

Source:IA2Table 15.3.1.2.1.4(data cutoff:28June 2019)

MedDRA: Medical Dictionary for Regulatory Activities; TEAE: treatment-emergent adverse event. Patients with 1 or more TEAEs within a level of MedDRA term are counted only once in that level.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of(1)30days after the last dose of the treatment towhich the patient was assigned,or(2) the daybeforestart of brigatinib therapy in crossover patients.

<div style=\"page-break-after: always\"></div>

## Treatment-related AEs

Table 50: TreatmentRelated TEAEs Occurring in ≥10% of Patients in Either Study or With a ≥5% Absolute Difference Between Arms in Study 301, All Grades by SOC and PT in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                                              | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|--------------------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| System Organ Class Preferred Term                            | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any                                            | 116 (85.3)                                    | 131 (95.6)                          | 105 (95.5)                                    | 221 (89.8)                                    |
| treatment-related                                            |                                               |                                     |                                               |                                               |
| TEAE Metabolism and nutrition                                | 25 (18.4)                                     | 29 (21.2)                           | 21 (19.1)                                     | 46 (18.7)                                     |
| disorders                                                    |                                               |                                     |                                               |                                               |
| Decreased appetite                                           | 7 (5.1)                                       | 18 (13.1)                           | 10 (9.1)                                      | 17 (6.9)                                      |
| Nervous system disorders                                     | 20 (14.7)                                     | 45 (32.8)                           | 28 (25.5)                                     | 48 (19.5)                                     |
| Dysgeusia                                                    | 6 (4.4)                                       | 23 (16.8)                           | 3 (2.7)                                       | 9 (3.7)                                       |
| Dizziness                                                    | 4 (2.9)                                       | 14 (10.2)                           | 4 (3.6)                                       | 8 (3.3)                                       |
| Eye disorders                                                | 12 (8.8)                                      | 67 (48.9)                           | 14 (12.7)                                     | 26 (10.6)                                     |
| Visual impairment                                            | 0                                             | 22 (16.1)                           | 4 (3.6)                                       | 4 (1.6)                                       |
| Photopsia                                                    | 0                                             | 27 (19.7)                           | 1 (0.9)                                       | 1 (0.4)                                       |
| Cardiac disorders                                            | 9 (6.6)                                       | 22 (16.1)                           | 10 (9.1)                                      | 19 (7.7)                                      |
| Bradycardia                                                  | 4 (2.9)                                       | 14 (10.2)                           | 2 (1.8)                                       | 6 (2.4)                                       |
| Vascular disorders                                           | 21 (15.4)                                     | 6 (4.4)                             | 18 (16.4)                                     | 39 (15.9)                                     |
| Hypertension                                                 | 20 (14.7)                                     | 2 (1.5)                             | 18 (16.4)                                     | 38 (15.4)                                     |
| Respiratory, thoracic, and                                   | 22 (16.2)                                     | 12 (8.8)                            | 30 (27.3)                                     | 52 (21.1)                                     |
| mediastinal disorders                                        |                                               |                                     |                                               |                                               |
| Cough                                                        | 9 (6.6)                                       | 3 (2.2)                             | 11 (10.0)                                     | 20 (8.1)                                      |
| Gastrointestinal disorders                                   | 73 (53.7)                                     | 109 (79.6)                          | 66 (60.0)                                     | 139 (56.5)                                    |
| Diarrhoea                                                    | 54 (39.7)                                     | 70 (51.1)                           | 38 (34.5)                                     | 92 (37.4)                                     |
| Nausea                                                       | 28 (20.6)                                     | 67 (48.9)                           | 36 (32.7)                                     | 64 (26.0)                                     |
| Vomiting                                                     | 12 (8.8)                                      | 40 (29.2)                           | 21 (19.1)                                     | 33 (13.4)                                     |
| Constipation                                                 | 7 (5.1)                                       | 32 (23.4)                           | 7 (6.4)                                       | 14 (5.7)                                      |
| Abdominal pain upper                                         | 3 (2.2)                                       | 12 (8.8)                            | 4 (3.6)                                       | 7 (2.8)                                       |
| Gastrooesophageal reflux                                     | 0                                             | 7 (5.1)                             | 0                                             | 0                                             |
| disease                                                      |                                               |                                     |                                               |                                               |
| Skin and subcutaneous tissue                                 | 43 (31.6)                                     | 23 (16.8)                           | 38 (34.5)                                     | 81 (32.9)                                     |
| disorders                                                    |                                               |                                     |                                               |                                               |
| Pruritus                                                     | 13 (9.6)                                      | 3 (2.2)                             | 8 (7.3)                                       | 21 (8.5)                                      |
| Dermatitis acneiform                                         | 9 (6.6)                                       | 2 (1.5)                             | 3 (2.7)                                       | 12 (4.9)                                      |
| Rash                                                         | 11 (8.1)                                      | 3 (2.2)                             | 1 (0.9)                                       | 12 (4.9)                                      |
| Musculoskeletal and connective                               | 21 (15.4)                                     | 18 (13.1)                           | 30 (27.3)                                     | 51 (20.7)                                     |
| tissue disorders spasms                                      |                                               |                                     |                                               |                                               |
| Muscle                                                       | 6 (4.4)                                       | 10 (7.3)                            | 19 (17.3)                                     | 25 (10.2)                                     |
| General disorders and                                        | 32 (23.5)                                     | 65 (47.4)                           | 38 (34.5)                                     | 70 (28.5)                                     |
| administration site conditions                               |                                               |                                     |                                               |                                               |
| Fatigue                                                      | 13 (9.6)                                      | 17 (12.4)                           | 20 (18.2)                                     | 33 (13.4)                                     |
| Asthenia                                                     | 6 (4.4)                                       | 13 (9.5)                            | 8 (7.3)                                       | 14 (5.7)                                      |
| Oedema peripheral                                            | 2 (1.5)                                       | 41 (29.9)                           | 6 (5.5)                                       | 8 (3.3)                                       |
| Investigations                                               | 75 (55.1)                                     | 73 (53.3)                           | 63 (57.3)                                     | 138 (56.1)                                    |
| Blood creatine                                               | 51 (37.5)                                     | 18 (13.1)                           | 35 (31.8)                                     | 86 (35.0)                                     |
| phosphokinase increased Aspartate aminotransferase increased | 27 (19.9)                                     | 28 (20.4)                           | 18 (16.4)                                     | 45 (18.3)                                     |
| Lipase increased                                             | 24 (17.6)                                     | 13 (9.5)                            | 19 (17.3)                                     | 43 (17.5)                                     |
| Amylase increased                                            | 19 (14.0)                                     | 8 (5.8)                             | 17 (15.5)                                     | 36 (14.6)                                     |
| Alanine aminotransferase increased                           | 21 (15.4)                                     | 39 (28.5)                           | 13 (11.8)                                     | 34 (13.8)                                     |
| Blood alkaline phosphatase increased                         | 10 (7.4)                                      | 14 (10.2)                           | 3 (2.7)                                       | 13 (5.3)                                      |
| Blood creatinine increased                                   | 2 (1.5)                                       | 14 (10.2)                           | 4 (3.6)                                       | 6 (2.4)                                       |
| Neutrophil count decreased                                   | 2 (1.5)                                       | 12 (8.8)                            | 3 (2.7)                                       | 5 (2.0)                                       |

Source: Table 15.3.2.2.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥10% of patients in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201 or that had a ≥5% absolute difference between arms in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib in Study 301 within the SOC.

<div style=\"page-break-after: always\"></div>

Table 51: Treatment-Related TEAEs Grade ≥3 Occurring in ≥2% of Patients in Either Study, by SOC and PT in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                                   | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|---------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| System Organ Class Preferred Term                 | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any Grade ≥3 treatment-related TEAE | 63 (46.3)                                     | 39 (28.5)                           | 50 (45.5)                                     | 113 (45.9)                                    |
| Blood and lymphatic system disorders              | 1 (0.7)                                       | 3 (2.2)                             | 1 (0.9)                                       | 2 (0.8)                                       |
| Neutropenia                                       | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |
| Metabolism and nutrition disorders                | 4 (2.9)                                       | 6 (4.4)                             | 4 (3.6)                                       | 8 (3.3)                                       |
| Hyponatraemia                                     | 1 (0.7)                                       | 0                                   | 3 (2.7)                                       | 4 (1.6)                                       |
| Vascular disorders                                | 9 (6.6)                                       | 0                                   | 4 (3.6)                                       | 13 (5.3)                                      |
| Hypertension                                      | 9 (6.6)                                       | 0                                   | 4 (3.6)                                       | 13 (5.3)                                      |
| Respiratory, thoracic, and mediastinal disorders  | 5 (3.7)                                       | 2 (1.5)                             | 4 (3.6)                                       | 9 (3.7)                                       |
| Pneumonitis                                       | 2 (1.5)                                       | 1 (0.7)                             | 4 (3.6)                                       | 6 (2.4)                                       |
| Gastrointestinal disorders                        | 4 (2.9)                                       | 10 (7.3)                            | 3 (2.7)                                       | 7 (2.8)                                       |
| Nausea                                            | 2 (1.5)                                       | 3 (2.2)                             | 1 (0.9)                                       | 3 (1.2)                                       |
| Diarrhoea                                         | 1 (0.7)                                       | 3 (2.2)                             | 0                                             | 1 (0.4)                                       |
| Investigations                                    | 44 (32.4)                                     | 21 (15.3)                           | 28 (25.5)                                     | 72 (29.3)                                     |
| Blood creatine phosphokinase increased            | 22 (16.2)                                     | 1 (0.7)                             | 14 (12.7)                                     | 36 (14.6)                                     |
| Lipase increased                                  | 15 (11.0)                                     | 3 (2.2)                             | 5 (4.5)                                       | 20 (8.1)                                      |
| Amylase increased                                 | 7 (5.1)                                       | 0                                   | 2 (1.8)                                       | 9 (3.7)                                       |
| Alanine aminotransferase increased                | 1 (0.7)                                       | 10 (7.3)                            | 4 (3.6)                                       | 5 (2.0)                                       |
| Aspartate aminotransferase increased              | 2 (1.5)                                       | 5 (3.6)                             | 3 (2.7)                                       | 5 (2.0)                                       |
| Neutrophil count decreased                        | 0                                             | 6 (4.4)                             | 2 (1.8)                                       | 2 (0.8)                                       |

Source: Table 15.3.2.6.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥2% of patients in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib in Study 301 within the SOC.

<div style=\"page-break-after: always\"></div>

## Updated safety study 301 data cut-off 28 June 2019

Table 52 : Treatment related TEAEs (in ≥10% of either treatment arm or ≥5% absolute difference between arms) by system organ class and preferred term (treated population, second interim analysis)

|                                                  | Number of Patients (%)   | Number of Patients (%)   |
|--------------------------------------------------|--------------------------|--------------------------|
| System Organ Class Preferred Term                | ArmA Brigatinib (N =136) | ArmB Crizotinib (N =137) |
| Patientswith anytreatment-relatedTEAE            | 124 (91.2)               | 131 (95.6)               |
| Metabolismandnutritiondisorders                  | 28 (20.6)                | 29 (21.2)                |
| Decreased appetite                               | 7 (5.1)                  | 18 (13.1)                |
| Nervoussystemdisorders                           | 22 (16.2)                | 46 (33.6)                |
| Dizziness                                        | 6 (4.4)                  | 16 (11.7)                |
| Dysgeusia                                        | 4 (2.9)                  | 17 (12.4)                |
| Eye disorders                                    | 13 (9.6)                 | 68 (49.6)                |
| Photopsia                                        | 0                        | 27 (19.7)                |
| Visual impairment                                | 0                        | 23 (16.8)                |
| Cardiac disorders                                | 15 (11.0)                | 30 (21.9)                |
| Bradycardia                                      | 5 (3.7)                  | 16 (11.7)                |
| Vascular disorders                               | 25 (18.4)                | 7 (5.1)                  |
| Hypertension                                     | 23 (16.9)                | 2 (1.5)                  |
| Respiratory, thoracic,and mediastinal disorders  | 28 (20.6)                | 11 (8.0)                 |
| Cough                                            | 13 (9.6)                 | 3 (2.2)                  |
| Gastrointestinaldisorders                        | 76 (55.9)                | 110 (80.3)               |
| Diarrhoea                                        | 55 (40.4)                | 72 (52.6)                |
| Nausea                                           | 31 (22.8)                | 69 (50.4)                |
| Vomiting                                         | 12 (8.8)                 | 41 (29.9)                |
| Constipation                                     | 8 (5.9)                  | 32 (23.4)                |
| Abdominal pain upper                             | 3 (2.2)                  | 14 (10.2)                |
| Gastrooesophageal reflux disease                 | 0                        | 7 (5.1)                  |
| Skin and subcutaneous tissue disorders           | 52 (38.2)                | 25 (18.2)                |
| Pruritus                                         | 18 (13.2)                | 3 (2.2)                  |
| Rash                                             | 12 (8.8)                 | 4 (2.9)                  |
| Dermatitis acneiform                             | 10 (7.4)                 | 2 (1.5)                  |
| Musculoskeletal andconnectivetissue disorders    | 27 (19.9)                | 21 (15.3)                |
| Myalgia                                          | 8 (5.9)                  | 0                        |
| Generaldisordersand administrationsiteconditions | 35 (25.7)                | 70 (51.1)                |
| Fatigue                                          | 13 (9.6)                 | 18 (13.1)                |
| Asthenia                                         | 9 (6.6)                  | 16 (11.7)                |
| Oedema peripheral                                | 3 (2.2)                  | 47 (34.3)                |
| Investigations                                   | 87 (64.0)                | 80 (58.4)                |
| Blood creatine phosphokinase increased           | 60 (44.1)                | 21 (15.3)                |
| Lipase increased                                 | 30 (22.1)                | 16 (11.7)                |
| Aspartate aminotransferase increased             | 29 (21.3)                | 32 (23.4)                |
| Amylase increased                                | 24 (17.6)                | 9 (6.6)                  |
| Alanine aminotransferase increased               | 24 (17.6)                | 45 (32.8)                |
| Blood alkaline phosphatase increased             | 13 (9.6)                 | 14 (10.2)                |
| Blood creatinine increased                       | 3 (2.2)                  | 13 (9.5)                 |
| Neutrophil count decreased                       | 2 (1.5)                  | 14 (10.2)                |

Source:IA2Table 15.3.1.2.2(data cutoff:28June 2019).

MedDRA:MedicalDictionaryforRegulatoryActivities;TEAE:treatment-emergent adverseevent.

Patients with 1 or more TEAEs within a level of MedDRA term are counted only once in that level.

Within each System Organ Class,Preferred Terms are ordered by decreasing frequency of TEAEin the brigatinib arm.

MedDRA Dictionary (Version 22.0)was used for coding adverseevents.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the daybeforestart of brigatinib therapy in crossover patients.

<div style=\"page-break-after: always\"></div>

Table 53: Severity of Treatment Related Treatment-Emergent Adverse Events (treated population, second interim analysis)

|                                         |           | Numberof Subjects (8)    | Numberof Subjects (8)    | Numberof Subjects (8)    | Numberof Subjects (8)    |
|-----------------------------------------|-----------|--------------------------|--------------------------|--------------------------|--------------------------|
| System Organ Class Preferred Term       | Intensity | ARM A Brigatinib (N=136) | ARM A Brigatinib (N=136) | ARM B Crizotinib (N=137) | ARM B Crizotinib (N=137) |
| Subjects WithAny Treatment Related TEAE | Overall   | 124                      | (91.2)                   | 131                      | (95.6)                   |
|                                         | Grade1    | 16                       | (11.8)                   | 42                       | (30.7)                   |
|                                         | Grade 2   | 32                       | (23.5)                   | 41                       | (29.9)                   |
|                                         | Grade 3   | 71                       | (52.2)                   | 42                       | (30.7)                   |
|                                         | Gradle 4  | 5                        | (3.7)                    | 6                        | (4.4)                    |
|                                         | Gradle 5  | 0                        |                          | 0                        |                          |

The treatment-related TEAEs Grade ≥ 3 by PT occurring in ≥ 3% of patients in the brigatinib or crizotinib arms were blood CPK increased (23.5% vs 0.7%, respectively), lipase increased (12.5% vs 3.6%, respectively), hypertension (7.4% vs 0%, respectively), amylase increased (5.9% vs 0.7%, respectively), AST increased (2.2% vs 5.1%, respectively), ALT increased (1.5% vs 8.0%, respectively), and neutrophil count decreased (0% vs 5.1%, respectively).

## Adverse drug reactions

The list and frequency of adverse drug reactions have been reviewed in the context of this application on the basis of the pooled safety data of patients treated at the 180 mg regimen from three clinical trials: a Phase 3 trial (study 301) in patients with advanced ALK positive NSCLC previously not treated with an ALK inhibitor (N = 136), a Phase 2 trial (study 201) in patients treated with Alunbrig with ALK positive NSCLC who previously progressed on crizotinib (N = 110), and a phase 1/2 dose escalation/expansion trial (study 101) in patients with advanced malignancies (N = 28).

Table 54: Adverse reactions reported in patients treated with Alunbrig (per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03) at the 180 mg regimen (N = 274)

| System organ class                   | Adverse reactions † all grades                                                                                                                                                                    | Adverse reactions Grade 3-4                                                                                       |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Infections and infestations          | Pneumonia a,b (15%) Upper respiratory tract infection (12.4%)                                                                                                                                     | Pneumonia a (5.5%)                                                                                                |
| Blood and lymphatic system disorders | Anaemia (46.7%) Lymphocyte count decreased (39.1%) APTT increased (35.5%) White blood cell count decreased (27.5%) Neutrophil count decreased (10.9%) Decreased platelet count (9.9%)             | Lymphocyte count decreased (13.5%) APTT increased (2.2%) Anaemia (1.8%) Neutrophil count decreased (0.7%)         |
| Metabolism and nutrition disorders   | Hyperglycaemia (60.9%) Hyperinsulinaemia c (52.2%) Hypophosphataemia (39.4%) Hypomagnesaemia (21.9%) Hypercalcaemia (20.8%) Hyponatraemia (20.4%) Hypokalaemia (18.6%) Decreased appetite (16.8%) | Hypophosphataemia (6.6%) Hyperglycaemia (6.6%) Hyponatraemia (3.3%) Hypokalaemia (1.1%) Decreased appetite (1.1%) |
| Psychiatric disorders                | Insomnia (9.5%)                                                                                                                                                                                   |                                                                                                                   |
| Nervous system disorders             | Headache d (33.2%) Peripheral neuropathy e (19.7%) Dizziness (15.3%) Memory impairment (3.6%) Dysgeusia (3.6%)                                                                                    | Headache d (1.8%) Peripheral neuropathy e (1.5%) Dizziness (0.4%)                                                 |
| Eye disorders                        | Visual disturbance f (13.5%)                                                                                                                                                                      | Visual disturbance f (1.1%)                                                                                       |
| Cardiac disorders                    | Bradycardia g (8.4%) Electrocardiogram QT prolonged (5.5%) Tachycardia h (4.7%) Palpitations (2.2%)                                                                                               | Electrocardiogram QT prolonged (1.1%) Bradycardia g (0.4%)                                                        |
| Vascular disorders                   | Hypertension i (29.6%)                                                                                                                                                                            | Hypertension i (11.3%)                                                                                            |

<div style=\"page-break-after: always\"></div>

| System organ class                                   | Adverse reactions † all grades                                                                                                                                                                                                                | Adverse reactions Grade 3-4                                                                                                                                                       |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Respiratory, thoracic and mediastinal disorders      | Cough (37.6%) Dyspnoea j (27%) Pneumonitis k (6.9%)                                                                                                                                                                                           | Pneumonitis k (3.3%) Dyspnoea j (2.9%)                                                                                                                                            |
| Gastrointestinal disorders                           | Lipase increased (54%) Diarrhoea (49.3%) Amylase increased (47.1%) Nausea (39.8%) Vomiting (26.3%) Abdominal pain l (21.5%) Constipation (20.8%) Stomatitis m (11.7%) Dry mouth (7.7%) Dyspepsia (6.9%) Flatulence (1.5%) Pancreatitis (0.4%) | Lipase increased (14.6%) Amylase increased (7.7%) Nausea (1.5%) Abdominal pain l (1.1%) Diarrhoea (1.1%) Vomiting (0.4%) Stomatitis m (0.4%) Dyspepsia (0.4%) Pancreatitis (0.4%) |
| Hepatobiliary disorders                              | AST increased (68.2%) ALT increased (48.9%) Alkaline phosphatase increased (37.2%) Blood lactate dehydrogenase increased (6.2%) Hyperbilirubinaemia (5.5%)                                                                                    | ALT increased (4.7%) AST increased (3.6%) Alkaline phosphatase increased (2.6%) Hyperbilirubinaemia (0.7%)                                                                        |
| Skin and subcutaneous tissue disorders               | Rash n (37.2%) Pruritus o (16.8%) Dry skin (4.7%) Photosensitivity reaction (3.6%)                                                                                                                                                            | Rash n (3.6%) Photosensitivity reaction (1.1%) Dry skin (0.4%) Pruritus o (0.4%)                                                                                                  |
| Musculoskeletal and connective tissue disorders      | Blood CPK increased (63.8%) Myalgia p (34.3%) Arthralgia (17.5%) Musculoskeletal chest pain (9.1%) Pain in extremity (7.3%) Musculoskeletal stiffness (1.1%)                                                                                  | Blood CPK increased (18.3%) Pain in extremity (0.7%) Musculoskeletal chest pain (0.4%) Myalgia p (0.4%)                                                                           |
| Renal and urinary disorders                          | Blood creatinine increased (20.8%)                                                                                                                                                                                                            |                                                                                                                                                                                   |
| General disorders and administration site conditions | Fatigue q (39.8%) Oedema r (18.2%) Pyrexia (13.5%) Non-cardiac chest pain (5.8%) Chest discomfort (3.6%) Pain (3.3%)                                                                                                                          | Fatigue q (1.8%) Pyrexia (0.7%) Oedema r (0.7%) Non-cardiac chest pain (0.4%)                                                                                                     |
| Investigations                                       | Blood cholesterol increased s (8%) Weight decreased (4%)                                                                                                                                                                                      | Weight decreased (0.4%)                                                                                                                                                           |

† The frequencies for ADR terms associated with chemistry and haematology laboratory changes were determined based on the frequency of abnormal laboratory shifts from baseline.

- a  Includes atypical pneumonia, pneumonia, pneumonia aspiration, pneumonia cryptococcal, lower respiratory tract infection, lower respiratory tract infection viral, lung infection

b  Includes Grade 5 events

c  Grade not applicable

d  Includes headache, sinus headache, head discomfort, migraine, tension headache

- e  Includes paraesthesia, peripheral sensory neuropathy, dysaesthesia, hyperaesthesia, hypoaesthesia, neuralgia, neuropathy peripheral, neurotoxicity, peripheral motor neuropathy, polyneuropathy, burning sensation, post herpetic neuralgia

f  Includes altered visual depth perception, cataract, colour blindness acquired, diplopia, glaucoma, intraocular pressure increased, macular oedema, photophobia, photopsia, retinal oedema, vision blurred, visual acuity reduced, visual field defect, visual impairment, vitreous detachment, vitreous floaters, amaurosis fugax

g  Includes bradycardia, sinus bradycardia

h  Includes sinus tachycardia, tachycardia, atrial tachycardia, heart rate increased

i  Includes blood pressure increased, diastolic hypertension, hypertension, systolic hypertension

j  Includes dyspnoea, dyspnoea exertional

k  Includes interstitial lung disease, pneumonitis

- l  Includes abdominal discomfort, abdominal distension, abdominal pain, abdominal pain lower, abdominal pain upper, epigastric discomfort.
- m  Includes aphthous stomatitis, stomatitis, aphthous ulcer, mouth ulceration, oral mucosal blistering
- n  Includes dermatitis acneiform, erythema, exfoliative rash, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, dermatitis, dermatitis allergic, dermatitis contact, generalised erythema, rash follicular, urticaria, drug eruption, toxic skin eruption
- o  Includes pruritus, pruritus allergic, pruritus generalised, pruritus genital, vulvovaginal pruritus
- p  Includes musculoskeletal pain, myalgia, muscle spasms, muscle tightness, muscle twitching, musculoskeletal discomfort

q  Includes asthenia, fatigue

- r  Includes eyelid oedema, face oedema, oedema peripheral, periorbital oedema, swelling face, generalised oedema, peripheral swelling, angioedema, lip swelling, periorbital swelling, skin swelling, swelling of eyelid

s  Includes blood cholesterol increased, hypercholesterolemia

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

Pulmonary AEs: EOPEs and Later-onset pneumonitis events

EOPEs occurred in 4 of the 136 patients (2.9%) in the brigatinib arm and no patients in the crizotinib arm. All EOPEs were reported as ILD or pneumonitis, and all occurred while the patient was taking 90 mg QD brigatinib (i.e., prior to escalation to 180 mg QD), with a range of onset of Day 3 to 8. The incidence of EOPEs in Study 301 was lower than the incidence reported in Study 201 (2.9% vs 6.4%).

The overall rate of ILD/pneumonitis at any time (cumulative early- and later-onset) was comparable between the brigatinib and crizotinib arms (3.7% vs 2.2%, respectively).

One of the 136 patients (0.7%) in the brigatinib arm and 3 of the 137 patients (2.2%) in the crizotinib arm had later-onset pneumonitis. The incidence of later-onset pneumonitis events in brigatinib-treated patients was lower in Study 301 compared with the brigatinib 90 mg QD → 180 mg QD arm in Study 201 (0.7% vs 2.7%).

Additionally, 1 of the 35 patients in the crizotinib arm who crossed over to brigatinib experienced pneumonitis on Day 3 of crossover; however, this patient had ground glass opacities on a chest CT scan before starting brigatinib.

The rate of these events in the ALK inhibitor-naïve setting (~3%) appears to be lower than in the crizotinib-refractory setting in Study 201 (~6%). The rate of EOPEs in Study 301 in patients who have crossed over from crizotinib to brigatinib was ~6.6% (4 of 61 patients). In Study 201, a multivariate analysis indicated that short washout (&lt;7 days) from crizotinib increased the risk of these pulmonary events.

## Bradycardia

Table 55: Summary of Bradycardia TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| TEAEs                                   | 11 (8.1)                                      | 23 (16.8)                           | 5 (4.5)                                       | 16 (6.5)                                      |
| Drug related                            | 7 (5.1)                                       | 20 (14.6)                           | 4 (3.6)                                       | 11 (4.5)                                      |
| Grade ≥3                                | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Grade ≥3, drug related                  | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Leading to study drug discontinuation a | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Leading to dose reduction               | 1 (0.7)                                       | 1 (0.7)                             | 0                                             | 1 (0.4)                                       |
| Leading to dose interruption            | 3 (2.2)                                       | 3 (2.2)                             | 0                                             | 3 (1.2)                                       |
| Treatment-emergent SAEs                 | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Drug related                            | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Grade ≥3                                | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Grade ≥3, drug related                  | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |

Source: Table 15.3.1.3.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

a

Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

<div style=\"page-break-after: always\"></div>

Table 56: Heart rate (by ECG) outlier analysis (treated population, second interim analysis)

|                  | NumberofPatients (%)      | NumberofPatients (%)      | NumberofPatients (%)   |
|------------------|---------------------------|---------------------------|------------------------|
|                  | ArmA Brigatinib (N = 136) | ArmB Crizotinib (N = 137) | Total (N = 273)        |
| Heart rate (bpm) | 130 (95.6)                | 133 (97.1)                | 263 (96.3)             |
| <60 bpm          | 59 (43.4)                 | 103 (75.2)                | 162 (59.3)             |
| <50 bpm          | 11 (8.1)                  | 46 (33.6)                 | 57 (20.9)              |
| Bradycardic      | 7 (5.1)                   | 38 (27.7)                 | 45 (16.5)              |
| Tachycardic      | 5 (3.7)                   | 7 (5.1)                   | 12 (4.4)               |

Source:IA2Table 15.3.4.8.1 (data cutoff:28June 2019).

bpm:beatsper minute;ECG:electrocardiogram.

Bradycardic:Heartrate&lt;50and&gt;25%reductionfrombaseline.

Tachycardic:Heartrate&gt;100and≥25%increasefrombaseline.

Table 57: Patients with bradycardia TEAEs by preferred term (treated population, second interim analysis)

|                                | NumberofPatients (%)      | NumberofPatients (%)     | NumberofPatients (%)   |
|--------------------------------|---------------------------|--------------------------|------------------------|
| PreferredTerm                  | ArmA Brigatinib (N = 136) | ArmB Crizotinib (N =137) | Total (N = 273)        |
| PatientswithanybradycardiaTEAE | 16 (11.8)                 | 32 (23.4)                | 48 (17.6)              |
| Bradycardia                    | 11 (8.1)                  | 21 (15.3)                | 32 (11.7)              |
| Sinusbradycardia               | 8 (5.9)                   | 11 (8.0)                 | 19 (7.0)               |
| Atrioventricularblock          | 0                         | 1 (0.7)                  | 1 (0.4)                |
| Heartrate decreased            | 0                         | 1 (0.7)                  | 1 (0.4)                |

Source:IA2Table15.3.1.4.1(data cutoff:28June 2019).MedDRA,Medical DictionaryforRegulatoryActivities; TEAE,treatment-emergentadverseevent.

Patientswith1ormoreTEAEswithin alevelofMedDRAtermarecountedonlyonceinthatlevel.

MedDRADictionary(Version22.0)wasusedforcodingadverseevents.

Treatment-emergentAEs aredefinedasAEsstarting/worseningonor afterthefirstdoseofstudytreatment andno later than the earliest of(1)30 days after thelast dose of thetreatment towhich the patient was assigned,or (2) the daybeforestart of brigatinibtherapyin crossoverpatients.

## Hypertension

Table 58 : Summary of Hypertension TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| TEAEs                                   | 31 (22.8)                                     | 10 (7.3)                            | 31 (28.2)                                     | 62 (25.2)                                     |
| Drug related                            | 20 (14.7)                                     | 2 (1.5)                             | 19 (17.3)                                     | 39 (15.9)                                     |
| Grade ≥3                                | 13 (9.6)                                      | 4 (2.9)                             | 11 (10.0)                                     | 24 (9.8)                                      |
| Grade ≥3, drug related                  | 9 (6.6)                                       | 0                                   | 5 (4.5)                                       | 14 (5.7)                                      |
| Leading to study drug discontinuation a | 0                                             | 0                                   | 0                                             | 0                                             |
| Leading to dose reduction               | 2 (1.5)                                       | 0                                   | 1 (0.9)                                       | 3 (1.2)                                       |
| Leading to dose interruption            | 7 (5.1)                                       | 0                                   | 3 (2.7)                                       | 10 (4.1)                                      |
| Treatment-emergent SAEs                 | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Drug related                            | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Grade ≥3                                | 0                                             | 0                                   | 0                                             | 0                                             |
| Grade ≥3, drug related                  | 0                                             | 0                                   | 0                                             | 0                                             |

Source: Table 15.3.1.2.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

a

Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

<div style=\"page-break-after: always\"></div>

Table 59: Patients with hypertension TEAEs by preferred term (treated population, second interim analysis)

|                                 | NumberofPatients(%o)      | NumberofPatients(%o)      | NumberofPatients(%o)   |
|---------------------------------|---------------------------|---------------------------|------------------------|
| PreferredTerm                   | ArmA Brigatinib (N = 136) | ArmB Crizotinib (N = 137) | Total (N = 273)        |
| PatientswithanyhypertensionTEAE | 44 (32.4)                 | 11 (8.0)                  | 55 (20.1)              |
| Hypertension                    | 43 (31.6)                 | 11 (8.0)                  | 54 (19.8)              |
| Diastolic hypertension          | 1 (0.7)                   | 0                         | 1 (0.4)                |
| Systolichypertension            | 1 (0.7)                   | 0                         | 1 (0.4)                |

Source:IA2Table15.3.1.4.1(datacutoff:28June2019)

MedDRA:Medical DictionaryforRegulatoryActivities;TEAE:treatment-emergent adverseevent.

Patientswith1 or moreTEAEswithinalevel ofMedDRA term arecountedonlyonceinthatlevel.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined asAEsstarting/worsening on or after thefirst dose of study treatment and no later than the earliest of (1)30days after thelast doseofthetreatment towhich thepatient was assigned,or(2) thedaybeforestartofbrigatinibtherapyincrossoverpatients.

## Gastro-intestinal Events

Table 60: Summary of Gastrointestinal TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| TEAEs                                   | 92 (67.6)                                     | 118 (86.1)                          | 88 (80.0)                                     | 180 (73.2)                                    |
| Drug related                            | 72 (52.9)                                     | 107 (78.1)                          | 64 (58.2)                                     | 136 (55.3)                                    |
| Grade ≥3                                | 7 (5.1)                                       | 15 (10.9)                           | 4 (3.6)                                       | 11 (4.5)                                      |
| Grade ≥3, drug related                  | 3 (2.2)                                       | 8 (5.8)                             | 3 (2.7)                                       | 6 (2.4)                                       |
| Leading to study drug discontinuation a | 1 (0.7)                                       | 2 (1.5)                             | 0                                             | 1 (0.4)                                       |
| Leading to dose reduction               | 1 (0.7)                                       | 9 (6.6)                             | 4 (3.6)                                       | 5 (2.0)                                       |
| Leading to dose interruption            | 7 (5.1)                                       | 12 (8.8)                            | 9 (8.2)                                       | 16 (6.5)                                      |
| Treatment-emergent SAEs                 | 5 (3.7)                                       | 7 (5.1)                             | 1 (0.9)                                       | 6 (2.4)                                       |
| Drug related                            | 2 (1.5)                                       | 1 (0.7)                             | 0                                             | 2 (0.8)                                       |
| Grade ≥3                                | 5 (3.7)                                       | 7 (5.1)                             | 1 (0.9)                                       | 6 (2.4)                                       |
| Grade ≥3, drug related                  | 2 (1.5)                                       | 1 (0.7)                             | 0                                             | 2 (0.8)                                       |

Source: Table 15.3.1.4.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily;

SAE, serious adverse event; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

a Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

<div style=\"page-break-after: always\"></div>

Table 61: Patients with gastrointestinal TEAEs by preferred term (treated population, second interim analysis)

|                                         | Number of Patients (%)     | Number of Patients (%)    | Number of Patients (%)   |
|-----------------------------------------|----------------------------|---------------------------|--------------------------|
| Preferred Term                          | Arm A Brigatinib (N = 136) | Arm B Crizotinib (N =137) | Total (N = 273)          |
| Patients with any gastrointestinal TEAE | 98 (72.1)                  | 120 (87.6)                | 218 (79.9)               |
| Diarrhoea                               | 71 (52.2)                  | 77 (56.2)                 | 148 (54.2)               |
| Nausea                                  | 41 (30.1)                  | 80 (58.4)                 | 121 (44.3)               |
| Vomiting                                | 28 (20.6)                  | 60 (43.8)                 | 88 (32.2)                |
| Constipation                            | 25 (18.4)                  | 57 (41.6)                 | 82 (30.0)                |
| Abdominal pain                          | 18 (13.2)                  | 20 (14.6)                 | 38 (13.9)                |
| Dyspepsia                               | 11 (8.1)                   | 22 (16.1)                 | 33 (12.1)                |
| Abdominal pain upper                    | 8 (5.9)                    | 24 (17.5)                 | 32 (11.7)                |
| Stomatitis                              | 11 (8.1)                   | 9 (6.6)                   | 20 (7.3)                 |
| Gastrooesophageal reflux disease        | 1 (0.7)                    | 15 (10.9)                 | 16 (5.9)                 |
| Dysphagia                               | 3 (2.2)                    | 12 (8.8)                  | 15 (5.5)                 |
| Mouth ulceration                        | 6 (4.4)                    | 2 (1.5)                   | 8 (2.9)                  |
| Abdominal distension                    | 4 (2.9)                    | 2 (1.5)                   | 6 (2.2)                  |
| Abdominal discomfort                    | 2 (1.5)                    | 3 (2.2)                   | 5 (1.8)                  |
| Abdominal pain lower                    | 1 (0.7)                    | 1 (0.7)                   | 2 (0.7)                  |
| Oral pain                               | 1 (0.7)                    | 1 (0.7)                   | 2 (0.7)                  |
| Aphthous ulcer                          | 1 (0.7)                    | 0                         | 1 (0.4)                  |
| Oral mucosalblistering                  | 0                          | 1 (0.7)                   | 1 (0.4)                  |

MedDRA: Medical Dictionary for Regulatory Activities; TEAE: treatment-emergent adverse event.

Source: IA2 Table 15.3.1.4.1 (data cutoff: 28 June 2019).

Patients with 1 or more TEAEs within alevel of MedDRA term are counted only once in that level.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the daybefore start of brigatinib therapy in crossover patients.

## Pancreatic Events

No patients had clinical pancreatitis in either study 201 or 301. Chemical pancreatitis TEAEs occurred in 22.8% of patients in the brigatinib arm and 15.3% of patients in the crizotinib arm. With updated safety data these number increased to 26.5% and 19.0% of patients in the brigatinib vs crizotinib arm. Grade ≥3 events also occurred more frequently in the brigatinib arm (16.2%) compared with the crizotinib arm (5.1%).

<div style=\"page-break-after: always\"></div>

Table 62: Summary of Increased Insulin/Hyperglycemia TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| TEAEs                                   | 8 (5.9)                                       | 6 (4.4)                             | 17 (15.5)                                     | 25 (10.2)                                     |
| Drug related                            | 4 (2.9)                                       | 1 (0.7)                             | 3 (2.7)                                       | 7 (2.8)                                       |
| Grade ≥3                                | 2 (1.5)                                       | 1 (0.7)                             | 2 (1.8)                                       | 4 (1.6)                                       |
| Grade ≥3, drug related                  | 0                                             | 0                                   | 0                                             | 0                                             |
| Leading to study drug discontinuation a | 0                                             | 0                                   | 0                                             | 0                                             |
| Leading to dose reduction               | 0                                             | 0                                   | 0                                             | 0                                             |
| Leading to dose interruption            | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Treatment-emergent SAEs                 | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Drug related                            | 0                                             | 0                                   | 0                                             | 0                                             |
| Grade ≥3                                | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Grade ≥3, drug related                  | 0                                             | 0                                   | 0                                             | 0                                             |

Source: Table 15.3.1.8.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

a Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

Increased Insulin/Hyperglycemia

Table 63: Patients with both elevated insulin and hyperglycaemia TEAEs by preferred term (treated population, second interim analysis)

|                                                   | Numberof Patients (%)    | Numberof Patients (%)    | Numberof Patients (%)   |
|---------------------------------------------------|--------------------------|--------------------------|-------------------------|
| PreferredTerm                                     | ArmA Brigatinib (N =136) | ArmB Crizotinib (N =137) | Total (N = 273)         |
| Patientswithanyelevated insulin/hyperglycemiaTEAE | 19 (14.0)                | 8 (5.8)                  | 27 (9.9)                |
| Hyperglycaemia                                    | 7 (5.1)                  | 6 (4.4)                  | 13 (4.8)                |
| Bloodinsulinincreased                             | 6 (4.4)                  | 1 (0.7)                  | 7 (2.6)                 |
| Hyperinsulinaemia                                 | 4 (2.9)                  | 0                        | 4 (1.5)                 |
| Bloodglucoseincreased                             | 3 (2.2)                  | 0                        | 3 (1.1)                 |
| Diabetesmellitus                                  | 1 (0.7)                  | 1 (0.7)                  | 2 (0.7)                 |
| Glycosylated hemoglobin increased                 | 1 (0.7)                  | 0                        | 1 (0.4)                 |

Source:IA2Table 15.3.1.4.1(data cutoff: 28June 2019).

MedDRA,MedicalDictionaryforRegulatoryActivities;TEAE,treatment-emergentadverseevent.

Patientswith1ormoreTEAEswithin alevelofMedDRAtermarecountedonlyonceinthatlevel.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the day before start of brigatinib therapy in crossover patients.

<div style=\"page-break-after: always\"></div>

Table 64: Summary of Hepatic TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| TEAEs                                   | 44 (32.4)                                     | 57 (41.6)                           | 27 (24.5)                                     | 71 (28.9)                                     |
| Drug related                            | 38 (27.9)                                     | 49 (35.8)                           | 21 (19.1)                                     | 59 (24.0)                                     |
| Grade ≥3                                | 10 (7.4)                                      | 19 (13.9)                           | 6 (5.5)                                       | 16 (6.5)                                      |
| Grade ≥3, drug related                  | 8 (5.9)                                       | 12 (8.8)                            | 4 (3.6)                                       | 12 (4.9)                                      |
| Leading to study drug discontinuation a | 2 (1.5)                                       | 4 (2.9)                             | 0                                             | 2 (0.8)                                       |
| Leading to dose reduction               | 5 (3.7)                                       | 9 (6.6)                             | 1 (0.9)                                       | 6 (2.4)                                       |
| Leading to dose interruption            | 12 (8.8)                                      | 17 (12.4)                           | 4 (3.6)                                       | 16 (6.5)                                      |
| Treatment-emergent SAEs                 | 2 (1.5)                                       | 2 (1.5)                             | 3 (2.7)                                       | 5 (2.0)                                       |
| Drug related                            | 2 (1.5)                                       | 2 (1.5)                             | 1 (0.9)                                       | 3 (1.2)                                       |
| Grade ≥3                                | 2 (1.5)                                       | 2 (1.5)                             | 3 (2.7)                                       | 5 (2.0)                                       |
| Grade ≥3, drug related                  | 2 (1.5)                                       | 2 (1.5)                             | 1 (0.9)                                       | 3 (1.2)                                       |

Source: Table 15.3.1.5.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

a Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

Table 65: Patients with hepatic TEAEs by preferred term (treated population, second interim analysis)

|                                     | Number of Patients (%)    | Number of Patients (%)     | Number of Patients (%)   |
|-------------------------------------|---------------------------|----------------------------|--------------------------|
| Preferred Term                      | Arm A Brigatinib (N =136) | Arm B Crizotinib (N = 137) | Total (N = 273)          |
| Patientswith anyhepaticTEAE         | 46 (33.8)                 | 60 (43.8)                  | 106 (38.8)               |
| Alanine aminotransferase increased  | 29 (21.3)                 | 48 (35.0)                  | 77 (28.2)                |
| Aspartate aminotransferaseincreased | 35 (25.7)                 | 36 (26.3)                  | 71 (26.0)                |
| Blood alkaline phosphataseincreased | 16 (11.8)                 | 17 (12.4)                  | 33 (12.1)                |
| Gamma-glutamyltransferaseincreased  | 3 (2.2)                   | 8 (5.8)                    | 11 (4.0)                 |
| Hypoalbuminaemia                    | 1 (0.7)                   | 10 (7.3)                   | 11 (4.0)                 |
| Bloodbilirubin increased            | 2 (1.5)                   | 3 (2.2)                    | 5 (1.8)                  |
| Cholestasis                         | 1 (0.7)                   | 1 (0.7)                    | 2 (0.7)                  |
| Hepatotoxicity                      | 1 (0.7)                   | 1 (0.7)                    | 2 (0.7)                  |
| Hypertransaminasaemia               | 1 (0.7)                   | 1 (0.7)                    | 2 (0.7)                  |
| Transaminases increased             | 2 (1.5)                   | 0                          | 2 (0.7)                  |
| Alanineaminotransferaseabnormal     | 0                         | 1 (0.7)                    | 1 (0.4)                  |
| Ascites                             | 0                         | 1 (0.7)                    | 1 (0.4)                  |
| Aspartate aminotransferase abnormal | 0                         | 1 (0.7)                    | 1 (0.4)                  |
| Drug-induced liver injury           | 0                         | 1 (0.7)                    | 1 (0.4)                  |
| Hepaticfunction abnormal            | 0                         | 1 (0.7)                    | 1 (0.4)                  |
| Transaminase abnormal               | 1 (0.7)                   | 0                          | 1 (0.4)                  |
| Hepatocellular injury               | 1 (0.7)                   | 0                          | 1 (0.4)                  |

Source:IA2 Table 15.3.1.4.1(data cutoff: 28 June 2019).

MedDRA: Medical Dictionary for Regulatory Activities; TEAE: treatment-emergent adverse event.

Patients with 1 or more TEAEs within alevel of MedDRA term are counted only once in that level.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the daybeforestart ofbrigatinib therapy in crossover patients.

<div style=\"page-break-after: always\"></div>

## Elevated CPK

Table 66: Summary of Elevated CPK TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| TEAEs                                   | 53 (39.0)                                     | 21 (15.3)                           | 39 (35.5)                                     | 92 (37.4)                                     |
| Drug related                            | 51 (37.5)                                     | 18 (13.1)                           | 35 (31.8)                                     | 86 (35.0)                                     |
| Grade ≥3                                | 22 (16.2)                                     | 2 (1.5)                             | 16 (14.5)                                     | 38 (15.4)                                     |
| Grade ≥3, drug related                  | 22 (16.2)                                     | 1 (0.7)                             | 14 (12.7)                                     | 36 (14.6)                                     |
| Leading to study drug discontinuation a | 0                                             | 0                                   | 0                                             | 0                                             |
| Leading to dose reduction               | 14 (10.3)                                     | 2 (1.5)                             | 7 (6.4)                                       | 21 (8.5)                                      |
| Leading to dose interruption            | 24 (17.6)                                     | 4 (2.9)                             | 10 (9.1)                                      | 34 (13.8)                                     |
| Treatment-emergent                      | 0                                             | 0                                   | 0                                             | 0                                             |
| Drug related                            | 0                                             | 0                                   | 0                                             | 0                                             |
| Grade ≥3                                | 0                                             | 0                                   | 0                                             | 0                                             |
| Grade ≥3, drug related                  | 0                                             | 0                                   | 0                                             | 0                                             |

Source: Table 15.3.1.12.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; CPK, creatine phosphokinase; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event. MedDRA version 20.0.

a Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

Table 67: Patients with elevated creatine phosphokinase TEAEs by preferred term (treated population, second interim analysis)

|                                                         | Number of Patients (%)     | Number of Patients (%)    | Number of Patients (%)   |
|---------------------------------------------------------|----------------------------|---------------------------|--------------------------|
| PreferredTerm                                           | Arm A Brigatinib (N = 136) | ArmB Crizotinib (N = 137) | Total (N = 273)          |
| Patientswithanybloodcreatine phosphokinaseincreasedTEAE | 63 (46.3)                  | 24 (17.5)                 | 87 (31.9)                |
| Bloodcreatinephosphokinaseincreased                     | 63 (46.3)                  | 23 (16.8)                 | 86 (31.5)                |
| Bloodcreatineincreased                                  | 0                          | 2 (1.5)                   | 2 (0.7)                  |
| Hypercreatinaemia                                       | 1 (0.7)                    | 0                         | 1 (0.4)                  |

Source:IA2Table15.3.1.4.1(data cutoff:28June2019).

MedDRA:Medical DictionaryforRegulatoryActivities;TEAE:treatment-emergent adverse event.

MedDRA Dictionary(Version22.0)wasusedfor coding adverseevents.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the day before start of brigatinib therapy in crossover patients.

<div style=\"page-break-after: always\"></div>

## Vision Impairment

Table 68: Summary of Vision Impairment TEAEs in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| TEAEs                                   | 14 (10.3)                                     | 75 (54.7)                           | 23 (20.9)                                     | 37 (15.0)                                     |
| Drug related                            | 8 (5.9)                                       | 68 (49.6)                           | 14 (12.7)                                     | 22 (8.9)                                      |
| Grade ≥3                                | 0                                             | 1 (0.7)                             | 3 (2.7)                                       | 3 (1.2)                                       |
| Grade ≥3, drug related                  | 0                                             | 1 (0.7)                             | 1 (0.9)                                       | 1 (0.4)                                       |
| Leading to study drug discontinuation a | 0                                             | 0                                   | 0                                             | 0                                             |
| Leading to dose reduction               | 0                                             | 0                                   | 2 (1.8)                                       | 2 (0.8)                                       |
| Leading to dose interruption            | 0                                             | 1 (0.7)                             | 2 (1.8)                                       | 2 (0.8)                                       |
| Treatment-emergent SAEs                 | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Drug related                            | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Grade ≥3                                | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Grade ≥3, drug related                  | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |

Source: Table 15.3.1.9.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

a Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

Table 69: Patients with vision impairment TEAEs by preferred term (treated population, second interim analysis)

|                                          | Number of Patients (%)    | Number of Patients (%)    | Number of Patients (%)   |
|------------------------------------------|---------------------------|---------------------------|--------------------------|
| Preferred Term                           | Arm A Brigatinib (N =136) | ArmB Crizotinib (N = 137) | Total (N = 273)          |
| Patients with any vision impairment TEAE | 19 (14.0)                 | 75 (54.7)                 | 94 (34.4)                |
| Photopsia                                | 1 (0.7)                   | 28 (20.4)                 | 29 (10.6)                |
| Visual impairment                        | 0                         | 23 (16.8)                 | 23 (8.4)                 |
| Vision blurred                           | 7 (5.1)                   | 13 (9.5)                  | 20 (7.3)                 |
| Photophobia                              | 1 (0.7)                   | 5 (3.6)                   | 6 (2.2)                  |
| Dry eye                                  | 3 (2.2)                   | 2 (1.5)                   | 5 (1.8)                  |
| Eye pain                                 | 2 (1.5)                   | 3 (2.2)                   | 5 (1.8)                  |
| Visual acuity reduced                    | 1 (0.7)                   | 3 (2.2)                   | 4 (1.5)                  |
| Vitreous floaters                        | 0                         | 4 (2.9)                   | 4 (1.5)                  |
| Diplopia                                 | 0                         | 3 (2.2)                   | 3 (1.1)                  |
| Night blindness                          | 0                         | 3 (2.2)                   | 3 (1.1)                  |
| Periorbital oedema                       | 2 (1.5)                   | 1 (0.7)                   | 3 (1.1)                  |
| Visual field defect                      | 0                         | 3 (2.2)                   | 3 (1.1)                  |
| Eyelid oedema                            | 2 (1.5)                   | 0                         | 2 (0.7)                  |
| Ocular hyperaemia                        | 1 (0.7)                   | 1 (0.7)                   | 2 (0.7)                  |
| Blindness unilateral                     | 0                         | 1 (0.7)                   | 1 (0.4)                  |
| Cataract                                 | 0                         | 1 (0.7)                   | 1 (0.4)                  |
| Dyschromatopsia                          | 0                         | 1 (0.7)                   | 1 (0.4)                  |
| Eye inritation                           | 0                         | 1 (0.7)                   | 1 (0.4)                  |
| Glaucoma                                 | 0                         | 1 (0.7)                   | 1 (0.4)                  |
| Hypermetropia                            | 0                         | 1 (0.7)                   | 1 (0.4)                  |
| Keratitis                                | 0                         | 1 (0.7)                   | 1 (0.4)                  |
| Papilloedema                             | 0                         | 1 (0.7)                   | 1 (0.4)                  |

<div style=\"page-break-after: always\"></div>

1 (0.7)

1 (0.7)

Source:IA2Table15.3.1.4.1(datacutoff:28June2019).

MedDRA:MedicalDictionaryforRegulatoryActivities;TEAE:treatment-emergentadverseevent.

Patientswith1 ormoreTEAEswithin alevelof MedDRA termarecountedonlyonceinthatlevel.

MedDRADictionary(Version22.0)wasusedforcodingadverseevents.

Treatment-emergentAEsaredefinedasAEsstarting/worseningonorafterthefirstdoseofstudytreatmentandno later than theearliestof(1)30days afterthelast doseof thetreatment towhich thepatientwas assigned,or(2) thedaybeforestartofbrigatinibtherapyincrossoverpatients.

## Serious adverse event/deaths/other significant events

## Serious adverse events

Table 70: TreatmentEmergent SAEs Occurring in ≥2% of Patients in Either Study by SOC and PT, Any NCI CTCAE Grade, in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                                                      | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|----------------------------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| System Organ Class Preferred Term                                    | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any treatment-emergent SAE                             | 34 (25.0)                                     | 45 (32.8)                           | 62 (56.4)                                     | 96 (39.0)                                     |
| Infections and infestations                                          | 7 (5.1)                                       | 14 (10.2)                           | 18 (16.4)                                     | 25 (10.2)                                     |
| Pneumonia                                                            | 5 (3.7)                                       | 4 (2.9)                             | 10 (9.1)                                      | 15 (6.1)                                      |
| Urinary tract infection                                              | 1 (0.7)                                       | 3 (2.2)                             | 0                                             | 1 (0.4)                                       |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 3 (2.2)                                       | 5 (3.6)                             | 15 (13.6)                                     | 18 (7.3)                                      |
| Neoplasm progression                                                 | 1 (0.7)                                       | 3 (2.2)                             | 9 (8.2)                                       | 10 (4.1)                                      |
| Malignant pleural effusion                                           | 1 (0.7)                                       | 0                                   | 4 (3.6)                                       | 5 (2.0)                                       |
| Respiratory, thoracic, and mediastinal disorders                     | 13 (9.6)                                      | 11 (8.0)                            | 16 (14.5)                                     | 29 (11.8)                                     |
| Pneumonitis                                                          | 2 (1.5)                                       | 2 (1.5)                             | 9 (8.2)                                       | 11 (4.5)                                      |
| Dyspnoea                                                             | 3 (2.2)                                       | 5 (3.6)                             | 3 (2.7)                                       | 6 (2.4)                                       |
| Pulmonary embolism                                                   | 3 (2.2)                                       | 4 (2.9)                             | 2 (1.8)                                       | 5 (2.0)                                       |
| Pleural effusion                                                     | 1 (0.7)                                       | 3 (2.2)                             | 0                                             | 1 (0.4)                                       |
| Gastrointestinal disorders                                           | 6 (4.4)                                       | 9 (6.6)                             | 4 (3.6)                                       | 10 (4.1)                                      |
| Diarrhoea                                                            | 3 (2.2)                                       | 1 (0.7)                             | 0                                             | 3 (1.2)                                       |
| General disorders and administration site conditions                 | 7 (5.1)                                       | 6 (4.4)                             | 4 (3.6)                                       | 11 (4.5)                                      |
| Asthenia                                                             | 3 (2.2)                                       | 0                                   | 0                                             | 3 (1.2)                                       |
| Non-cardiac chest pain                                               | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |

Source: Table 15.3.2.3.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; incl, including; MedDRA, Medical Dictionary for Regulatory Activities; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; PT, Preferred Term; QD, once daily; SAE, serious adverse event; SOC, System Organ Class.

Includes SAEs that occurred in ≥2% of patients in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib in Study 301 within the SOC.

0

0

<div style=\"page-break-after: always\"></div>

Table 71: TreatmentRelated SAEs Occurring in ≥2% of Patients in Either Study by SOC and PT, Any NCI CTCAE Grade, in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                                  | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|--------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| System Organ Class Preferred Term                | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any treatment-related SAE          | 13 (9.6)                                      | 5 (3.6)                             | 20 (18.2)                                     | 33 (13.4)                                     |
| Respiratory, thoracic, and mediastinal disorders | 4 (2.9)                                       | 1 (0.7)                             | 9 (8.2)                                       | 13 (5.3)                                      |
| Pneumonitis                                      | 2 (1.5)                                       | 1 (0.7)                             | 9 (8.2)                                       | 11 (4.5)                                      |

Source: Table 15.3.2.4.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; PT, Preferred Term; QD, once daily; SAE, serious adverse event; SOC, System Organ Class.

Includes SAEs that occurred in ≥2% of patients in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib in Study 301 within the SOC.

Table 72: TreatmentEmergent SAEs (in ≥2% of Patients in Either treatment arm) by SOC and PT (Treated population, second interim analysis)

|                                                                           | Number of Patients (%)    | Number of Patients (%)     |
|---------------------------------------------------------------------------|---------------------------|----------------------------|
| System Organ Class Preferred Term                                         | Arm A Brigatinib (N =136) | Arm B Crizotinib (N = 137) |
| Patients with at least 1 treatment-emergent SAE                           | 45 (33.1)                 | 51 (37.2)                  |
| Infections and infestations                                               | 9 (6.6)                   | 17 (12.4)                  |
| Pneumonia                                                                 | 6 (4.4)                   | 5 (3.6)                    |
| Urinary tract infection                                                   | 1 (0.7)                   | 3 (2.2)                    |
| Respiratory tract infection                                               | 0                         | 3 (2.2)                    |
| Neoplasms benign, malignant, and unspecified (including cysts and polyps) | 9 (6.6)                   | 8 (5.8)                    |
| Neoplasm progression                                                      | 3 (2.2)                   | 3 (2.2)                    |
| Respiratory, thoracic, and mediastinal disorders                          | 15 (11.0)                 | 13 (9.5)                   |
| Dyspnoea                                                                  | 3 (2.2)                   | 6 (4.4)                    |
| Pulmonary embolism                                                        | 3 (2.2)                   | 5 (3.6)                    |
| Interstitial lung disease                                                 | 3 (2.2)                   | 0                          |
| Pleural effusion                                                          | 2 (1.5)                   | 3 (2.2)                    |
| General disorders and administration site conditions                      | 9 (6.6)                   | 5 (3.6)                    |
| Pyrexia                                                                   | 4 (2.9)                   | 0                          |
| Asthenia                                                                  | 3 (2.2)                   | 0                          |

Source:IA2Table15.3.1.3.1(data cutoff:28June 2019).

MedDRA: Medical Dictionary for Regulatory Activities; SAE: serious adverse event; TEAE: treatment-emergent adverse event.

Patients with 1 or more TEAEs within a level of MedDRA term are counted only once in that level.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the day before start of brigatinib therapy in crossover patients.

<div style=\"page-break-after: always\"></div>

Table 73: TreatmentEmergent SAEs Grade ≥3 (in ≥2% of Patients in Either treatment arm) by SOC and PT (Treated population, second interim analysis)

|                                                                           | Number of Patients (%)    | Number of Patients (%)    | Number of Patients (%)    | Number of Patients (%)    |
|---------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| System Organ Class                                                        | Arm A Brigatinib (N =136) | Arm A Brigatinib (N =136) | Arm B Crizotinib (N =137) | Arm B Crizotinib (N =137) |
| PreferredTerm                                                             | Any                       | Grade ≥3                  | Any                       | Grade≥3                   |
| Patientswith any Grade≥3 treatment-emergent SAE                           | 45 (33.1)                 | 39 (28.7)                 | 51 (37.2)                 | 41 (29.9)                 |
| Infections and infestations                                               | 9 (6.6)                   | 7 (5.1)                   | 17 (12.4)                 | 11 (8.0)                  |
| Pneumonia                                                                 | 6 (4.4)                   | 4 (2.9)                   | 5 (3.6)                   | 5 (3.6)                   |
| Urinary tract infection                                                   | 1 (0.7)                   | 1 (0.7)                   | 3 (2.2)                   | 3 (2.2)                   |
| Neoplasms benign, malignant, and unspecified (including cysts and polyps) | 9 (6.6)                   | 7 (5.1)                   | 8 (5.8)                   | 6 (4.4)                   |
| Neoplasm progression                                                      | 3 (2.2)                   | 3 (2.2)                   | 3 (2.2)                   | 3 (2.2)                   |
| Respiratory, thoracic, and mediastinal disorders                          | 15 (11.0)                 | 13 (9.6)                  | 13 (9.5)                  | 10 (7.3)                  |
| Dyspnoea                                                                  | 3 (2.2)                   | 3 (2.2)                   | 6 (4.4)                   | 4 (2.9)                   |
| Pulmonary embolism                                                        | 3 (2.2)                   | 3 (2.2)                   | 5 (3.6)                   | 4 (2.9)                   |

Source:IA2 Table 15.3.1.3.1.4 (data cutoff: 28 June 2019).

MedDRA: Medical Dictionary for Regulatory Activities; SAE: serious adverse event; TEAE: treatment-emergent adverse event.

Patients with 1 or more TEAEs within a level of MedDRA term are counted only once in that level.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the day before start of brigatinib therapy in crossover patients.

Updated safety data show that treatment-related SAEs occurred in 16 patients (11.8%) in the brigatinib arm and 5 patients (3.6%) in the crizotinib arm. The treatment-related SAEs that occurred in more than 1 patient in the brigatinib arm were pneumonitis (1.5%) and ILD (2.2%). No treatmentrelated SAEs by PT occurred in more than 1 patient in the crizotinib arm.

<div style=\"page-break-after: always\"></div>

## Deaths

Table 74: TEAEs Leading to Death Within 30 Days After Last Dose and Deaths Possibly Related to Study Drug in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                                                                         | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Preferred Term                                                                          | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any TEAE leading to death occurring within 30 days after the last dose or | 7 (5.1)                                       | 7 (5.1)                             | 11 (10.0)                                     | 18 (7.3)                                      |
| Cerebrovascular accident                                                                | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| General physical health deterioration                                                   | 1 (0.7)                                       | 2 (1.5)                             | 0                                             | 1 (0.4)                                       |
| Lung adenocarcinoma                                                                     | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Malignant pleural effusion                                                              | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Multiple organ dysfunction syndrome                                                     | 1 (0.7)                                       | 0                                   | 0                                             | 1 (0.4)                                       |
| Neoplasm progression                                                                    | 1 (0.7)                                       | 0                                   | 8 (7.3)                                       | 9 (3.7)                                       |
| Pneumonia                                                                               | 1 (0.7)                                       | 1 (0.7)                             | 1 (0.9)                                       | 2 (0.8)                                       |
| Cognitive disorder                                                                      | 0                                             | 0                                   | 1 (0.9)                                       | 1 (0.4)                                       |
| Ischaemic stroke                                                                        | 0                                             | 1 (0.7)                             | 0                                             | 0                                             |
| Pleural effusion                                                                        | 0                                             | 1 (0.7)                             | 0                                             | 0                                             |
| Respiratory failure                                                                     | 0                                             | 1 (0.7)                             | 0                                             | 0                                             |
| Sudden death                                                                            | 0                                             | 0                                   | 1 (0.9) a                                     | 1 (0.4)                                       |
| Tumour haemorrhage                                                                      | 0                                             | 1 (0.7)                             | 0                                             | 0                                             |

Source: Table 15.3.2.11 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; TEAE, treatment-emergent adverse event.

MedDRA version 20.0.

Frequencies were sorted by descending frequency of PT for brigatinib in Study 301.

a Assessed by the investigator as possibly treatment related (Study 201 Addendum Table 14.3.2.7).

<div style=\"page-break-after: always\"></div>

Table 75: AEs leading to death occurring within 30 days after last dose of study drug and deaths possibly related to study drug (treated population, second interim analysis)

|                                                                                                        | Number of Patients (%)   | Number of Patients (%)   |
|--------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|
| System Organ Class Preferred Term                                                                      | ARMA Brigatinib (N =136) | ARMB Crizotinib (N =137) |
| PatientsWithAt least1TEAELeading toDeaths Occurring within 30Days of Last Dose or Related toStudy Drug | 9 (6.6)                  | 10 (7.3)                 |
| Infections And Infestations                                                                            | 2 (1.5)                  | 1 (0.7)                  |
| Pneumonia                                                                                              | 2 (1.5)                  | 1 (0.7)                  |
| Neoplasms Benign, Malignant And Unspecified (Incl Cysts And                                            | 5 (3.7)                  | 3 (2.2)                  |
| Neoplasm Progression                                                                                   | 2 (1.5)                  | 1 (0.7)                  |
| Lung Adenocarcinoma                                                                                    | 1 (0.7)                  | 0                        |
| Malignant Pleural Effusion                                                                             | 1 (0.7)                  | 0                        |
| Metastases To Meninges                                                                                 | 1 (0.7)                  | 0                        |
| Malignant NeoplasmProgression                                                                          | 0                        | 1 (0.7)                  |
| Tumour Haemorrhage                                                                                     | 0                        | 1 (0.7)                  |
| Nervous System Disorders                                                                               | 1 (0.7)                  | 1 (0.7)                  |
| Cerebrovascular Accident                                                                               | 1 (0.7)                  | 0                        |
| Ischaemic Stroke                                                                                       | 0                        | 1 (0.7)                  |
| Respiratory, Thoracic And Mediastinal Disorders                                                        | 0                        | 4 (2.9)                  |
| Dyspnoea                                                                                               | 0                        | 1 (0.7)                  |
| Pleural Effusion                                                                                       | 0                        | 1 (0.7)                  |
| Pulmonary Embolism                                                                                     | 0                        | 1 (0.7)                  |
| Respiratory Failure                                                                                    | 0                        | 1 (0.7)                  |
| GeneralDisordersAndAdministrationSiteConditions                                                        | 1 (0.7)                  | 1 (0.7)                  |
| Multiple Organ Dysfunction Syndrome                                                                    | 1 (0.7)                  | 0                        |
| GeneralPhysical Health Deterioration                                                                   | 0                        | 1 (0.7)                  |

Source:IA2Table15.3.1.2.6(data cutoff:28June2019)AE:adverseevent;MedDRA:MedicalDictionary for Regulatory Activities.

Patients with one or more AEs within a level of MedDRA term are counted only once in that level.

MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of the treatment to which the patient was assigned, or (2) the daybeforestart of brigatinibtherapyin crossoverpatients.

## Laboratory findings

## Clinical chemistry

Table 76: CTCAE Grade Shift in Clinical Chemistry Laboratory Parameters From Baseline: Any Worsening From Baseline and Worsening to Grade 3 or 4 in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                       | Study 301                               | Study 301                               | Study 301                     | Study 301                     | Study 201                               | Study 201                               | Total Brigatinib                        | Total Brigatinib                        |
|-----------------------|-----------------------------------------|-----------------------------------------|-------------------------------|-------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| Laboratory Parameter  | Brigatinib 90 mg QD → 180 mg QD N = 136 | Brigatinib 90 mg QD → 180 mg QD N = 136 | Crizotinib 250 mg BID N = 137 | Crizotinib 250 mg BID N = 137 | Brigatinib 90 mg QD → 180 mg QD N = 110 | Brigatinib 90 mg QD → 180 mg QD N = 110 | Brigatinib 90 mg QD → 180 mg QD N = 246 | Brigatinib 90 mg QD → 180 mg QD N = 246 |
|                       | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                | Shift to Any Grade n (%)      | Shift to Grade 3/4 n (%)      | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                |
| CPK increased         | 100 (73.5)                              | 19 (14.0)                               | 80 (58.4)                     | 6 (4.4)                       | 55 (50.0)                               | 15 (13.6)                               | 155 (63.0)                              | 34 (13.8)                               |
| AST increased         | 89 (65.4)                               | 3 (2.2)                                 | 89 (65.0)                     | 6 (4.4)                       | 71 (64.5)                               | 4 (3.6)                                 | 160 (65.0)                              | 7 (2.8)                                 |
| Lipase increased      | 66 (48.5)                               | 19 (14.0)                               | 45 (32.8)                     | 10 (7.3)                      | 55 (50.0)                               | 11 (10.0)                               | 121 (49.2)                              | 30 (12.2)                               |
| ALT increased         | 62 (45.6)                               | 4 (2.9)                                 | 100 (73.0)                    | 16 (11.7)                     | 50 (45.5)                               | 6 (5.5)                                 | 112 (45.5)                              | 10 (4.1)                                |
| Amylase increased     | 61 (44.9)                               | 8 (5.9)                                 | 27 (19.7)                     | 3 (2.2)                       | 47 (42.7)                               | 9 (8.2)                                 | 108 (43.9)                              | 17 (6.9)                                |
| Glucose increased     | 60 (44.1)                               | 10 (7.4)                                | 47 (34.3)                     | 5 (3.6)                       | 76 (69.1)                               | 8 (7.3)                                 | 136 (55.3)                              | 18 (7.3)                                |
| ALP increased         | 46 (33.8)                               | 4 (2.9)                                 | 60 (43.8)                     | 1 (0.7)                       | 44 (40.0)                               | 3 (2.7)                                 | 90 (36.6)                               | 7 (2.8)                                 |
| Phosphorous decreased | 41 (30.1)                               | 3 (2.2)                                 | 44 (32.1)                     | 5 (3.6)                       | 36 (32.7)                               | 8 (7.3)                                 | 77 (31.3)                               | 11 (4.5)                                |
| Magnesium             | 27 (19.9)                               | 0                                       | 6 (4.4)                       | 0                             | 22 (20.0)                               | 0                                       | 49 (19.9)                               | 0                                       |

decreased

<div style=\"page-break-after: always\"></div>

|                      | Study 301                               | Study 301                               | Study 301                     | Study 301                     | Study 201                               | Study 201                               | Total Brigatinib                        | Total Brigatinib                        |
|----------------------|-----------------------------------------|-----------------------------------------|-------------------------------|-------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                      | Brigatinib 90 mg QD → 180 mg QD N = 136 | Brigatinib 90 mg QD → 180 mg QD N = 136 | Crizotinib 250 mg BID N = 137 | Crizotinib 250 mg BID N = 137 | Brigatinib 90 mg QD → 180 mg QD N = 110 | Brigatinib 90 mg QD → 180 mg QD N = 110 | Brigatinib 90 mg QD → 180 mg QD N = 246 | Brigatinib 90 mg QD → 180 mg QD N = 246 |
| Laboratory Parameter | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                | Shift to Any Grade n (%)      | Shift to Grade 3/4 n (%)      | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                |
| Sodium decreased     | 21 (15.4)                               | 3 (2.2)                                 | 14 (10.2)                     | 3 (2.2)                       | 25 (22.7)                               | 4 (3.6)                                 | 46 (18.7)                               | 7 (2.8)                                 |
| Calcium increased    | 20 (14.7)                               | 0                                       | 2 (1.5)                       | 0                             | 22 (20.0)                               | 0                                       | 42 (17.1)                               | 0                                       |
| Potassium increased  | 20 (14.7)                               | 0                                       | 35 (25.5)                     | 4 (2.9)                       | 18 (16.4)                               | 0                                       | 38 (15.4)                               | 0                                       |
| Creatinine increased | 19 (14.0)                               | 0                                       | 41 (29.9)                     | 0                             | 18 (16.4)                               | 0                                       | 37 (15.0)                               | 0                                       |
| Albumin decreased    | 14 (10.3)                               | 0                                       | 66 (48.2)                     | 4 (2.9)                       | 10 (9.1)                                | 0                                       | 24 (9.8)                                | 0                                       |
| Calcium decreased    | 13 (9.6)                                | 0                                       | 83 (60.6)                     | 1 (0.7)                       | 12 (10.9)                               | 0                                       | 25 (10.2)                               | 0                                       |
| Glucose decreased    | 13 (9.6)                                | 0                                       | 11 (8.0)                      | 0                             | 8 (7.3)                                 | 1 (0.9)                                 | 21 (8.5)                                | 1 (0.4)                                 |
| Potassium decreased  | 13 (9.6)                                | 0                                       | 5 (3.6)                       | 1 (0.7)                       | 25 (22.7)                               | 2 (1.8)                                 | 38 (15.4)                               | 2 (0.8)                                 |
| Sodium increased     | 13 (9.6)                                | 0                                       | 16 (11.7)                     | 0                             | 9 (8.2)                                 | 0                                       | 22 (8.9)                                | 0                                       |
| Bilirubin increased  | 5 (3.7)                                 | 0                                       | 3 (2.2)                       | 1 (0.7)                       | 8 (7.3)                                 | 2 (1.8)                                 | 13 (5.3)                                | 2 (0.8)                                 |
| Magnesium increased  | 4 (2.9)                                 | 0                                       | 9 (6.6)                       | 4 (2.9)                       | 6 (5.5)                                 | 1 (0.9)                                 | 10 (4.1)                                | 1 (0.4)                                 |
| aPTT increased a     | -                                       | -                                       | -                             | -                             | 36 (32.7)                               | 2 (1.8)                                 | -                                       | -                                       |
| INR increased a      | -                                       | -                                       | -                             | -                             | 7 (6.4)                                 | 2 (1.8)                                 | -                                       | -                                       |

Source: Table 15.3.7.1 and 15.3.7.2 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BID, twice daily; CPK, creatinine phosphokinase; CTCAE, Common Terminology Criteria for Adverse Events; INR, international normalized ratio; QD, once daily.

a aPTT and INR were not measured in Study 301.

Table 77: CTCAE grade shift in clinical chemistry laboratory parameters from baseline: any worsening from baseline and worsening to grade 3 or 4 (treated population, second interim analysis)

|                      | Arm A Brigatinib (N =136)   | Arm A Brigatinib (N =136)   | Arm B Crizotinib (N = 137)   | Arm B Crizotinib (N = 137)   |
|----------------------|-----------------------------|-----------------------------|------------------------------|------------------------------|
| LaboratoryParameter  | Shift to Any Grade n (%)    | Shift toGrade3 014 n (%)    | Shift to Any Grade n (%)     | Shift toGrade3 014 n (%)     |
| CPK increased        | 102 (75.0)                  | 32 (23.5)                   | 85 (62.0)                    | 6 (4.4)                      |
| AST increased        | 96 (70.6)                   | 6 (4.4)                     | 94 (68.6)                    | 7 (5.1)                      |
| Lipase increased     | 78 (57.4)                   | 23 (16.9)                   | 48 (35.0)                    | 13 (9.5)                     |
| ALTincreased         | 70 (51.5)                   | 7 (5.1)                     | 103 (75.2)                   | 17 (12.4)                    |
| Amylase increased    | 69 (50.7)                   | 9 (6.6)                     | 33 (24.1)                    | 4 (2.9)                      |
| Glucose increased    | 75 (55.1)                   | 10 (7.4)                    | 50 (36.5)                    | 5 (3.6)                      |
| ALP increased        | 48 (35.3)                   | 4 (2.9)                     | 65 (47.4)                    | 2 (1.5)                      |
| Phosphorousdecreased | 55 (40.4)                   | 5 (3.7)                     | 52 (38.0)                    | 8 (5.8)                      |
| Magnesiumdecreased   | 28 (20.6)                   | 0                           | 9 (6.6)                      | 0                            |
| Sodium decreased     | 24 (17.6)                   | 4 (2.9)                     | 14 (10.2)                    | 3 (2.2)                      |
| Calcium increased    | 29 (21.3)                   | 0                           | 2 (1.5)                      | 0                            |
| Potassiumincreased   | 32 (23.5)                   | 2 (1.5)                     | 42 (30.7)                    | 5 (3.6)                      |
| Creatinine increased | 33 (24.3)                   | 0                           | 45 (32.8)                    | 0                            |
| Albumin decreased    | 19 (14.0)                   | 1 (0.7)                     | 69 (50.4)                    | 5 (3.6)                      |
| Potassium decreased  | 18 (13.2)                   | 1 (0.7)                     | 6 (4.4)                      | 1 (0.7)                      |
| Calcium decreased    | 19 (14.0)                   | 0                           | 88 (64.2)                    | 2 (1.5)                      |
| Sodium increased     | 21 (15.4)                   | 0                           | 19 (13.9)                    | 0                            |
| Glucose decreased    | 17 (12.5)                   | 0                           | 14 (10.2)                    | 0                            |
| Bilirubin increased  | 6 (4.4)                     | 0                           | 4 (2.9)                      | 1 (0.7)                      |
| Magnesium increased  | 8 (5.9)                     | 0                           | 11 (8.0)                     | 5 (3.6)                      |

Source: IA2 Table 15.3.4.2.3 (data cutoff: 28 June 2019).

ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CPK: creatinine phosphokinase; CTCAE: Common Terminology Criteriafor AdverseEvents.

Subjectswithnobaselinedatawhohavepost-baseline datawith amaximumofgrade3or 4wil1 beincludedin the increasing/decreasing to a maximum of grade 3 or 4 groups, respectively.

Baseline is defined as the last observation before first dose of study drug.

<div style=\"page-break-after: always\"></div>

## Haematology

Table 78 : CTCAE Grade Shift in Haematology Laboratory Parameters From Baseline: Any Worsening From Baseline and Worsening to Grade 3 or 4 in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                      | Study 301                               | Study 301                               | Study 301                     | Study 301                     | Study 201                                           | Study 201                                           | Total Brigatinib                        | Total Brigatinib                        |
|----------------------|-----------------------------------------|-----------------------------------------|-------------------------------|-------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------|-----------------------------------------|
| Laboratory           | Brigatinib 90 mg QD → 180 mg QD N = 136 | Brigatinib 90 mg QD → 180 mg QD N = 136 | Crizotinib 250 mg BID N = 137 | Crizotinib 250 mg BID N = 137 | Brigatinib 90 mg QD → 180 mg QD N = 110 to Shift to | Brigatinib 90 mg QD → 180 mg QD N = 110 to Shift to | Brigatinib 90 mg QD → 180 mg QD N = 246 | Brigatinib 90 mg QD → 180 mg QD N = 246 |
| Parameter            | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                | Shift to Any Grade n (%)      | Shift to Grade 3/4 n (%)      | Shift Any Grade n (%)                               | Grade 3/4 n (%)                                     | Shift to Any Grade n (%)                | Shift to Grade 3/4 n (%)                |
| Hemoglobin decreased | 43 (31.6)                               | 2 (1.5)                                 | 42 (30.7)                     | 1 (0.7)                       | 57 (51.8)                                           | 2 (1.8)                                             | 100 (40.7)                              | 4 (1.6)                                 |
| Lymphopenia          | 27 (19.9)                               | 6 (4.4)                                 | 25 (18.2)                     | 5 (3.6)                       | 50 (45.5)                                           | 18 (16.4)                                           | 77 (31.3)                               | 24 (9.8)                                |
| ANC decreased        | 8 (5.9)                                 | 0                                       | 30 (21.9)                     | 5 (3.6)                       | 18 (16.4)                                           | 2 (1.8)                                             | 26 (10.6)                               | 2 (0.8)                                 |
| Platelets decreased  | 7 (5.1)                                 | 0                                       | 7 (5.1)                       | 1 (0.7)                       | 9 (8.2)                                             | 0                                                   | 16 (6.5)                                | 0                                       |
| WBCdecreased a       | -                                       | -                                       | -                             | -                             | 28 (25.5)                                           | 0                                                   | -                                       | -                                       |

Source: Table 15.3.7.3 and 15.3.7.4 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: ANC, absolute neutrophil count; BID, twice daily; CTCAE, Common Terminology Criteria for Adverse Events; QD, once daily; WBC, white blood cells.

a Shifts in WBC were not assessed in Study 301.

Table 79: CTCAE grade shift in haematology laboratory parameters from baseline: Any worsening from baseline and worsening to Grade 3 or 4 (treated population, second interim analysis)

|                          | Arm A Brigatinib (N =136)   | Arm A Brigatinib (N =136)   | ArmB Crizotinib (N = 137)   | ArmB Crizotinib (N = 137)   |
|--------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| LaboratoryParameter      | ShifttoAny Grade n (%)      | ShifttoGrade3 014 n (%)     | ShifttoAny Grade n (%)      | ShifttoGrade3 014 n (%)     |
| Hemoglobindecreased      | 54 (39.7)                   | 3 (2.2)                     | 49 (35.8)                   | 2 (1.5)                     |
| Lymphocytecountdecreased | 36 (26.5)                   | 12 (8.8)                    | 28 (20.4)                   | 6 (4.4)                     |
| Neutrophilcountdecreased | 10 (7.4)                    | 1 (0.7)                     | 30 (21.9)                   | 11 (8.0)                    |
| Plateletsdecreased       | 12 (8.8)                    | 0                           | 7 (5.1)                     | 1 (0.7)                     |

Source:IA2Table 15.3.4.2.3 (data cutoff:28June 2019).

CTCAE:CommonTerminologyCriteriaforAdverseEvents.

Baselineisdefined asthelastobservationbeforefirstdoseofstudydrug

Subjectswithnobaselinedatawhohavepost-baselinedatawith amaximumofgrade3or 4wil1beincludedin the increasing/decreasingtoamaximumofgrade3or4groups,respectively

## Insulin

Table 80 : Shift in Insulin From Baseline to Highest or Lowest Postbaseline Value in Terms of Normal Range in Study 301 and Study 201, Treated Population (First Interim Analysis for Study 301)

|                                | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|--------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Insulin shift to lowest value  |                                               |                                     |                                               |                                               |
| Unable to evaluate             | 5 (3.7)                                       | 6 (4.4)                             | 6 (5.5)                                       | 11 (4.5)                                      |
| No change from baseline        | 94 (69.1)                                     | 73 (53.3)                           | 78 (70.9)                                     | 172 (69.9)                                    |
| Shift to low                   | 8 (5.9)                                       | 24 (17.5)                           | 8 (7.3)                                       | 16 (6.5)                                      |
| Normal to low                  | 6 (4.4)                                       | 16 (11.7)                           | 5 (4.5)                                       | 11 (4.5)                                      |
| High to low                    | 1 (0.7)                                       | 4 (2.9)                             | 0                                             | 1 (0.4)                                       |
| Unknown to low                 | 1 (0.7)                                       | 4 (2.9)                             | 3 (2.7)                                       | 4 (1.6)                                       |
| Insulin shift to highest value |                                               |                                     |                                               |                                               |
| Unable to evaluate             | 5 (3.7)                                       | 6 (4.4)                             | 6 (5.5)                                       | 11 (4.5)                                      |

<div style=\"page-break-after: always\"></div>

|                         | Study 301                                     | Study 301                           | Study 201 Brigatinib mg QD → 180 mg   | Total Brigatinib Brigatinib 90 mg QD → 180 mg   |
|-------------------------|-----------------------------------------------|-------------------------------------|---------------------------------------|-------------------------------------------------|
|                         | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | 90 QD N = 110 n (%)                   | QD N = 246 n (%)                                |
| No change from baseline | 67 (49.3)                                     | 80 (58.4)                           | 34 (30.9)                             | 101 (41.1)                                      |
| Shift to high           | 53 (39.0)                                     | 34 (24.8)                           | 67 (60.9)                             | 120 (48.8)                                      |
| Low to high             | 1 (0.7)                                       | 0                                   | 3 (2.7)                               | 4 (1.6)                                         |
| Normal to high          | 50 (36.8)                                     | 33 (24.1)                           | 59 (53.6)                             | 109 (44.3)                                      |
| Unknown to high         | 2 (1.5)                                       | 1 (0.7)                             | 5 (4.5)                               | 7 (2.8)                                         |

Source: Table 15.3.7.5 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; QD, once daily.

Table 81: Shift in insulin from baseline to highest or lowest postbaseline value in terms of normal range (treated population, second interim analysis)

|                            | Number ofPatients(%)      | Number ofPatients(%)      | Number ofPatients(%)   |
|----------------------------|---------------------------|---------------------------|------------------------|
|                            | ArmA Brigatinib (N = 136) | ArmB Crizotinib (N = 137) | Total (N = 273)        |
| Insulinshifttolowestvalue  |                           |                           |                        |
| No changefrom baseline     | 93 (68.4)                 | 73 (53.3)                 | 166 (60.8)             |
| Shift to low               | 10 (7.4)                  | 26 (19.0)                 | 36 (13.2)              |
| Normal tolow               | 8 (5.9)                   | 18 (13.1)                 | 26 (9.5)               |
| High to low                | 1 (0.7)                   | 4 (2.9)                   | 5 (1.8)                |
| Unknown tolow              | 1 (0.7)                   | 4 (2.9)                   | 5 (1.8)                |
| Insulinshifttohighestvalue |                           |                           |                        |
| Nochangefrombaseline       | 63 (46.3)                 | 80 (58.4)                 | 143 (52.4)             |
| Shift to high              | 59 (43.4)                 | 36 (26.3)                 | 95 (34.8)              |
| Low to high                | 2 (1.5)                   | 0                         | 2 (0.7)                |
| Normal to high             | 55 (40.4)                 | 35 (25.5)                 | 90 (33.0)              |
| Unknown tohigh             | 2 (1.5)                   | 1 (0.7)                   | 3 (1.1)                |

Source:IA2 Table 15.3.4.3.2.1 and15.3.4.3.2.2(data cutoff: 28June 2019).

ShiftsfromUnknown correspond tosubjectswith missing baseline results but results available post baseline.

## Vital signs, physical findings, and other observations related to safety

## Heart rate by ECG

Table 82 : Heart rate (by ECG) outlier analysis (Treated population, second interim analysis)

|                  | Number of Patients (%)    | Number of Patients (%)    | Number of Patients (%)   |
|------------------|---------------------------|---------------------------|--------------------------|
|                  | ArmA Brigatinib (N = 136) | ArmB Crizotinib (N = 137) | Total (N = 273)          |
| Heart rate (bpm) | 130 (95.6)                | 133 (97.1)                | 263 (96.3)               |
| <60 bpm          | 59 (43.4)                 | 103 (75.2)                | 162 (59.3)               |
| <50bpm           | 11 (8.1)                  | 46 (33.6)                 | 57 (20.9)                |
| Bradycardic      | 7 (5.1)                   | 38 (27.7)                 | 45 (16.5)                |
| Tachycardic      | 5 (3.7)                   | 7 (5.1)                   | 12 (4.4)                 |

Source:IA2Table15.3.4.8.1 (data cutoff:28June 2019).

bpm:beatsperminute;ECG:electrocardiogram.

Bradycardic:Heartrate&lt;50and≥25%reductionfrombaseline.

Tachycardic:Heartrate&gt;100and&gt;25%increasefrombaseline.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:IA2Figure15.3.4.3.1.1（data cutoff:28June2019).

Figure 22: Mean pulse rate by visit (treated population, second interim analysis)

## Blood pressure

Table 83 : Blood pressure shifts from baseline to worst value postbaseline (treated population, second interim analysis)

|                                                        | Number of Patients (%)    | Number of Patients (%)     | Number of Patients (%)   |
|--------------------------------------------------------|---------------------------|----------------------------|--------------------------|
|                                                        | Arm A Brigatinib (N =136) | Arm B Crizotinib (N = 137) | Total (N = 273)          |
| Maximumshiftofsystolicbloodpressure frombaseline(mmHg) |                           |                            |                          |
| Evalbaseline<120                                       | 56                        | 54                         | 110                      |
| No change                                              | 4 (7.1)                   | 13 (24.1)                  | 17 (15.5)                |
| <120 to 120-139                                        | 22 (39.3)                 | 25 (46.3)                  | 47 (42.7)                |
| <120 to 140-159                                        | 20 (35.7)                 | 11 (20.4)                  | 31 (28.2)                |
| <120 to ≥160                                           | 9 (16.1)                  | 5 (9.3)                    | 14 (12.7)                |
| No postbaseline value                                  | 1 (1.8)                   | 0                          | 1 (0.9)                  |
| Eval baseline 120-139                                  | 59                        | 69                         | 128                      |
| 120-139 to<120                                         | 2 (3.4)                   | 4 (5.8)                    | 6 (4.7)                  |
| No change                                              | 8 (13.6)                  | 30 (43.5)                  | 38 (29.7)                |
| 120-139 to 140-159                                     | 32 (54.2)                 | 27 (39.1)                  | 59 (46.1)                |
| 120-139 to ≥160                                        | 17 (28.8)                 | 6 (8.7)                    | 23 (18.0)                |
| No postbaseline value                                  | 0                         | 2 (2.9)                    | 2 (1.6)                  |
| Evalbaseline 140-159                                   | 18                        | 13                         | 31                       |
| 140-159 to<120                                         | 0                         | 0                          | 0                        |
| 140-159 to 120-139                                     | 0                         | 1 (7.7)                    | 1 (3.2)                  |
| No change                                              | 6 (33.3)                  | 9 (69.2)                   | 15 (48.4)                |
| 140-159 to ≥160                                        | 12 (66.7)                 | 3 (23.1)                   | 15 (48.4)                |
| No postbaseline value                                  | 0                         | 0                          | 0                        |
| Eval baseline ≥160                                     | 3                         | 1                          | 4                        |
| ≥160 to <120                                           | 0                         | 0                          | 0                        |
| ≥160 to 120-139                                        | 0                         | 0                          | 0                        |
| ≥160 to 140-159                                        | 0                         | 1 (100)                    | 1 (25.0)                 |
| No change                                              | 3 (100)                   | 0                          | 3 (75.0)                 |
| No postbaseline value                                  | 0                         | 0                          | 0                        |

<div style=\"page-break-after: always\"></div>

Shiftfrombaseline

Source:IA2 Table 15.3.4.4.4 and 15.3.4.4.5 (data cutoff: 28 June 2019). Eval: evaluable.

| One-level increase                                          | 66 (48.5)   | 55 (40.1)   | 121 (44.3)   |
|-------------------------------------------------------------|-------------|-------------|--------------|
| Two-level increase                                          | 37 (27.2)   | 17 (12.4)   | 54 (19.8)    |
| Three-level increase                                        | 9 (6.6)     | 5 (3.6)     | 14 (5.1)     |
| Maximumshiftof diastolicbloodpressure from baseline (mm Hg) |             |             |              |
| Eval baseline <80                                           | 78          | 83          | 161          |
| No change                                                   | 13 (16.7)   | 37 (44.6)   | 50 (31.1)    |
| <80 to 80-89                                                | 30 (38.5)   | 36 (43.4)   | 66 (41.0)    |
| <80 to 90-99                                                | 22 (28.2)   | 8 (9.6)     | 30 (18.6)    |
| <80 to≥100                                                  | 12 (15.4)   | 1 (1.2)     | 13 (8.1)     |
| Nopostbaselinevalue                                         | 1 (1.3)     | 1 (1.2)     | 2 (1.2)      |
| Eval baseline 80-89                                         | 39          | 41          | 80           |
| 80-89 to<80                                                 | 2 (5.1)     | 6 (14.6)    | 8 (10.0)     |
| No change                                                   | 5 (12.8)    | 19 (46.3)   | 24 (30.0)    |
| 80-89 to 90-99                                              | 23 (59.0)   | 16 (39.0)   | 39 (48.8)    |
| 80-89 to ≥100                                               | 9 (23.1)    | 0           | 9 (11.3)     |
| No postbaseline value                                       | 0           | 0           | 0            |
| Evalbaseline90-99                                           | 16          | 12          | 28           |
| 90-99 to<80                                                 | 0           | 3 (25.0)    | 3 (10.7)     |
| 90-99 to 80-89                                              | 1 (6.3)     | 3 (25.0)    | 4 (14.3)     |
| No change                                                   | 9 (56.3)    | 5 (41.7)    | 14 (50.0)    |
| 90-99 to ≥100                                               | 6 (37.5)    | 0           | 6 (21.4)     |
| No postbaseline value                                       | 0           | 1 (8.3)     | 1 (3.6)      |
| Eval baseline ≥100                                          | 3           | 1           | 4            |
| ≥100 to<80                                                  | 0           | 0           | 0            |
| ≥100 to 80-89                                               | 0           | 0           | 0            |
| ≥100 to 90-99                                               | 0           | 1(100)      | 1 (25.0)     |
| No change                                                   | 3 (100)     | 0           | 3 (75.0)     |
| Nopostbaselinevalue                                         | 0           | 0           | 0            |
| Shiftfrombaseline                                           |             |             |              |
| One-level increase                                          | 59 (43.4)   | 52 (38.0)   | 111 (40.7)   |
| Two-level increase                                          | 31 (22.8)   | 8 (5.8)     | 39 (14.3)    |
| Three-level increase                                        | 12 (8.8)    | 1 (0.7)     | 13 (4.8)     |

## ECG findings

Table 84 : QTcF outlier analysis (treated population, second interim analysis)

|                              | NumberofPatients(%o)       | NumberofPatients(%o)     | NumberofPatients(%o)   |
|------------------------------|----------------------------|--------------------------|------------------------|
|                              | Arm A Brigatinib (N = 136) | ArmB Crizotinib (N =137) | Total (N = 273)        |
| QT interval (ms)             | 130 (95.6)                 | 133 (97.1)               | 263 (96.3)             |
| >500andbaseline≤50o          | 2 (1.5)                    | 9 (6.6)                  | 11 (4.0)               |
| QTcFmaximumchangeontreatment | 130 (95.6)                 | 133 (97.1)               | 263 (96.3)             |
| No increase                  | 15 (11.0)                  | 9 (6.6)                  | 24 (8.8)               |
| >0to<30ms                    | 63 (46.3)                  | 61 (44.5)                | 124 (45.4)             |
| 30 to60ms                    | 41 (30.1)                  | 50 (36.5)                | 91 (33.3)              |
| >60 ms                       | 11 (8.1)                   | 13 (9.5)                 | 24 (8.8)               |
| QTcF (ms)                    | 130 (95.6)                 | 133 (97.1)               | 263 (96.3)             |
| >500andbaseline≤500          | 4 (2.9)                    | 3 (2.2)                  | 7 (2.6)                |
| >480andbaseline≤480          | 8 (5.9)                    | 7 (5.1)                  | 15 (5.5)               |
| >450 andbaseline≤450         | 25 (18.4)                  | 32 (23.4)                | 57 (20.9)              |

Source:IA2 Table 15.3.4.8.1(data cutoff:28June 2019).QTcF,QT interval corrected(Fridericia).

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Intrinsic factors

Age

Table 85 : TEAEs of All Grades by Patient Age (&lt;65 Years vs ≥65 Years) Occurring in ≥10% of Patients in Either Subgroup in the Brigatinib Arm by SOC and PT in Study 301, Treated Population (First Interim Analysis)

|                                                      | Brigatinib 90 mg QD → 180 mg QD   | Brigatinib 90 mg QD → 180 mg QD   |
|------------------------------------------------------|-----------------------------------|-----------------------------------|
| System Organ Class Preferred Term                    | <65 Years N = 92 n (%)            | ≥65 Years N = 44 n (%)            |
| Patients with any TEAE                               | 88 (95.7)                         | 44 (100)                          |
| Infections and infestations                          | 33 (35.9)                         | 17 (38.6)                         |
| Pneumonia                                            | 3 (3.3)                           | 5 (11.4)                          |
| Blood and lymphatic system disorders                 | 1 (1.1)                           | 7 (15.9)                          |
| Anaemia                                              | 0                                 | 5 (11.4)                          |
| Nervous system disorders                             | 35 (38.0)                         | 16 (36.4)                         |
| Headache                                             | 18 (19.6)                         | 2 (4.5)                           |
| Dizziness                                            | 8 (8.7)                           | 5 (11.4)                          |
| Vascular disorders                                   | 29 (31.5)                         | 7 (15.9)                          |
| Hypertension                                         | 25 (27.2)                         | 6 (13.6)                          |
| Respiratory, thoracic, and mediastinal disorders     | 49 (53.3)                         | 28 (63.6)                         |
| Cough                                                | 23 (25.0)                         | 11 (25.0)                         |
| Dyspnoea                                             | 13 (14.1)                         | 11 (25.0)                         |
| Gastrointestinal disorders                           | 64 (69.6)                         | 32 (72.7)                         |
| Diarrhoea                                            | 42 (45.7)                         | 25 (56.8)                         |
| Nausea                                               | 24 (26.1)                         | 12 (27.3)                         |
| Vomiting                                             | 17 (18.5)                         | 8 (18.2)                          |
| Constipation                                         | 12 (13.0)                         | 8 (18.2)                          |
| Skin and subcutaneous tissue disorders               | 42 (45.7)                         | 18 (40.9)                         |
| Pruritus                                             | 13 (14.1)                         | 5 (11.4)                          |
| Rash                                                 | 10 (10.9)                         | 4 (9.1)                           |
| Musculoskeletal and connective tissue disorders      | 41 (44.6)                         | 20 (45.5)                         |
| Back pain                                            | 10 (10.9)                         | 7 (15.9)                          |
| General disorders and administration site conditions | 45 (48.9)                         | 23 (52.3)                         |
| Fatigue                                              | 15 (16.3)                         | 9 (20.5)                          |
| Asthenia                                             | 7 (7.6)                           | 8 (18.2)                          |
| Pyrexia                                              | 9 (9.8)                           | 6 (13.6)                          |
| Investigations                                       | 62 (67.4)                         | 24 (54.5)                         |
| Blood creatine phosphokinase increased               | 42 (45.7)                         | 11 (25.0)                         |
| Aspartate aminotransferase increased                 | 22 (23.9)                         | 9 (20.5)                          |
| Alanine aminotransferase increased                   | 18 (19.6)                         | 8 (18.2)                          |
| Lipase increased                                     | 16 (17.4)                         | 10 (22.7)                         |
| Amylase increased                                    | 12 (13.0)                         | 7 (15.9)                          |
| Blood alkaline phosphatase increased                 | 11 (12.0)                         | 2 (4.5)                           |

Source: Table 15.3.3.1.1 (data cutoff: 19 February 2018).

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥10% of patients in either subgroup in the brigatinib arm in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib within the SOC.

<div style=\"page-break-after: always\"></div>

Table 86 : TEAEs Grade ≥3 by Patient Age (&lt;65 Years vs ≥65 Years) Occurring in ≥2% of Patients in the Total Brigatinib Arm by SOC and PT in Study 301, Treated Population (First Interim Analysis for Study 301)

|                                                  | Brigatinib 90 mg QD → 180 mg QD   | Brigatinib 90 mg QD → 180 mg QD   |
|--------------------------------------------------|-----------------------------------|-----------------------------------|
| System Organ Class Preferred Term                | <65 Years N = 92 n (%)            | ≥65 Years N = 44 n (%)            |
| Patients with any Grade ≥3 TEAE                  | 50 (54.3)                         | 33 (75.0)                         |
| Infections and infestations                      | 3 (3.3)                           | 6 (13.6)                          |
| Pneumonia                                        | 2 (2.2)                           | 3 (6.8)                           |
| Vascular disorders                               | 12 (13.0)                         | 2 (4.5)                           |
| Hypertension                                     | 11 (12.0)                         | 2 (4.5)                           |
| Respiratory, thoracic, and mediastinal disorders | 6 (6.5)                           | 7 (15.9)                          |
| Dyspnoea                                         | 1 (1.1)                           | 2 (4.5)                           |
| Pulmonary embolism                               | 2 (2.2)                           | 1 (2.3)                           |
| Investigations                                   | 33 (35.9)                         | 15 (34.1)                         |
| Blood creatine phosphokinase increased           | 17 (18.5)                         | 5 (11.4)                          |
| Lipase increased                                 | 10 (10.9)                         | 8 (18.2)                          |
| Amylase increased                                | 4 (4.3)                           | 3 (6.8)                           |
| Blood alkaline phosphatase increased             | 3 (3.3)                           | 0                                 |

Source: Table 15.3.3.1.2 (data cutoff: 19 February 2018).

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System

Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥2% of patients in the total brigatinib arm in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib within the SOC.

<div style=\"page-break-after: always\"></div>

Race

Table 87 : TEAEs of All Grades by Race (Asian vs NonAsian) Occurring in ≥10% of Patients in Either Subgroup in the Brigatinib Arm by SOC and PT in Study 301, Treated Population (First Interim Analysis)

|                                                      | Brigatinib 90 mg QD → 180 mg QD   | Brigatinib 90 mg QD → 180 mg QD   |
|------------------------------------------------------|-----------------------------------|-----------------------------------|
| System Organ Class Preferred Term                    | Asian N = 59 n (%)                | Non-Asian N = 77 n (%)            |
| Patients with any TEAE                               | 58 (98.3)                         | 74 (96.1)                         |
| Infections and infestations                          | 20 (33.9)                         | 30 (39.0)                         |
| Upper respiratory tract infection                    | 9 (15.3)                          | 0                                 |
| Nervous system disorders                             | 23 (39.0)                         | 28 (36.4)                         |
| Headache                                             | 7 (11.9)                          | 13 (16.9)                         |
| Dizziness                                            | 9 (15.3)                          | 4 (5.2)                           |
| Vascular disorders                                   | 14 (23.7)                         | 22 (28.6)                         |
| Hypertension                                         | 14 (23.7)                         | 17 (22.1)                         |
| Respiratory, thoracic, and mediastinal disorders     | 34 (57.6)                         | 43 (55.8)                         |
| Cough                                                | 14 (23.7)                         | 20 (26.0)                         |
| Dyspnoea                                             | 7 (11.9)                          | 17 (22.1)                         |
| Gastrointestinal disorders                           | 43 (72.9)                         | 53 (68.8)                         |
| Diarrhoea                                            | 27 (45.8)                         | 40 (51.9)                         |
| Nausea                                               | 12 (20.3)                         | 24 (31.2)                         |
| Vomiting                                             | 8 (13.6)                          | 17 (22.1)                         |
| Constipation                                         | 12 (20.3)                         | 8 (10.4)                          |
| Abdominal pain                                       | 3 (5.1)                           | 8 (10.4)                          |
| Stomatitis                                           | 6 (10.2)                          | 4 (5.2)                           |
| Skin and subcutaneous tissue disorders               | 30 (50.8)                         | 30 (39.0)                         |
| Pruritus                                             | 12 (20.3)                         | 6 (7.8)                           |
| Rash                                                 | 10 (16.9)                         | 4 (5.2)                           |
| Rash erythematous                                    | 6 (10.2)                          | 1 (1.3)                           |
| Musculoskeletal and connective tissue disorders      | 26 (44.1)                         | 35 (45.5)                         |
| Back pain                                            | 8 (13.6)                          | 9 (11.7)                          |
| Arthralgia                                           | 2 (3.4)                           | 8 (10.4)                          |
| General disorders and administration site conditions | 30 (50.8)                         | 38 (49.4)                         |
| Fatigue                                              | 7 (11.9)                          | 17 (22.1)                         |
| Asthenia                                             | 2 (3.4)                           | 13 (16.9)                         |
| Pyrexia                                              | 6 (10.2)                          | 9 (11.7)                          |
| Malaise                                              | 6 (10.2)                          | 0                                 |
| Investigations                                       | 34 (57.6)                         | 52 (67.5)                         |
| Blood creatine phosphokinase increased               | 22 (37.3)                         | 31 (40.3)                         |
| Aspartate aminotransferase increased                 | 16 (27.1)                         | 15 (19.5)                         |
| Alanine aminotransferase increased                   | 16 (27.1)                         | 10 (13.0)                         |
| Lipase increased                                     | 10 (16.9)                         | 16 (20.8)                         |
| Amylase increased                                    | 10 (16.9)                         | 9 (11.7)                          |
| Blood alkaline phosphatase increased                 | 7 (11.9)                          | 6 (7.8)                           |
| Blood cholesterol increased                          | 6 (10.2)                          | 1 (1.3)                           |

Source: Table 15.3.3.2.1 (data cutoff: 19 February 2018).

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System

Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥10% of patients in either subgroup in the brigatinib arm in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib within the SOC.

<div style=\"page-break-after: always\"></div>

Table 88 : TEAEs Grade ≥3 by Race (Asian vs Non -Asian) Occurring in ≥2% of Patients in the Total Brigatinib Arm by SOC and PT in Study 301, Treated Population (First Interim Analysis)

|                                                  | Brigatinib 90 mg QD → 180 mg QD   | Brigatinib 90 mg QD → 180 mg QD   |
|--------------------------------------------------|-----------------------------------|-----------------------------------|
| System Organ Class Preferred Term                | Asian N = 59 n (%)                | Non-Asian N = 77 n (%)            |
| Patients with any Grade ≥3 TEAE                  | 32 (54.2)                         | 51 (66.2)                         |
| Infections and infestations                      | 4 (6.8)                           | 5 (6.5)                           |
| Pneumonia                                        | 3 (5.1)                           | 2 (2.6)                           |
| Vascular disorders                               | 5 (8.5)                           | 9 (11.7)                          |
| Hypertension                                     | 5 (8.5)                           | 8 (10.4)                          |
| Respiratory, thoracic, and mediastinal disorders | 4 (6.8)                           | 9 (11.7)                          |
| Dyspnoea                                         | 0                                 | 3 (3.9)                           |
| Pulmonary embolism                               | 0                                 | 3 (3.9)                           |
| Investigations                                   | 22 (37.3)                         | 26 (33.8)                         |
| Blood creatine phosphokinase increased           | 13 (22.0)                         | 9 (11.7)                          |
| Lipase increased                                 | 7 (11.9)                          | 11 (14.3)                         |
| Amylase increased                                | 4 (6.8)                           | 3 (3.9)                           |
| Blood alkaline phosphatase increased             | 0                                 | 3 (3.9)                           |

Source: Table 15.3.3.2.2 (data cutoff: 19 February 2018).

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System

Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥2% of patients in the total brigatinib arm in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib within the SOC.

## Extrinsic factors

Prior chemotherapy

Table 89 : TEAEs of All Grades by Prior Chemotherapy (Yes vs No) Occurring in ≥10% of Patients in Either Subgroup in the Brigatinib Arm by SOC and PT in Study 301, Treated Population (First Interim Analysis)

|                                                  | Brigatinib 90 mg QD → 180 mg QD   | Brigatinib 90 mg QD → 180 mg QD   |
|--------------------------------------------------|-----------------------------------|-----------------------------------|
| System Organ Class Preferred Term                | Yes N = 36 n (%)                  | No N = 100 n (%)                  |
| Patients with any TEAE                           | 36 (100)                          | 96 (96.0)                         |
| Nervous system disorders                         | 13 (36.1)                         | 38 (38.0)                         |
| Headache                                         | 4 (11.1)                          | 16 (16.0)                         |
| Dizziness                                        | 3 (8.3)                           | 10 (10.0)                         |
| Eye disorders                                    | 8 (22.2)                          | 11 (11.0)                         |
| Vision blurred                                   | 4 (11.1)                          | 3 (3.0)                           |
| Vascular disorders                               | 7 (19.4)                          | 29 (29.0)                         |
| Hypertension                                     | 6 (16.7)                          | 25 (25.0)                         |
| Respiratory, thoracic, and mediastinal disorders | 25 (69.4)                         | 52 (52.0)                         |
| Cough                                            | 13 (36.1)                         | 21 (21.0)                         |
| Dyspnoea                                         | 8 (22.2)                          | 16 (16.0)                         |
| Productive Cough                                 | 5 (13.9)                          | 5 (5.0)                           |
| Gastrointestinal disorders                       | 24 (66.7)                         | 72 (72.0)                         |
| Diarrhoea                                        | 16 (44.4)                         | 51 (51.0)                         |
| Nausea                                           | 11 (30.6)                         | 25 (25.0)                         |
| Vomiting                                         | 8 (22.2)                          | 17 (17.0)                         |
| Constipation                                     | 6 (16.7)                          | 14 (14.0)                         |
| Skin and subcutaneous tissue disorders           | 18 (50.0)                         | 42 (42.0)                         |

<div style=\"page-break-after: always\"></div>

|                                                      | Brigatinib 90 mg QD → 180 mg QD   | Brigatinib 90 mg QD → 180 mg QD   |
|------------------------------------------------------|-----------------------------------|-----------------------------------|
| System Organ Class Preferred Term                    | Yes N = 36 n (%)                  | No N = 100 n (%)                  |
| Pruritus                                             | 6 (16.7)                          | 12 (12.0)                         |
| Rash                                                 | 6 (16.7)                          | 8 (8.0)                           |
| Musculoskeletal and connective tissue disorders      | 18 (50.0)                         | 43 (43.0)                         |
| Back pain                                            | 4 (11.1)                          | 13 (13.0)                         |
| Arthralgia                                           | 4 (11.1)                          | 6 (6.0)                           |
| Musculoskeletal chest pain                           | 5 (13.9)                          | 2 (2.0)                           |
| General disorders and administration site conditions | 21 (58.3)                         | 47 (47.0)                         |
| Fatigue                                              | 8 (22.2)                          | 16 (16.0)                         |
| Asthenia                                             | 5 (13.9)                          | 10 (10.0)                         |
| Pyrexia                                              | 8 (22.2)                          | 7 (7.0)                           |
| Investigations                                       | 26 (72.2)                         | 60 (60.0)                         |
| Blood creatine phosphokinase increased               | 16 (44.4)                         | 37 (37.0)                         |
| Aspartate aminotransferase increased                 | 10 (27.8)                         | 21 (21.0)                         |
| Alanine aminotransferase increased                   | 10 (27.8)                         | 16 (16.0)                         |
| Lipase increased                                     | 9 (25.0)                          | 17 (17.0)                         |
| Amylase increased                                    | 7 (19.4)                          | 12 (12.0)                         |
| Blood alkaline phosphatase increased                 | 6 (16.7)                          | 7 (7.0)                           |

Source: Table 15.3.3.3.1 (data cutoff: 19 February 2018).

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System

Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥10% of patients in either subgroup in the brigatinib arm in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib within the SOC.

<div style=\"page-break-after: always\"></div>

Table 90 : TEAEs Grade ≥3 by Prior Chemotherapy (Yes vs No) Occurring in ≥2% of Patients in the Total Brigatinib Arm by SOC and PT in Study 301, Treated Population (First Interim Analysis)

|                                                  | Brigatinib 90 mg QD → 180 mg QD   | Brigatinib 90 mg QD → 180 mg QD   |
|--------------------------------------------------|-----------------------------------|-----------------------------------|
| System Organ Class Preferred Term                | Yes N = 36 n (%)                  | No N = 100 n (%)                  |
| Patients with any Grade ≥3 TEAE                  | 26 (72.2)                         | 57 (57.0)                         |
| Infections and infestations                      | 2 (5.6)                           | 7 (7.0)                           |
| Pneumonia                                        | 1 (2.8)                           | 4 (4.0)                           |
| Vascular disorders                               | 2 (5.6)                           | 12 (12.0)                         |
| Hypertension                                     | 2 (5.6)                           | 11 (11.0)                         |
| Respiratory, thoracic, and mediastinal disorders | 3 (8.3)                           | 10 (10.0)                         |
| Dyspnoea                                         | 1 (2.8)                           | 2 (2.0)                           |
| Pulmonary embolism                               | 0                                 | 3 (3.0)                           |
| Investigations                                   | 19 (52.8)                         | 29 (29.0)                         |
| Blood creatine phosphokinase increased           | 9 (25.0)                          | 13 (13.0)                         |
| Lipase increased                                 | 7 (19.4)                          | 11 (11.0)                         |
| Amylase increased                                | 4 (11.1)                          | 3 (3.0)                           |
| Blood alkaline phosphatase increased             | 1 (2.8)                           | 2 (2.0)                           |

Source: Table 15.3.3.3.2 (data cutoff: 19 February 2018).

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; SOC, System Organ Class; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in ≥2% of patients in the total brigatinib arm in Study 301.

MedDRA version 20.0.

Frequencies were sorted by International Order of SOC and descending frequency of PT for brigatinib within the SOC.

## Discontinuation due to adverse events

Table 91: TEAEs Leading to Study Drug Discontinuation in More Than 1 Patient in Either Study by PT in Study 301 and Study 201, Treated Population (First Interim Analysis of Study 301)

|                                             | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|---------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Preferred Term                              | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any TEAE leading to treatment | 16 (11.8)                                     | 12 (8.8)                            | 12 (10.9)                                     | 28 (11.4)                                     |
| Pneumonitis                                 | 3 (2.2)                                       | 1 (0.7)                             | 3 (2.7)                                       | 6 (2.4)                                       |
| Interstitial lung disease                   | 2 (1.5)                                       | 0                                   | 0                                             | 2 (0.8)                                       |
| Pneumonia                                   | 2 (1.5)                                       | 0                                   | 2 (1.8)                                       | 4 (1.6)                                       |
| Alanine aminotransferase increased          | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |
| Neoplasm progression                        | 0                                             | 2 (1.5)                             | 2 (1.8)                                       | 2 (0.8)                                       |

Source: Table 15.3.2.8.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: AE, adverse event; BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in more than 1 patient in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201.

MedDRA version 20.0.

Frequencies were sorted by descending frequency of PT for brigatinib in Study 301.

a Study 201 does not include patients who had an AE action of 'Drug Withdrawn' and a primary reason for treatment discontinuation of 'Progressive Disease.'

<div style=\"page-break-after: always\"></div>

Table 92: TEAEs Leading to Study Drug Discontinuation by system organ class and preferred term (Treated Population, second interim analysis) -Study 301

|                                                         | Number of Patients (%)   | Number of Patients (%)    |
|---------------------------------------------------------|--------------------------|---------------------------|
| SystemOrganClass PreferredTerm                          | ARMA Brigatinib (N =136) | ARMB Crizotinib (N = 137) |
| Patients With At least 1 TEAE Leading to Study Drug     |                          |                           |
| Discontinuation                                         | 17 (12.5)                | 12 (8.8)                  |
| InfectionsAndInfestations                               | 3 (2.2)                  | 0                         |
| Pneumonia                                               | 3 (2.2)                  | 0                         |
| NeoplasmsBenign,MalignantAnd Unspecified (Incl CystsAnd |                          |                           |
| Polyps)                                                 | 2 (1.5)                  | 3 (2.2)                   |
| DiffuseLargeB-Cell Lymphoma                             | 1 (0.7)                  | 0                         |
| MetastasesToCentral NervousSystem                       | 1 (0.7)                  | 0                         |
| Neoplasm Progression                                    | 0                        | 2 (1.5)                   |
| Hodgkins Disease                                        | 0                        | 1 (0.7)                   |
| Psychiatric Disorders                                   | 1 (0.7)                  | 1 (0.7)                   |
| Delirium                                                | 1 (0.7)                  | 0                         |
| Schizophrenia                                           | 0                        | 1 (0.7)                   |
| Nervous System Disorders                                | 1 (0.7)                  | 2 (1.5)                   |
| Cerebrovascular Accident                                | 1 (0.7)                  | 0                         |
| Ischaemic Stroke                                        | 0                        | 1 (0.7)                   |
| Seizure                                                 | 0                        | 1 (0.7)                   |
| Cardiac Disorders                                       | 2 (1.5)                  | 0                         |
| Bradycardia                                             | 2 (1.5)                  | 0                         |
| Respiratory, Thoracic And Mediastinal Disorders         | 5 (3.7)                  | 2 (1.5)                   |
| Pneumonitis                                             | 3 (2.2)                  | 1 (0.7)                   |
| Interstitial Lung Disease                               | 2 (1.5)                  | 0                         |
| Respiratory Failure                                     | 0                        | 1 (0.7)                   |
| GastrointestinalDisorders                               | 1 (0.7)                  | 2 (1.5)                   |
| Dysphagia                                               | 1 (0.7)                  | 0                         |
| Diahoea                                                 | 0                        | 1 (0.7)                   |
| Nausea                                                  | 0                        | 1 (0.7)                   |
| SkinAnd SubcutaneousTissueDisorders                     | 1 (0.7)                  | 0                         |
| Rash Pruritic                                           | 1 (0.7)                  | 0                         |
| Investigations                                          | 1 (0.7)                  | 3 (2.2)                   |
| AlanineAminotransferaseIncreased                        | 1 (0.7)                  | 3 (2.2)                   |
| Aspartate Aminotransferase Increased                    | 1 (0.7)                  | 1 (0.7)                   |
| Blood Alkaline Phosphatase Increased                    | 1 (0.7)                  | 0                         |
| BloodBilirubinIncreased                                 | 0                        | 1 (0.7)                   |

Source:IA2Table15.3.1.2.3(datacutoff:28June2019)

AE:adverse event;incl:including;MedDRA:Medical Dictionary forRegulatoryActivities;TEAE:treatmentemergent adverseevent.

PatientswithoneormoreAEswithin alevelof MedDRA term arecounted only onceinthat level.

MedDRADictionary(Version22.0)wasusedforcodingadverseevents.

Treatment-emergentAEs aredefined asAEsstarting/worseningon or afterthefirstdoseof study treatment andno later than the earliestof(1)30 days after thelast dose ofthe treatment towhich thepatientwasassigned.or(2) thedaybeforestart of brigatinibtherapyincrossoverpatients.

<div style=\"page-break-after: always\"></div>

## AEs leading to dose interruption or dose reduction

Table 93: TEAEs Leading to Dose Interruption in More Than 1 Patient in Either Study by PT in Study 301 and Study 201, Treated Population (First Interim Analysis of Study 301)

|                                                     | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|-----------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Preferred Term                                      | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any TEAE leading to dose interruption | 72 (52.9)                                     | 58 (42.3)                           | 68 (61.8)                                     | 140 (56.9)                                    |
| Blood creatine phosphokinase increased              | 24 (17.6)                                     | 4 (2.9)                             | 10 (9.1)                                      | 34 (13.8)                                     |
| Lipase increased                                    | 16 (11.8)                                     | 4 (2.9)                             | 4 (3.6)                                       | 20 (8.1)                                      |
| Amylase increased                                   | 8 (5.9)                                       | 1 (0.7)                             | 3 (2.7)                                       | 11 (4.5)                                      |
| Hypertension                                        | 7 (5.1)                                       | 0                                   | 3 (2.7)                                       | 10 (4.1)                                      |
| Alanine aminotransferase increased                  | 5 (3.7)                                       | 16 (11.7)                           | 2 (1.8)                                       | 7 (2.8)                                       |
| Diarrhoea                                           | 5 (3.7)                                       | 3 (2.2)                             | 1 (0.9)                                       | 6 (2.4)                                       |
| Aspartate aminotransferase increased                | 3 (2.2)                                       | 7 (5.1)                             | 2 (1.8)                                       | 5 (2.0)                                       |
| Bradycardia                                         | 3 (2.2)                                       | 3 (2.2)                             | 0                                             | 3 (1.2)                                       |
| Dyspnoea                                            | 3 (2.2)                                       | 1 (0.7)                             | 2 (1.8)                                       | 5 (2.0)                                       |
| Pneumonia                                           | 3 (2.2)                                       | 4 (2.9)                             | 3 (2.7)                                       | 6 (2.4)                                       |
| Asthenia                                            | 2 (1.5)                                       | 0                                   | 0                                             | 2 (0.8)                                       |
| Confusional state                                   | 2 (1.5)                                       | 0                                   | 0                                             | 2 (0.8)                                       |
| Dizziness                                           | 2 (1.5)                                       | 1 (0.7)                             | 0                                             | 2 (0.8)                                       |
| Electrocardiogram QT prolonged                      | 2 (1.5)                                       | 2 (1.5)                             | 5 (4.5)                                       | 7 (2.8)                                       |
| Erythema                                            | 2 (1.5)                                       | 0                                   | 1 (0.9)                                       | 3 (1.2)                                       |
| Hyperamylasaemia                                    | 2 (1.5)                                       | 0                                   | 0                                             | 2 (0.8)                                       |
| Hyperinsulinaemia                                   | 2 (1.5)                                       | 0                                   | 0                                             | 2 (0.8)                                       |
| Nausea                                              | 2 (1.5)                                       | 7 (5.1)                             | 3 (2.7)                                       | 5 (2.0)                                       |
| Pneumonitis                                         | 2 (1.5)                                       | 1 (0.7)                             | 8 (7.3)                                       | 10 (4.1)                                      |
| Pyrexia                                             | 2 (1.5)                                       | 1 (0.7)                             | 1 (0.9)                                       | 3 (1.2)                                       |
| Rash                                                | 2 (1.5)                                       | 0                                   | 0                                             | 2 (0.8)                                       |
| Rash pruritic                                       | 2 (1.5)                                       | 0                                   | 1 (0.9)                                       | 3 (1.2)                                       |
| Decreased appetite                                  | 1 (0.7)                                       | 2 (1.5)                             | 2 (1.8)                                       | 3 (1.2)                                       |
| Dyspepsia                                           | 1 (0.7)                                       | 0                                   | 2 (1.8)                                       | 3 (1.2)                                       |
| Malignant pleural effusion                          | 1 (0.7)                                       | 0                                   | 2 (1.8)                                       | 3 (1.2)                                       |
| Urinary tract infection                             | 1 (0.7)                                       | 3 (2.2)                             | 0                                             | 1 (0.4)                                       |
| Vomiting                                            | 1 (0.7)                                       | 5 (3.6)                             | 4 (3.6)                                       | 5 (2.0)                                       |
| Appendicitis                                        | 0                                             | 0                                   | 2 (1.8)                                       | 2 (0.8)                                       |
| Blood creatinine increased                          | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |
| Cognitive disorder                                  | 0                                             | 0                                   | 2 (1.8)                                       | 2 (0.8)                                       |
| Hyponatraemia                                       | 0                                             | 0                                   | 2 (1.8)                                       | 2 (0.8)                                       |
| Neoplasm progression                                | 0                                             | 0                                   | 3 (2.7)                                       | 3 (1.2)                                       |
| Neutropenia                                         | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |
| Neutrophil count decreased                          | 0                                             | 5 (3.6)                             | 2 (1.8)                                       | 2 (0.8)                                       |
| Non-cardiac chest pain                              | 0                                             | 2 (1.5)                             | 0                                             | 0                                             |
| Oedema peripheral                                   | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |
| Rash erythematous                                   | 0                                             | 0                                   | 3 (2.7)                                       | 3 (1.2)                                       |
| Rash maculo-papular                                 | 0                                             | 0                                   | 2 (1.8)                                       | 2 (0.8)                                       |

Source: Table 15.3.2.10.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; TEAE, treatmentemergent adverse event.

Includes TEAEs that occurred in more than 1 patient in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201. MedDRA version 20.0.

Frequencies were sorted by descending frequency of PT for brigatinib in Study 301.

<div style=\"page-break-after: always\"></div>

Table 94: TEAEs Leading to Dose Reduction in More Than 1 Patient in Either Study by PT in Study 301 and Study 201, Treated Population (First Interim Analysis of Study 301)

|                                                  | Study 301                                     | Study 301                           | Study 201                                     | Total Brigatinib                              |
|--------------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Preferred Term                                   | Brigatinib 90 mg QD → 180 mg QD N = 136 n (%) | Crizotinib 250 mg BID N = 137 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 110 n (%) | Brigatinib 90 mg QD → 180 mg QD N = 246 n (%) |
| Patients with any TEAE leading to dose reduction | 39 (28.7)                                     | 29 (21.2)                           | 32 (29.1)                                     | 71 (28.9)                                     |
| Blood creatine phosphokinase increased           | 14 (10.3)                                     | 2 (1.5)                             | 7 (6.4)                                       | 21 (8.5)                                      |
| Lipase increased                                 | 7 (5.1)                                       | 1 (0.7)                             | 2 (1.8)                                       | 9 (3.7)                                       |
| Amylase increased                                | 4 (2.9)                                       | 0                                   | 1 (0.9)                                       | 5 (2.0)                                       |
| Aspartate aminotransferase increased             | 2 (1.5)                                       | 1 (0.7)                             | 0                                             | 2 (0.8)                                       |
| Hypertension                                     | 2 (1.5)                                       | 0                                   | 1 (0.9)                                       | 3 (1.2)                                       |
| Pneumonitis                                      | 2 (1.5)                                       | 1 (0.7)                             | 2 (1.8)                                       | 4 (1.6)                                       |
| Rash pruritic                                    | 2 (1.5)                                       | 0                                   | 1 (0.9)                                       | 3 (1.2)                                       |
| Alanine aminotransferase increased               | 1 (0.7)                                       | 8 (5.8)                             | 0                                             | 1 (0.4)                                       |
| Decreased appetite                               | 1 (0.7)                                       | 2 (1.5)                             | 2 (1.8)                                       | 3 (1.2)                                       |
| Nausea                                           | 1 (0.7)                                       | 6 (4.4)                             | 2 (1.8)                                       | 3 (1.2)                                       |
| Diarrhoea                                        | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |
| Electrocardiogram QT prolonged                   | 0                                             | 1 (0.7)                             | 2 (1.8)                                       | 2 (0.8)                                       |
| Hyponatraemia                                    | 0                                             | 0                                   | 2 (1.8)                                       | 2 (0.8)                                       |
| Oedema peripheral                                | 0                                             | 3 (2.2)                             | 0                                             | 0                                             |
| Rash maculo-papular                              | 0                                             | 0                                   | 2 (1.8)                                       | 2 (0.8)                                       |
| Vomiting                                         | 0                                             | 2 (1.5)                             | 0                                             | 0                                             |

Source: Table 15.3.2.9.1 (data cutoff: Study 301, 19 February 2018; Study 201, 29 September 2017).

Abbreviations: BID, twice daily; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; QD, once daily; TEAE, treatment-emergent adverse event.

Includes TEAEs that occurred in more than 1 patient in the brigatinib or crizotinib arms in Study 301 or the brigatinib 90 mg QD → 180 mg QD arm in Study 201.

MedDRA version 20.0.

Frequencies were sorted by descending frequency of PT for brigatinib in Study 301.

<div style=\"page-break-after: always\"></div>

Table 95: TEAEs Leading to dose interruption (in more than 1 patient in either treatment arm) by system organ class and preferred term (treated population, second interim analysis) -Study 301

|                                                          | Number of Patients (%)   | Number of Patients (%)   |
|----------------------------------------------------------|--------------------------|--------------------------|
| SystemOrganClass Preferred Term                          | ARMA Brigatinib (N =136) | ARMB Crizotinib (N =137) |
| Patients With At least 1 TEAELeading toDose Interruption | 90 (66.2)                | 64 (46.7)                |
| Infections And Infestations                              | 10 (7.4)                 | 10 (7.3)                 |
| Pneumonia                                                | 4 (2.9)                  | 4 (2.9)                  |
| Influenza                                                | 2 (1.5)                  | 0                        |
| Lower RespiratoryTract Infection                         | 2 (1.5)                  | 0                        |
| UrinaryTract Infection                                   | 1 (0.7)                  | 3 (2.2)                  |
| BloodAndLymphaticSystemDisorders                         | 2 (1.5)                  | 4 (2.9)                  |
| Anaemia                                                  | 2 (1.5)                  | 0                        |
| Neutropenia                                              | 0                        | 4 (2.9)                  |
| Metabolism And NutritionDisorders                        | 6 (4.4)                  | 2 (1.5)                  |
| Hyperamylasaemia                                         | 2 (1.5)                  | 0                        |
| Hyperinsulinaemia                                        | 2 (1.5)                  | 0                        |
| Decreased Appetite                                       | 1 (0.7)                  | 2 (1.5)                  |
| PsychiatricDisorders                                     | 2 (1.5)                  | 0                        |
| Confusional State                                        | 2 (1.5)                  | 0                        |
| NervousSystem Disorders                                  | 7 (5.1)                  | 2 (1.5)                  |
| Headache                                                 | 4 (2.9)                  | 0                        |
| Dizziness                                                | 2 (1.5)                  | 1 (0.7)                  |
| Cardiac Disorders                                        | 5 (3.7)                  | 6 (4.4)                  |
| Bradycardia                                              | 3 (2.2)                  | 4 (2.9)                  |
| Vascular Disorders                                       | 8 (5.9)                  | 1 (0.7)                  |
| Hypertension                                             | 8 (5.9)                  | 0                        |
| Respiratory,ThoracicAnd Mediastinal Disorders            | 12 (8.8)                 | 5 (3.6)                  |
| Dyspnoea                                                 | 3 (2.2)                  | 1 (0.7)                  |
| Pneumonitis                                              | 3 (2.2)                  | 1 (0.7)                  |
| Interstitial LungDisease                                 | 2 (1.5)                  | 0                        |
| GastrointestinalDisorders Diarrhoea                      | 12 (8.8) 5 (3.7)         | 18 (13.1) 5 (3.6)        |
| Nausea                                                   | 2 (1.5)                  | 8 (5.8)                  |
| Vomiting Abdominal Pain                                  | 2 (1.5)                  | 5 (3.6) 2 (1.5)          |
| Dyspepsia                                                | 1 (0.7) 1 (0.7)          | 2 (1.5)                  |
| SkinAndSubcutaneousTissueDisorders                       | 11 (8.1)                 | 1 (0.7)                  |
| Erythema                                                 | 2 (1.5)                  | 0                        |
| Rash                                                     | 2 (1.5)                  | 0                        |
| Rash Pruritic                                            | 2 (1.5)                  | 0                        |
| Musculoskeletal And ConnectiveTissueDisorders            | 4 (2.9)                  | 3 (2.2)                  |
| Back Pain                                                | 3 (2.2)                  | 0                        |
| General DisordersAndAdministrationSiteConditions         | 10 (7.4)                 | 7 (5.1)                  |
| Pyrexia                                                  | 5 (3.7)                  | 1 (0.7)                  |
| Asthenia                                                 | 2 (1.5)                  | 1 (0.7)                  |
| OedemaPeripheral                                         | 0                        | 3 (2.2)                  |
| Non-Cardiac Chest Pain                                   | 0                        | 2 (1.5)                  |
| Investigations                                           | 60 (44.1)                | 36 (26.3)                |
| Blood CreatinePhosphokinaseIncreased                     | 34 (25.0)                | 6 (4.4)                  |
| Lipase Increased                                         | 18 (13.2)                | 6 (4.4)                  |
| Amylase Increased                                        | 9 (6.6)                  | 2 (1.5)                  |
| AlanineAminotransferaseIncreased                         | 7 (5.1)                  | 17 (12.4)                |
| Aspartate Aminotransferase Increased                     | 5 (3.7)                  | 8 (5.8)                  |
| Electrocardiogram Qt Prolonged                           | 2 (1.5)                  | 2 (1.5)                  |
| BloodAlkalinePhosphataseIncreased                        | 2 (1.5)                  | 0                        |
| Neutrophil Count Decreased                               | 0                        | 7 (5.1)                  |
| Blood CreatinineIncreased                                | 0 2 (1.5)                | 3 (2.2) 2 (1.5)          |
| Injury,Poisoning,andProcedural Complications             | 2 (1.5)                  | 1 (0.7)                  |
| Femoral NeckFracture                                     |                          |                          |

Source:IA2Table15.3.1.2.5(datacutoff:28June2019)

AE:adverse event;MedDRA:Medical DictionaryforRegulatoryActivities;TEAE:treatment-emergent adverse event.Patientswith 1 ormoreAEswithin alevel of MedDRA term are counted only once in thatlevel.MedDRA Dictionary (Version 22.0) was used for coding adverse events.

Treatment-emergent AEs aredefined asAEsstarting/worseningon or after thefirst doseof study treatment and no later than the earliest of(1) 30 days after the last dose of the treatment towhich the patient was assigned,or (2) thedaybeforestart of brigatinib therapy in crossoverpatients.

<div style=\"page-break-after: always\"></div>

Table 96: TEAEs leading to dose reduction (in more than 1 patient in either treatment arm) by system organ class and preferred term (treated population, second interim analysis) -Study 301

|                                                       | Number of Patients (%)    | Number of Patients (%)    |
|-------------------------------------------------------|---------------------------|---------------------------|
| System Organ Class Preferred Term                     | Arm A Brigatinib (N =136) | Arm B Crizotinib (N =137) |
| Patientswith at least 1TEAE leading to dose reduction | 52 (38.2)                 | 34 (24.8)                 |
| InfectionsAndInfestations                             | 2 (1.5)                   | 3 (2.2)                   |
| Influenza                                             | 1 (0.7)                   | 2 (1.5)                   |
| BloodAnd LymphaticSystemDisorders                     | 1 (0.7)                   | 2 (1.5)                   |
| Neutropenia                                           | 0                         | 2 (1.5)                   |
| Metabolism And NutritionDisorders                     | 1 (0.7)                   | 2 (1.5)                   |
| Decreased Appetite                                    | 1 (0.7)                   | 2 (1.5)                   |
| Cardiac Disorders                                     | 1 (0.7)                   | 3 (2.2)                   |
| Bradycardia                                           | 1 (0.7)                   | 3 (2.2)                   |
| Vascular Disorders                                    | 3 (2.2)                   | 1 (0.7)                   |
| Hypertension                                          | 3 (2.2)                   | 0                         |
| Respiratory, Thoracic And Mediastinal Disorders       | 6 (4.4)                   | 2 (1.5)                   |
| Pneumonitis                                           | 2 (1.5)                   | 1 (0.7)                   |
| GastrointestinalDisorders                             | 3 (2.2)                   | 9 (6.6)                   |
| Nausea                                                | 1 (0.7)                   | 5 (3.6)                   |
| Diarrhoea                                             | 0                         | 2 (1.5)                   |
| Vomiting                                              | 0                         | 2 (1.5)                   |
| SkinAndSubcutaneous TissueDisorders                   | 6 (4.4)                   | 1 (0.7)                   |
| Rash Pruritic                                         | 2 (1.5)                   | 0                         |
| General DisordersAnd AdministrationSiteConditions     | 0                         | 7 (5.1)                   |
| Oedema Peripheral                                     | 0                         | 3 (2.2)                   |
| Peripheral Swelling                                   | 0                         | 2 (1.5)                   |
| Investigations                                        | 37 (27.2)                 | 14 (10.2)                 |
| Blood CreatinePhosphokinase Increased                 | 21 (15.4)                 | 2 (1.5)                   |
| Lipase Increased                                      | 9 (6.6)                   | 1 (0.7)                   |
| AmylaseIncreased                                      | 6 (4.4)                   | 0                         |
| AspartateAminotransferaseIncreased                    | 3 (2.2)                   | 1 (0.7)                   |
| AlanineAminotransferaseIncreased                      | 2 (1.5)                   | 8 (5.8)                   |
| Neutrophil Count Decreased                            | 0                         | 3 (2.2)                   |

Source:IA2Table15.3.1.2.4(data cutoff:28June2019)

MedDRA:MedicalDictionaryforRegulatoryActivities;TEAE:treatment-emergent adverse event.

MedDRA Dictionary (Version 22.0)was used for coding adverse events.

Patients with 1 or more TEAEs within a level of MedDRA term are counted only once in that level.

Treatment-emergent AEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of(1)30 days afterthe last dose ofthe treatment towhich the patient was assigned,or(2) the day before start of brigatinib therapy in crossover patients.

## Post marketing experience

Available safety data from post marketing sources are consistent with the known safety profile on brigatinib; no new safety concerns were identified. The MAH continues to actively monitor safety information from post marketing sources, as well as within the overall clinical development program.

## 2.5.1. Discussion on clinical safety

The safety database regarding the safety of brigatinib are from both the 201 and 301 studies, and 110 and 136 patients, respectively, have received the recommended dose. Updated safety data from the 301 study have been provided during the procedure using the data cut-off 28 June 2019. The updated median exposure of brigatinib is prolonged to 24.3 months compared to 9.2 months (range 0-18) before and versus 17.2 months (range: 0-39) in the 201 study. More than two thirds of the patients were exposed to brigatinib for more than 12 months. The mean relative dose intensity of brigatinib was close to 90% in the 201 study and 96.9% in the 301 study, which is considered reassuring and it is expected that the first ALK-TKI is better tolerated than the following treatments. The exposure of almost 2 years allow for a sufficient assessment of the safety profile of brigatinib in the ALK inhibitor naïve setting.

<div style=\"page-break-after: always\"></div>

Updated data from the pivotal study 301 show that nearly all patients had adverse events with brigatinib and ~91% of these AEs were treatment-related. The most common clinical AEs in the 301 study (brigatinib vs crizotinib) included decreased appetite (8.8% vs 19%), dysgeusia (2.9% vs 13.9%), dizziness (14.7% vs 20.4%), visual impairment (0 vs 16.8%), photopsia (0.7% vs 20.4%), bradycardia (8.1% vs 15.3%), hypertension (31.6% vs 8%), diarrhea (52.2% vs 56.2%), nausea (30.1% vs 58.4%), vomiting (20.6% vs 43.8%), constipation (18.4% vs 41.6%), fatigue (19.1% vs 22.6%), and peripheral oedema (6.6% vs 44.5%). More grade 3-4 AEs were observed in patients treated with brigatinib (66.2% vs 53.3%); and this was also observed for treatment-related grade 3-4 events (55.9% vs 35%). Treatment-related events seem to be consistent with the pattern of the treatment-emergent AEs, and it is noted that more GI toxicity events were deemed treatment-related with crizotinib. Grade 3 treatment-related AEs were more common with brigatinib, especially regarding CPK, lipase and amylase increased and hypertension. The incidence of grade ≥ 3 treatment-related AEs increased a bit with longer exposure, but clinically symptomatic events were rare and the overall rates are acceptable. Adverse events of special interest with clinically significant impact observed with either brigatinib or crizotinib included early-onset pneumonitis (EOPE), bradycardia, hypertension, GI events, hepatic events, creatine phosphokinase (CPK) elevation, and vision impairment. The incidence of EOPE was lower in the ALK TKI naive setting compared to study 201 (2.9% vs 6.4%). This was a very early onset event, as all events were observed within the first 8 days and before dose-escalation. It was initially agreed that the prolongation of the washout period from &lt;7 days to 10 days could have proven beneficial, but with updated safety data with double as many patients in the sample size (35 vs 61 patients), the rate was similar to the one observed in the second-line setting, i.e. 6.6% of those patients who crossed over to brigatinib after crizotinib. Hence, the lower incidence of EOPE in the firstline setting may be attributed to the ALK inhibitor-naïve setting. The rate of EOPE of ~3% in the firstline setting did not change with updated data and the events were clinically manageable due to the early onset and no fatal cases were observed in the first-line setting. The rate of other pneumonitis events was similar between the treatment arms.  Bradycardia was less frequent in the brigatinib arm (11.8%) compared with the crizotinib arm (23.4%), but was rarely of high grade. It is noted that slightly more patients had bradycardia in both arms with longer follow-up. However, the incidence is still acceptable and the event is considered clinically manageable. Hypertension was common in the brigatinib arm (32.4%) compared with the crizotinib arm (8.2%). Grade ≥ 3 hypertension was observed in 11.8% of patients with brigatinib and 2.9% of patients with crizotinib; however, the event is medically and clinically manageable. More GI toxicity were observed with crizotinib, especially nausea, vomiting and constipation. However, a similar incidence of diarrhea was observed with both study treatments. It is noted that high-grade treatment-related events were observed in 5.1% on brigatinib vs 10.9% of patients in the crizotinib arm. Because very few patients discontinued treatments due to GI toxicity, these events are considered overall clinically manageable. Hepatic events occurred in 33.8% of patients in the brigatinib arm and 43.8% of patients in the crizotinib arm.  The Grade ≥ 3 AEs that occurred in more than 1 patient in the brigatinib or crizotinib arms were blood ALP increased (2.9% vs 0.7%), ALT increased (3.7% vs 10.2%), AST increased (3.7% vs 6.6%), and gamma-glutamyltransferase increased (1.5% vs 2.2%). It is noted that there were no clinically symptomatic hepatoxicity events, and no patients met the Hy's law lab oratory criteria in either study. Hence, the level of hepatotoxicity is considered acceptable. Elevated CPK was very common with brigatinib (46.3%) compared with crizotinib (17.5%), and grade ≥ 3 events were markedly more frequent with brigatinib (24.3%) compared to crizotinib (1.5%). However, the number of patients with clinical symptoms such as myalgia or musculoskeletal pain was similar between arms, so this class effect is considered clinically manageable. Vision impairment occurred in markedly fewer patients on brigatinib (14.0%) compared with crizotinib (54.7%), and although these events were only of high grade in 1 patient on crizotinib (photopsia), this is considered a clinically significant difference. The incidence and severity of vision impairment events in brigatinib treated patients did not change significantly with updated data.

<div style=\"page-break-after: always\"></div>

As part of this procedure, increased blood cholesterol was identified as a new ADR with a frequency of 8.0% (see section 4.8 of the SmPC).

Serious adverse events were more common with crizotinib (37.2% vs 33.1%) and it is noted that with brigatinib the most common serious events were pneumonia and pneumonitis. Updated safety data increased the incidences slightly, probably due to the longer exposure, but the level of SAEs and treatment-related SAEs are still acceptable.

There was a similar number of deaths with any AEs in each arm (9 vs 10 patients) of the 301 study; and of the nine deaths in the brigatinib arm, 5 are agreed to be lung-cancer related. There were no treatment-related deaths.

A shift to any grade of clinical chemistry was more common with crizotinib compared to brigatinib regarding ALT increased, potassium increased, creatinine increased, albumin decreased, and calcium decreased. However, the shifts were rarely to grade 3-4 toxicity except for ALT increased (12.4%). Any shifts that were observed more commonly with brigatinib were lipase increased, amylase increased, glucose increased, magnesium decreased, calcium increased, and potassium decreased. Again, the shifts were rarely to grade 3-4 toxicity. Updated safety data showed a small increase of the incidences; however, this is acceptable and expected with longer exposure.

Discontinuations due to AEs are more frequent with brigatinib (12.5%) vs crizotinib (8.8%), and was mostly due to ILD/pneumonitis and pneumonia. The discontinuation rates with brigatinib are similar in the 201 and 301 studies and are considered acceptable. Dose interruptions due to an AE also occurred more frequently with brigatinib (66.2% vs 46.7%) and it is noted that this was due to increased CPK, lipase, amylase or hypertension in many cases. Dose interruptions for crizotinib were mainly due to increased ALT, AST and decreased neutrophils and clinical AEs of nausea and vomiting. Dose reductions were also more common with brigatinib but again dominated by clinical chemistry AEs (CPK, amylase and lipase increased), while the AEs leading to dose reduction of crizotinib were clinical AEs such as nausea and vomiting. The recommendations for dose modifications with elevation of CPK are further clarified and strengthened in section 4.2 of the SmPC. Updated safety data do not change this pattern significantly and data are consistent with the known safety profiles of the study drugs.

## 2.5.2. Conclusions on clinical safety

The comparison of the safety profiles of brigatinib or crizotinib in the ALK inhibitor naïve setting is now possible due to updated safety data with a median exposure to brigatinib of almost 2 years. Overall, the toxicities with brigatinib are well known and updated data confirm that the safety profile for brigatinib in the first-line setting is acceptable and no new safety issues have been raised. It is particularly reassuring that there were no new case of EOPE and the events are clinically manageable.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The CHMP endorsed the Risk Management Plan version 5.3 with the following content:

## Safety concerns

Table 97. Summary of the safety concerns

| Important identified risks   | Pulmonary toxicity (including EOPE and later-onset pneumonitis)   |
|------------------------------|-------------------------------------------------------------------|
| Important potential risks    | None                                                              |
| Missing information          | None                                                              |

Abbreviation: EOPE, early-onset pulmonary event.

## Pharmacovigilance plan

Table  98. Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                     | Summary of Objectives                                                                                                                                                            | Safety Concerns Addressed                                                                                                                                                        | Milestones                                                                                                                                                                       | Due Dates                                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the MA                                                                            | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the MA                                                                            | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the MA                                                                            | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the MA                                                                            | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the MA                                                                            |
| None                                                                                                                                                                             | Not applicable                                                                                                                                                                   | Not applicable                                                                                                                                                                   | Not applicable                                                                                                                                                                   | Not applicable                                                                                                                                                                   |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional MA or a MA under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional MA or a MA under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional MA or a MA under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional MA or a MA under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional MA or a MA under exceptional circumstances |
| None                                                                                                                                                                             | Not applicable                                                                                                                                                                   | Not applicable                                                                                                                                                                   | Not applicable                                                                                                                                                                   | Not applicable                                                                                                                                                                   |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                    |
| EU PASS                                                                                                                                                                          | To describe the occurrence and risk factors of EOPE in ALK+ NSCLC patients treated with brigatinib.                                                                              | Pulmonary toxicity (including EOPE and later--onset pulmonary events)                                                                                                            | PRAC/CHMP Protocol approval                                                                                                                                                      | 17 Oct 2019                                                                                                                                                                      |
|                                                                                                                                                                                  | To assess patient receipt and use of the brigatinib PAC.                                                                                                                         |                                                                                                                                                                                  | Final report                                                                                                                                                                     | 31 Dec 2024                                                                                                                                                                      |

Abbreviations: ALK+, anaplastic lymphoma kinase positive; EOPE, early-onset pulmonary event(s); EU, European Union; MA, marketing authorization; NSCLC, non -small-cell lung cancer; PAC, patient alert card; PASS, post authorisation safety study; PRAC, Pharmacovigilance Risk Assessment Committee; CHMP, Committee for Medicinal Products for Human Use

## Risk minimisation measures

Table 99. Summary Table of Pharmacovigilance Activities and Risk Minimization Activities

| Safety Concern                                                                              | Routine Risk Minimization Activities                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pulmonary toxicity (including EOPE and later-onset pneumonitis) (important identified risk) | Routine risk communication: SmPC Section 4.8 (pulmonary adverse reactions) Routine risk minimization activities recommending specific clinical measures to address the risk: Recommended dose modifications for ILD/pneumonitis are included in SmPC Section 4.2. Recommendation on monitoring of respiratory symptoms in case of severe pneumonitis events is included in SmPC Section 4.4. |

Abbreviations: EOPE, early-onset pulmonary event; ILD, interstitial lung disease; SmPC, Summary of Product Characteristics.

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly. Annex II has been revised to reflect the new due date for the provision of the final results from study 301.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The information in the Patient Information Leaflet (PIL) adequately reflects both the currently approved indication and the proposed indication.

In accordance with articles 59(3) and 61(1) of Directive 2001/83/EC, the MAH included the results of user testing of the Patient Information Leaflet (PL) during the review of the initial marketing authorization application for Alunbrig.

The additional indication is intended to treat NSCLC and has a similar safety profile. Furthermore, there have been no changes to the layout of the PIL. Therefore, the MAH has not conducted a user consultation on the PIL in relation to the additional proposed indication on the basis that there has been no change that may affect the readability of the PL.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The Applicant is seeking an extension of indication to include treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously untreated with an ALK-inhibitor. The proposed revised wording of indication is the following:

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor.

In addition to the current indication:

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

## 3.1.2. Available therapies and unmet medical need

Other available therapies for this patient population in the ALK-TKI naïve setting are mainly the second-generation ALK-TKIs alectinib and ceritinib. In principle, chemotherapy and the first generation ALK-TKI crizotinib are also approved for first-line therapy, but due to inferior efficacy compared to alectinib and ceritinib in the first-line setting, these options are rarely used. Checkpoint inhibitors may also be used in combination with platinum-based chemotherapy, however, the median PFS with checkpoint inhibitors and platinum-based chemotherapy in this setting has been shown to be approximately 8 to 9 months in comparison to a PFS of 34.8 months on alectinib (Camidge et al. 2019), 16.6 months with ceritinib, and 10.4 months with crizotinib.

<div style=\"page-break-after: always\"></div>

Hence, the targeted patient population has a number of options in the context of a palliative setting with a chance of a median progression-free survival of almost 3 years in the proposed setting with alectinib. The median OS with alectinib in the same setting is still immature (Alecensa II/01 EPAR).

## 3.1.3. Main clinical studies

The pivotal study for this application is the multicenter, randomised phase 3 ALTA 1L trial, comparing brigatinib with crizotinib in the ALK TKI-naïve setting. 275 patients were randomised 1:1 in 92 investigational sites across the world, mainly in the EU (55 sites) and the Asia-Pacific (24 sites). The study was fully recruited by 14 months; however, initial efficacy data presented are with less than a year of follow-up (11.1 months for the brigatinib arm) and from data cut-off 19 February 2018. Updated efficacy data are presented from data cut-off 28 June 2019 with a follow-up of 24.9 months for the brigatinib arm.

The primary endpoint is PFS by BIRC and the key secondary endpoints tested hierarchically are confirmed ORR, intracranial ORR, intracranial PFS, and OS.

## 3.2. Favourable effects

The primary analysis of PFS by BIRC was improved from 9.8 months on crizotinib to not reached with a HR of 0.492 and based on 26.3% events with brigatinib vs 45.7% events with crizotinib. Updated data from the second IA show that the median PFS by BIRC was improved from 11.0 months to 24.0 months (95%CI: 18.5, NE) with a HR of 0.489 and based on 46% events with brigatinib vs 63% events with crizotinib.

The updated key secondary endpoint of confirmed ORR by BIRC was improved by approximately 10%, so more patients had an overall response to brigatinib 73.7% (95%CI: 65.52; 80.87) compared to crizotinib 61.6% (95%CI: 52.94; 69.74).

Updated intracranial ORR for patients with any brain metastases at baseline (n=90) is improved with brigatinib i.e. 66% (95%CI: 50.69; 79.14) vs 16.3% (95%CI: 7.32; 29.66) with crizotinib. Updated intracranial PFS in patients with any brain metastases at baseline showed a median iPFS of 24 months with brigatinib vs 5.69 months with crizotinib.

Overall, 70 deaths have been reported by the updated data cut-off, and consequently the median OS has still not been reached in either arm. The event rates are 24.1% in the brigatinib arm and 26.8% in the crizotinib arm.

Time to response were similar between the arms and the median was approximately 1.8 months, which is consistent with previous data on brigatinib and other ALKTKI's. The DOR by BIRC was not reached (95%CI: 19.38, NE) for brigatinib and 13.8 months (95%CI: 9.30, 20.80) for crizotinib.

## 3.3. Uncertainties and limitations about favourable effects

OS results will be confounded by the allowed crossover from crizotinib to brigatinib at time of progression and subsequent treatments, but even so, no detrimental effect on OS is observed with updated data. The final PFS and OS analysis will be submitted post authorisation (see Annex II).

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

In the pivotal study 301, nearly all patients had adverse events with brigatinib and ~91% of patients had treatment-related AEs. The most common clinical AEs in the 301 study (brigatinib vs crizotinib) included decreased appetite (8.8% vs 19%), dysgeusia (2.9% vs 13.9%), dizziness (14.7% vs 20.4%), visual impairment (0 vs 16.8%), photopsia (0.7% vs 20.4%), bradycardia (8.1% vs 15.3%), hypertension (31.6 vs 8%), diarrhea (52.2% vs 56.2%), nausea (30.1% vs 58.4%), vomiting (20.6% vs 43.8), constipation (18.4 vs 41.6%), fatigue (19.1% vs 22.6%), and peripheral oedema (6.6% vs 44.5%). Grade 3 AEs were observed more frequently in patients treated with brigatinib (72.8% vs 61.3%); and this was also observed for treatment-related grade 3 events (46.3% vs 25.5%).

Regarding treatment-related events, these seem to be consistent with the pattern of the treatmentemergent AEs. Grade 3 treatment-related AEs were more common with brigatinib, especially regarding CPK and lipase increased.

Adverse events of special interest included EOPE, bradycardia, hypertension, GI events, hepatic events, CPK elevation, and vision impairment. The incidence of EOPE was lower in the ALK inhibitor naïve setting compared to study 201 (2.9% vs 6.4%) and was observed within the first 8 days of treatment with brigatinib and before dose-escalation. Grade 3 4 ILD/pneumonitis  events were reported in 2.2 % of patients. Additionally, 3.7% of patients experienced pneumonitis later in treatment. The rate of other pneumonitis events was similar between treatment arms. Bradycardia was less frequent in the brigatinib arm (11.8%) compared with the crizotinib arm (23.4%), and was rarely of high grade. Hypertension was common in the brigatinib arm (32.4%) compared with the crizotinib arm (8.2%) and grade ≥ 3 events were observed in 11.8% of patients in the brigatinib arm and 2.9% of patients in the crizotinib arm. GI toxicity were frequently observed with crizotinib, especially nausea, vomiting and constipation. However, a similar incidence of diarrhea was observed with both study treatments. High-grade treatment-related events were observed in 5.1% on brigatinib vs 10.9% of patients in the crizotinib arm. Hepatic events occurred in 33.8% of patients in the brigatinib arm and 43.8% of patients in the crizotinib arm. There were no clinically symptomatic hepatoxicity events, and no patients met the Hy ' s law laboratory criteria in either study. Elevated CPK was very common with brigatinib (46.3%) compared with crizotinib (17.5%), and grade ≥ 3 events were more frequent with brigatinib (24.3%) compared to crizotinib (1.5%). The proportion of patients with myalgia or musculoskeletal pain was similar between treatment arms. Vision impairment occurred less frequent on brigatinib (14%) compared with crizotinib (54.7%), and an event of high grade was observed in 1 patient on crizotinib (photopsia).

Serious adverse events were more common with crizotinib (37.2% vs 33.1%).

A shift to any grade of clinical chemistry were more common with crizotinib compared to brigatinib regarding ALT increased, potassium increased, creatinine increased, albumin decreased, and calcium decreased. The shifts were rarely to grade 3-4 toxicity except for ALT increased (12.4%). Any shifts that were observed more commonly with brigatinib were lipase increased, amylase increased, glucose increased, magnesium decreased, calcium increased, and potassium decreased. The shifts were rarely to grade 3-4 toxicity.

Discontinuations due to AEs were observed more frequently with brigatinib (12.5%) vs crizotinib (8.8%), and was mostly due to ILD/pneumonitis and pneumonia in the brigatinib arm.

## 3.5. Uncertainties and limitations about unfavourable effects

There are currently no major uncertainties in relation to the safety profile of brigatinib.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 100 : Effects Table for Alunbrig for ALK+ NSCLC in the ALK TKI naive setting (data cut-off: 28 June 2019)

| Effect                             | Short description                  | Unit                               | Treatment Alunbrig N=137           | Control Crizotinib N=138           | Uncertainties / Strength of evidence     |                                    |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------------|------------------------------------|
| Favourable Effects                 | Favourable Effects                 | Favourable Effects                 | Favourable Effects                 | Favourable Effects                 | Favourable Effects                       | Favourable Effects                 |
| Primary endpoint                   | Primary endpoint                   | Primary endpoint                   | Primary endpoint                   | Primary endpoint                   | Primary endpoint                         | Primary endpoint                   |
| PFS                                | BIRC assessed                      | Months                             | 24                                 | 11                                 | HR 0.49 (95%CI: 0.68) P<0.0001           | 0.35,                              |
| Key secondary endpoints            | Key secondary endpoints            | Key secondary endpoints            | Key secondary endpoints            | Key secondary endpoints            | Key secondary endpoints                  | Key secondary endpoints            |
| ORR                                | Confirmed                          | (N)%                               | 101 (73.7)                         | 85 (61.6)                          | ORR 1.73 P=0.0342                        |                                    |
| DOR                                | Confirmed                          | Months                             | NE (19.4, NE)                      | 13.8 (9.3, 20.8)                   |                                          |                                    |
| OS                                 | Overall survival                   | Months                             | NE (NE, NE)                        | NE (NE, NE)                        | HR 0.916 (~25% events both arms)         | in                                 |
| iORR                               | Intracranial ORR                   | % (95% CI)                         | 66 (50.7, 79.1)                    | 16.3 (7.32, 29.7)                  | Any brain metastases baseline n=90       | at                                 |
| iPFS                               | Intracranial PFS                   | Months (95% CI)                    | 24 (16.9, NE)                      | 5.6 (3.9, NE)                      | Any brain metastases baseline n=88 total | at                                 |
| Unfavourable Effects               | Unfavourable Effects               | Unfavourable Effects               | Unfavourable Effects               | Unfavourable Effects               | Unfavourable Effects                     | Unfavourable Effects               |
| ≥ 1 AE                             | AE                                 | %                                  | 99.3                               | 100                                |                                          |                                    |
| Gr 3-4                             | AE                                 | %                                  | 66.2                               | 53.3                               |                                          |                                    |
| SAE                                | AE                                 | %                                  | 33.1                               | 37.2                               |                                          |                                    |
| AE discont.                        | AE                                 | %                                  | 12.5                               | 8.8                                |                                          |                                    |
| Adverse events (treatment-related) | Adverse events (treatment-related) | Adverse events (treatment-related) | Adverse events (treatment-related) | Adverse events (treatment-related) | Adverse events (treatment-related)       | Adverse events (treatment-related) |
| GI disorders                       | TEAE ≥Grade 3                      | %                                  | 76.5 8.8                           | 88.3 15.3                          |                                          |                                    |
| Eye disorders                      | TEAE ≥Grade 3                      | %                                  | 16.2 0                             | 54.7 0.7                           |                                          |                                    |
| Bradycardia                        | TEAE                               | %                                  | 11.8                               | 23.4                               |                                          |                                    |
| Hypertensio n                      | TEAE                               | %                                  | 32.4                               | 8.0                                |                                          |                                    |
| Oedema                             | TEAE                               | %                                  | 6.6                                | 44.5                               |                                          |                                    |
| CPK incr.                          | TEAE                               | %                                  | 46.3                               | 17.5                               |                                          |                                    |

Abbreviations: AE: Adverse event; ADR: treatment-related AE; SAE: Serious AE; Gr.: grade; discont.: discontinuation;  Incr.: Increased.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Efficacy of brigatinib was demonstrated in the ALK TKI-naïve setting, as one line of chemotherapy was allowed, and this is reflected in the indication and considered acceptable. The observed 13 months improvement of PFS by BIRC (HR 0.49) is statistically significant and is considered clinically meaningful in this non-curable setting. Moreover, the data are now considered mature with median follow up of ~2 years in the brigatinib arm. Intracranial efficacy results are considered supportive of the primary endpoint and show a clinically relevant treatment effect. Updated efficacy data regarding PFS, provided during the procedure, show a clinically and statistically significant 13 months improvement, a 10% improvement in ORR, and a prolongation of DOR, which are supportive of the primary efficacy endpoint. Moreover, there are no signs of a detrimental effect on OS with brigatinib.

<div style=\"page-break-after: always\"></div>

With a median exposure of ~2 years allow for a sufficient assessment of the safety profile of brigatinib, and the incidence of AEs, ADRs, and AEs of special interest did not change clinically significantly.

## 3.7.2. Balance of benefits and risks

The improvement of PFS, ORR, DOR and intracranial efficacy is balanced with the safety profile of brigatinib in the first-line setting.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Alunbrig as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected     |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|----------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II, IIIA and IIIB |

Extension of indication to include first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor for Alunbrig. The addition of a new indication is supported by data from Study 301 (AP2611313-301; ALTA 1L), a phase 3, randomized, open label, comparative, multicenter, international phase 3 study. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, the due date for the submission of the Annex II condition has been updated. The Package leaflet and labelling are updated in accordance. The RMP version 5.3 has been approved. Minor editorial corrections are also proposed.

The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II, IIIA and IIIB and to the Risk Management Plan are recommended.

<div style=\"page-break-after: always\"></div>

This recommendation is subject to the following amended condition:

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                                                     | Due date     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Post-authorisation efficacy study (PAES): In order to further characterise the efficacy and safety of brigatinib in the treatment of patients with ALK positive NSCLC, the MAH should submit the clinical study report of the phase III study AP26113-13-301 comparing brigatinib versus crizotinib in patients with advanced ALK+ NSCLC who have not previously received ALK-directed therapy. | 30 June 2021 |

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above

## Summary

Please refer to Scientifi c Discussion 'Alunbrig EMEA/H/C/004248/II/0003

## Attachments

1. Product Information (changes highlighted) as adopted by the CHMP on 27 February 2020.